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Abstract: 
Heart Rate Variability describes the beat-to-beat variation in heart rate arising from 
activity of the sympathetic and parasympathetic branches of the Autonomic Nervous 
System (ANS). Reduced ANS tone measured by reduced heart rate variability (HRV) is 
a powerful predictor of adverse diagnosis in patients and is associated with increased 
mortality. Published research suggests that inflammation has a deleterious effect on 
Autonomic Nervous System tone.  
 
This study aimed to: establish if mild inflammatory conditions are associated with 
changes in autonomic tone as defined by heart rate variability studies in the following 
conditions: 
a. Influenza vaccination 
b. Reduction in oesophageal inflammation 
c. Reduction  in weight 
 
The aim of the first study was to assess the link between inflammation resulting from 
the influenza vaccination and the associated changes on heart rate variability. 71 
healthy volunteers opting to have a routine influenza vaccination were investigated for 
potential changes in cardiovascular autonomic tone associated with the temporary 
inflammatory effects of an Influenza vaccination. A number of temporal and frequency 
domain parameters of heart rate and breathing were assessed 2-5 days prior to 
vaccination and 1-4 days post vaccination. A sub-group of 15 volunteers who reported 
significant symptomatic reaction to the vaccination for at least 24 hours following 
vaccination displayed a statistically significant (p=<0.02) reduction in five of the six 
HRV parameters obtained during metronome-guided breathing. There was no evidence 
of significant reduction in autonomic tone following vaccination in the full sample of 
71 volunteers. 
The aim of the second study was to establish whether inflammation resulting from 
erosive or non-erosive oesophagitis caused by gastro-oesophageal reflux disease had 
any association with changes in heart rate variability. 12 volunteers with non-erosive 
oesophageal reflux disease (NERD) and 8 with erosive oesophageal reflux disease 
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(ERD) were investigated for HRV after initial diagnosis under gastroscopy. HRV 
assessment was repeated following 8 weeks of treatment with a proton-pump inhibitor 
(PPI). Initial reflux symptoms and response to PPI treatment were assessed using the 
GERD Impact Scale questionnaire. All participants had effective symptom response to 
treatment and there was no significant difference in symptoms score between NERD 
and ERD groups. There was a small but statistically significant increase in HRV 
detected following PPI treatment in the ERD group (p=0.05). 
The aim of the third study was to assess the link between obesity / pro-inflammatory 
adiposity, weight loss and the associated changes in heart rate variability. 38 clinically 
obese volunteers (BMI 30-39) with a family history of diabetes were reviewed for 
HRV prior to and following a lifestyle intervention designed to reduce body weight and 
BMI. Volunteers underwent repeated HRV studies after 4 months and 8 months of 
treatment. Volunteers on average achieved a weight loss of 11.5% (±6.0). There were 
statistically significant changes in HRV parameters in sub-group A (BMI ≥36) and 
correlation of biochemical measures with weight loss. These results further elucidate 
the effect of mild inflammatory triggers on autonomic tone as measured by HRV. 
These effects and their significance are discussed in detail in this document. The 
significance of the ‘cholinergic anti-inflammatory pathway’ is discussed with respect to 
the inflammatory conditions investigated. Suggestions for further work are proposed.   
 
In conclusion it is entirely possible to measure subtle changes in heart rate variability 
associated with mild inflammation and that on the evidence presented here these 
changes in heart rate variability are hypothesised to be reversible.  
 
My original contribution to knowledge is: 
1. Changes in heart rate variability are associated with low grade inflammation 
resulting from the Influenza vaccination, erosive oesophagitis and increased 
adiposity. 
2.  Measurement of subtle changes in autonomic tone, associated with 
inflammatory challenges is possible and concurs with other published research. 
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3. The level of HRV attenuation does appear to be linked to those with a higher 
level of inflammation. In each study the most significant results came from 
subgroups of volunteers either demonstrating: a higher level of symptom 
severity, erosive oesophagitis or were in a subgroup of participants with the 
highest BMI / adipose tissue. 
4. In the early stages of reduced heart rate variability we see that concurrent 
reduction in inflammation is associated with an increase in autonomic tone. 
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Chapter 1: Introduction 
1.1 Overview 
 
Autonomic function testing is a routine clinical assessment performed by the Medical 
Physics Department at Poole Hospital. The assessment involves measurement of 
frequency and temporal parameters during a series of non-invasive bedside 
provocations. A full description of the assessment of autonomic function is detailed in 
Chapter 2.  
The autonomic function assessment technique implemented at Poole Hospital has been 
refined over many years and incorporates a range of different measures designed to test 
the dual branches of the autonomic nervous system. Although the autonomic nervous 
system is a hugely complex system governing many important systems within the 
body, we can infer from the control over cardiovascular heart rate variability, the 
overall “health” of the autonomic nervous system by using a relatively simple set of 
heart rate measures. 
Vasallo and Allen (1997) published research relating to a small group of patients with 
acute pneumonia. Their findings showed that autonomic function was reduced 
temporarily due to the inflammatory effect from pneumonia. This temporary reduction 
in autonomic tone improved after six weeks and further still at six months in 
conjunction with an improvement in the patient’s overall health state. Previous research 
has documented the effects of inflammation on autonomic tone; these papers are 
referenced in the following chapters.  
This PhD research incorporates three different projects with one common theme: the 
effect of inflammation on the autonomic nervous system. The first project addresses the 
effect of the Influenza vaccination on autonomic tone. Most published research in this 
area has looked at inflammatory blood markers after vaccination. We decided that 
although relatively subtle, the influenza vaccination offered the opportunity to look at 
the effect of low-grade inflammation on the autonomic nervous system prior to, and 
two days following vaccination. The second area of research addresses the effect of 
gastro-oesophageal reflux disease and erosive and non-erosive oesophagitis on 
autonomic tone before and after an eight-week healing dose of proton pump inhibitor 
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(PPI) therapy. The third area of research involves a cohort of clinically obese non-
diabetic volunteers with a strong family history of diabetes undertaking an intensive 
eight-month weight loss, exercise and lifestyle programme with autonomic function 
testing, physiological measurement and blood testing.  
 
These three pieces of research related through one common theme of the “subtle effect 
of inflammation on autonomic tone” would offer the opportunity to refine the current 
autonomic measurement technique. The following document aims to discuss this 
research in detail. 
 
1.2 Scientific Background 
 
The nervous system comprises the central nervous system (CNS) incorporating the 
brain and spinal cord and the peripheral nervous system composed of the efferent and 
afferent nerve pathways that communicate between the CNS and the body’s organ 
systems (Appenzeller and Oribe 1997). The autonomic nervous system is part of the 
peripheral nervous system and is responsible for regulating involuntary body functions. 
The CNS transmits signals to muscles and glands via the efferent division of the 
autonomic nervous system. The efferent branch of the autonomic nervous system is 
responsible for controlling many important functions within the human body, including 
innervation of smooth muscle, cardiac muscle and exocrine and endocrine glands 
(Sherwood 2010).  
Functionally the ANS operates without conscious control; it is governed by the 
hypothalamus and medulla oblongata (Furness 2006). Dysfunction of the ANS is 
associated with an increase in morbidity and mortality (Vinik 2012 and O’Brien et al 
1991). Autonomic dysfunction and its clinical manifestations are associated with a 
range of peripheral and central nervous system disorders; these have been classified in 
the Task Force of the European Society of Cardiology and the North American Society 
of Pacing and Electrophysiology Consensus Statement of 1996. A general attenuation 
in autonomic control is associated with an increase in age, but is especially prevalent in 
those with long term diabetes mellitus and cardiovascular disease (Kempler et al 2002). 
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The Hoorn Study has also shown that reduced autonomic function is associated with a 
higher rate of mortality, particularly when associated with other conditions such as 
diabetes (Gerritsen et al 2001). 
 
Autonomic dysfunction is difficult to measure objectively due to the dual innervation 
of the two branches of the ANS. Despite this, routine non-invasive assessment of 
autonomic function is taking place in the clinical setting; many of the methods 
implemented are based on the standard Ewing tests developed in the 1970’s (Ravits 
1997). Many tests now exist to determine the degree of loss of autonomic function; 
these include the tilt table test and the sudomotor tests for sweating. The most 
commonly used and most reliable measures of autonomic function assess 
cardiovascular autonomic control, looking at heart rate variability (Stein et al l994). 
HRV is derived from tests such as the forced breathing and the Valsalva manoeuvre. 
These tests will be discussed in more detail in the following chapters. 
 
Heart rate variability can be assessed using an electrocardiogram (ECG), which records 
cardiac-induced skin potentials at the body’s surface (Laizzo 2009). Five easily 
recognisable features of the ECG trace are known by the letters P-QRS-T, the Q, R and 
S waves known as the QRS complex; indicate ventricular depolarisation (Laizzo 2009). 
The timing of the QRS complex over many heartbeats is easily measured by identifying 
the peak of the R wave, which is the most distinctive feature of the complex. 
Fluctuations in the inter-beat intervals can be used to assess autonomic control over 
cardiovascular function, which can manifest in changes in the variability of the R-R 
interval sequence compared with normal controls (Ravits 1997). 
 
Haemodynamic measures such as heart rate and blood pressure vary on a beat to beat 
basis (Akselrod et al 1981). The moment to moment changes in heart rate vary in 
response to many factors apart from those governed by the autonomic nervous system. 
These include exercise, emotional state and activities such as eating, drinking and 
nicotine (Low 1993). 
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Heart rate variability is reduced in patients with stable coronary heart disease (CHD) 
(Gerritsen et al 2001), and it is suggested that this reduction in HRV is present before a 
patient becomes symptomatic (Liao et al 2002). Hayano et al (1990) found evidence to 
suggest that there is a correlation between reduction in HRV and severity of CHD 
determined by angiography. Although HRV is decreased in CHD the exact mechanisms 
are not known (Gerritsen 2001). Increased risk of death in cardiac patients is thought to 
be associated with the increased risk of life threatening arrhythmia (Bigger et al 1992). 
Huikuri et al (1999) found that impaired autonomic function is also associated with 
non-fatal cardiovascular events in the general population therefore other mechanisms 
must be involved. 
 
Using spectral analysis of autonomic function a decrease in HRV has been observed in 
patients following acute myocardial infarction (Bigger et al 1991). This reduction in 
HRV appears to be a transient occurrence. There is evidence that HRV partially 
recovers following the event, but remains at a lower level than healthy controls (Bigger 
et al 1991). Decreased HRV is also associated with congestive heart failure (Brouwer et 
al 1996), hypertension (Huikuri et al 1996), neurological conditions such as 
Parkinson’s disease (Korpelainen et al 1996) chronic renal disease (Friedman 1995) 
and following pneumonia (Vassallo and Allen 1997). 
 
For over a century it has been widely recognised that vagal modulation of the sinus 
node activity occurs at respiratory frequency (Sin et al 2012), meaning that changes in 
heart rate variability are linked to respiratory pattern. In light of this finding, 
assessment of cardiovascular autonomic function through the measurement of R-R 
interval variability with deep breathing has increasingly been used as an index for 
autonomic control (Malliani and Montano 2002). Power spectral analysis of regulated 
forced breathing in time with a metronome indicates high frequency (HF) power to be 
confined mainly to a narrow peak at the respiratory frequency (Bloomfield et al 2001). 
 
This PhD study used both temporal and spectral analysis of forced breathing as a 
method to assess autonomic dysfunction during two standardised breathing cycles, (6 
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and 10 breaths per minute), of two minutes duration per cycle, while simultaneously 
recording chest wall movement. A number of other parameters were also 
simultaneously recorded; these included heart rate variability measures during maximal 
handgrip (see section 2.2.12), Valsalva Manoeuvre (see section 2.2.9) and lying to 
standing (see section 2.2.10), and other measures including Photoplethysmography (see 
section 2.2.18), beat to beat finger blood pressure (see section 2.2.14), and pupilometry, 
(see section 2.2.15). 
 
We previously developed a technique for short-term measurement of chest 
plethysmography using a pressure cuff worn around the chest to infer first 
approximation of breathing by measuring chest wall movement during metronome-
guided breathing and measurement of heart rate for the assessment of cardio-
ventilatory coupling (Perring and Jones, 2003). We established that in asymptomatic 
Type one diabetics, while the amplitude of heart rate variation falls with age in normal 
volunteers, the correlation between heart rate and chest wall movement is stable with 
age in the absence of diabetic autonomic neuropathy. We indicated that correlation 
between heart rate and chest wall movement is a better indicator of diabetic autonomic 
attenuation than measurement of heart rate alone. We established that a breathing rate 
of 6 breaths per minute (0.1 Hz) gave optimum amplitude of heart rate variation and 
optimum correlation between heart rate and chest wall movement.  
 
1.3 Rationale 
 
The inflammatory response is both deleterious and protective within the body often at 
the same time, causing cell death and tissue damage while protecting against trauma 
and infection. The inflammatory response is initially governed by the afferent arm of 
the autonomic nervous system, activating an opposing motor response in the vagus that 
suppresses cytokine production. Detection of injury and infection activates a 
cholinergic anti-inflammatory pathway (Tracey 2007). Inflammation is known to 
significantly affect autonomic function and research suggests it may be more involved 
in disease processes (such as cancer, atherosclerosis and asthma) than previously 
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thought (Krishnamoorthy and Honn 2006). A host of research has been published 
reporting a link between inflammatory disease states (such as rheumatoid arthritis 
(Pontet et al 2003), diabetes mellitus, and other autoimmune disorders) and autonomic 
impairment (Toussirot et al 1993). In most clinical conditions characterized by an 
increase of inflammatory markers (for example in diabetes or acute coronary 
syndromes), a reduction in heart-rate variability parameters is consistently observed in 
high risk patients, strengthening the connection between inflammation and autonomic 
dysfunction (Lombardi 2004). 
 
 
1.4 Aims of the Research 
The main aims of this research are to: 
 
1. Establish if mild inflammatory conditions (elicited by the conditions listed 
below) are  associated with changes in autonomic tone as defined by heart rate 
variability studies: 
a. Influenza vaccination 
b. Reduction in oesophageal inflammation 
c. Reduction in weight 
 
2. Further refine our age-matched normal ranges of autonomic heart rate variation 
based on metronome guided breathing and simultaneous chest 
plethysmography.  
 
3. Establish the reproducibility of measures of heart rate variability. 
 
4. Further illuminate the mechanism of ANS disruption by inflammatory 
processes. 
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1.5 Defining terminology used in this document 
 
Many different terms are used throughout the literature to describe a reduction in the 
performance of the autonomic nervous system. The following terms have been used 
interchangeably in this document: 
 
 Autonomic dysfunction 
 Dysautonomia 
 Cardiac autonomic neuropathy 
 Decreased / attenuated autonomic tone 
 Autonomic dysregulation 
 Autonomic failure 
 Decreased or attenuated heart rate variability 
 
  
9 
2 Chapter 2: Review of Literature 
Chapter 2: Review of Literature 
 
2.1 The Autonomic Nervous System 
 
2.1.1 Anatomy of the Autonomic Nervous System (ANS) 
 
The ANS performs vital regulatory functions, maintaining internal physiological 
homeostasis independent of volitional activity (Laizzo 2009). The ANS is 
predominantly reflexive by nature; it controls multiple organ systems including cardio-
respiratory, gastrointestinal, sexual function, thermo-regulation, and genito-urinary 
(Guyton 2006). These systems are for the most part independent of conscious control, 
but can be affected by heightened emotional stress such as fear.  
 
Unlike skeletal muscles, organs innervated by the ANS would often still function with 
limited or no nerve supply, for example the heart still beats when removed from the 
body (Tortora and Derrickson 2011 and Mathias and Bannister 2006). In the case of 
heart rate control, for example, the ANS does not initiate each heart contraction, but 
instead is involved in the ‘fine-tuning’ of heart rate, in order to respond to the demands 
of the body.  
 
The ANS is anatomically and functionally divided into two distinct divisions (see 
Figure 1). The sympathetic (thoracolumbar) and parasympathetic (craniosacral) 
pathways (Shields 1993), which often function in an antagonistic way, are then further 
divided into the pre and post-ganglionic tracts. The pathways arising from the cranial 
and sacral area of the spinal cord carry the parasympathetic fibres; these have long 
cholinergic pre-ganglionic fibres and short cholinergic postganglionic fibres (Laizzo 
2009). Those from the thoracic and lumbar region carry the sympathetic fibres (Loewy 
and Spyer 1990); these have short cholinergic preganglionic fibres and long adrenergic 
postganglionic fibres.  
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Parasympathetic and sympathetic preganglionic fibres release the same 
neurotransmitter, acetylcholine, but the postganglionic fibres release two different 
neurotransmitters. Parasympathetic postganglionic fibres release acetylcholine, and 
most sympathetic postganglionic fibres release noradrenaline (Sherwood 2010).  
 
       
Figure 1. Branches of the autonomic nervous system cited in: Furness J (2006)  
The organisation of the autonomic nervous system: Peripheral connections. Autonomic Neuroscience: 
Basic and Clinical 130, 1-5  Key: 1 Eye, 2 lacrimal glands, 3 intracranial arteries, 4,5 salivary glands, 6 
airways, 7 brown fat, 8 heart, 9 liver, 10 spleen, 11 pancreas, 12 gallbladder, 13 adrenal glands, 14 
tubular GI tract, 15 kidney, 16 bladder, 17 genital organs, 18 prevertebral ganglia and plexus, 19, 20 
sympathetic chains.   
 
The central autonomic system is composed of several interconnected areas in the 
brainstem and spinal cord. It is responsible for tonic, reflex, and adaptive control of 
autonomic function (Benarroch 1997). The structures forming the central autonomic 
network are distributed at the level of the cerebral cortex, hypothalamus, midbrain, 
pons, and medulla (Loewy 1990).  
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The hypothalamus is one of the most important areas of the brain, which is connected 
to both branches of the ANS (Sandroni 1998, Vinik 2012). The anterior and medial 
portion controls parasympathetic division and the posterior and lateral portions control 
sympathetic activity. The hypothalamus is the main control and integration centre of 
the ANS (Tortora 2011). 
 
The peripheral part of the sympathetic autonomic nervous system passes through 
anatomically complex ganglia leading to various organs of the body including the eyes, 
lungs, heart, stomach, pancreas, liver, the intestine, kidneys, and sex organs (Furness 
2006). The majority of the action of the parasympathetic nervous system in contrast is 
delivered by the vagus nerve, innervating the lungs, heart, intestine, pancreas, spleen, 
gallbladder, liver, kidneys, bladder and sex organs (Laizzo 2009).  
 
Physiologically the body responds differently to sympathetic and parasympathetic 
stimulation. Sympathetic stimulation generally causes excitatory responses such as 
those experienced in “fight or flight response,” increased heart rate (HR), blood 
pressure (BP) and sweating. The pupils dilate, blood flow to the kidneys and gut 
constrict and the liver releases glucose (Sherwood 2010). Sympathetic stimulation is 
more widespread and longer lasting than parasympathetic responses (Tortora 2011). 
Parasympathetic innervation generally has the opposite effect conserving and restoring 
energy; most of the responses are related to digestion, absorption of food and 
elimination of waste (Sherwood 2010). The parasympathetic branch is also responsible 
for decreasing heart rate, bronchoconstriction and constriction of the pupils. Both 
systems have associated sensory fibres that send feedback information into the central 
nervous system regarding the functional condition of the target tissues, and despite 
common misconceptions that the two systems are entirely antagonistic, they work 
together to control visceral organs and vasculature (Furness 2006). 
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2.1.1.1 Efferent and Afferent Pathways 
 
The ANS is predominantly an efferent system transmitting impulses away from the 
Central Nervous System (CNS) to peripheral organ systems (Freeman 2006). The 
efferent systems are neural (autonomic nervous system) and hormonal 
(neuroendocrine) (Mathias and Bannister 2006). Its effects include control of heart rate 
and force of contraction, constriction and dilatation of blood vessels, contraction and 
relaxation of smooth muscle in various organs, pupillary size and secretions from 
exocrine and endocrine glands. Autonomic nerves constitute all of the efferent fibres, 
which leave the CNS, except for those, which innervate skeletal muscle (Freeman 
2006).  
“The efferent limb of neuronal autonomic reflexes consists of specific preganglionic 
nerves that synapse in autonomic ganglia, with postganglionic fibres. These 
postganglionic fibres mediate the desired response at the effector organ. The efferent 
limbs of these reflexes may also involve the somatic nervous system (e.g. coughing and 
vomiting). Simple reflexes are completed entirely within the organ concerned, whereas 
more complex reflexes are controlled by the higher autonomic centres in the CNS, 
principally the hypothalamus” (Pratt et al 2005). 
There are some afferent autonomic fibres which transmit information from the 
periphery back to the CNS which are concerned with the mediation of visceral 
sensation and the regulation of vasomotor and respiratory reflexes, for example the 
baroreceptors and chemoreceptors in the carotid sinus and aortic arch which are 
important in the control of heart rate, blood pressure and respiratory activity (Freeman 
2006). These afferent fibres are usually carried to the CNS by major autonomic nerves 
such as the vagus, splanchnic or pelvic nerves, with some afferent pain fibres from 
blood vessels carried by somatic nerves (Pratt et al 2005). Autonomic and endocrine 
regulation occurs in the hypothalamus, spinal cord, and brain stem. Overlap within the 
brain occurs not only between areas involved in autonomic and endocrine outputs but 
also between these and regions controlling the somatomotor system. 
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2.1.1.2 Enteric Nervous System 
 
A third division of the autonomic nervous system is called the enteric nervous system, 
which consists of a collection of neurons embedded in the wall of the entire 
gastrointestinal tract (Furness 2006). The vagal nerve innervates parasympathetic fibres 
covering the length of the gastrointestinal tract apart from the last half of the large 
intestine, which is governed by the sacral spinal cord (Tortora 2011). Over the last 
thirty years there has been an increase in research into this complex area. Two 
interconnected networks of neurones are located in the two main plexus, the myenteric 
plexus of Auerbach and the submucosal plexus of Meissner (Tortora 2011). Both 
plexus contain afferent and efferent neurones, which bring about reflex changes in gut 
motility via excitatory or inhibitory action on the smooth muscle and also the 
regulation of secretion and absorption by mucosal cells (Mathias 2006). The extrinsic 
autonomic nervous system is semi-autonomous and can continue to carry out its motor 
function without intervention from the central nervous system (Mathias 2006). 
Extrinsic innervation consists of parasympathetic vagal and sacral nerves S2-S4 and 
thoracolumbar sympathetic nerves T5-L3. The interactions between the sympathetic, 
parasympathetic, brain and enteric nervous system integrate activity in the different 
regions of the gut and coordinate activity between the gut and other organs. 
Gastrointestinal disorders may be caused by a myopathic or neuropathic process such 
as muscular dystrophy (myopathic) or Hirschsprung’s or Chaga’s disease 
(neuropathic). Central nervous system disorders associated with gastrointestinal 
dysmotility include Parkinsonism and Shy-Drager syndrome (Mathias 2006). 
 
 
2.1.2 Cardiovascular Autonomic Control 
 
Fluctuations in heart rate and blood pressure reflect the dynamic response of the 
cardiovascular control system to physiological changes. Heart rate is controlled by 
membrane processes of the sino-atrial node, which is governed by innervations from 
both divisions of the autonomic nervous system (Crick et al 2000). The main periodic 
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fluctuations are respiratory sinus arrhythmia, baroreflex, and thermoregulation related 
variability of heart rate. The most obvious fluctuation is in response to respiration 
where the heart rate increases during inspiration and slows down during expiration. The 
magnitude of the response depends on the rate and depth of respiration (Brown and 
Bolton 2002). An inverse relationship between breathing rate and frequency power has 
previously been reported (Brown and Bolton 2002). Beat to beat variation in heart rate 
or heart rate variability (HRV) is an important indicator of physiological resiliency and 
behavioural flexibility, reflecting the body’s ability to adapt effectively to stress. The 
normal variability in heart rate is due to the synergistic action of the two divisions of 
the autonomic nervous system either accelerating or decelerating heart rate depending 
on the predominance of one system over the other. Heart rate demonstrates the net 
effect of the parasympathetic system (vagal tone will dominate resting heart rate) and 
the sympathetic system (will increases heart rate) in healthy individuals. At rest both 
divisions of the ANS are active with the parasympathetic or the vagal division 
dominant. 
The best-known cardiovascular negative feedback mechanism is that of the 
baroreceptor arc (Tortora 2011). The baroreceptors, which are located in the carotid 
sinuses and aortic arch, are sensitive to pressure and are referred to as high-pressure 
sensors. The baroreceptors function by transmitting signals through the vagal portion of 
the autonomic nervous system to the arterial system to enhance vasodilation and 
decrease blood pressure in response to an increase in arterial pressure. This occurs 
reflexively when the baroreceptors are stretched by an increase in blood pressure 
(Guyton 2006). 
 
2.1.3 General Features of Autonomic Dysfunction  
 
In autonomic dysfunction the particular functions affected differ from patient to patient. 
Generally patients are elderly, and men are more likely to be affected than women 
(Bannister 1988). The most dramatic symptom and most common reason for seeking 
medical advice is postural dizziness or orthostatic hypotension (Khurana 2002) due to 
loss of predominantly sympathetically mediated reflexes with severity ranging from 
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light-headedness to syncope on standing. This can be judged from the duration of 
standing time to the onset of orthostatic symptoms (Khurana 1988 and 2002). 
 
A generalised loss of sweating in the lower extremities may also present with heat 
intolerance, as control of thermoregulation is lost. This is thought to be due to damage 
to the sympathetic pathway resulting in sudomotor and vasomotor abnormalities 
(Clarke et al 1979). Salivation is another important secretomotor function that affects 
taste perception, oral lubrication, and antimicrobial activity. If a patient has to drink 
whilst eating to aid deglutition, it would suggest a loss of more than 50% salivary 
function (Wolff 1995). 
 
Disturbance in micturition is a common early symptom in both genders. Bladder 
symptoms are a combination of increased urgency, frequency, and nocturia due to 
uninhibited detrusor activity or incontinence due to sphincter weakness. A loss of 
sensation for bladder fullness and urine retention is often also experienced (Low 1997). 
Bowel control is often compromised causing gastrointestinal motility disorders. This is 
caused by damage to the sympathetic and parasympathetic nervous system (Clarke et al 
1979) causing patients to experience chronic constipation, nocturnal diarrhoea, or 
faecal incontinence. 
 
 
2.1.4 Factors Affecting Autonomic Function 
 
Factors affecting autonomic function are age, gender, level of exercise, high body mass 
index (Vinik and Erbas 2001) and medications (Sandroni 1998). An almost linear 
relationship can be seen between increased age and decreased respiratory sinus 
arrhythmia from age 18-80 years (Fagard 2001 and Schwartz et al 1991). It is known 
that sympathetic activity increases progressively with aging (Thijssen et al 2006 and 
Yamada et al 1989). During tests of autonomic function in healthy volunteers Braune et 
al (1996) and Low et al (1997) found that for both the Valsalva Manoeuvre and Forced 
Breathing, heart rate variability was reduced with age. Rodrigues (2010) found these 
  
16 
changes however, were not associated with gender, Moodithaya and Avadhany (2012) 
and Low et al (1997) found that during forced breathing there was no discernible 
difference for gender but during the Valsalva manoeuvre they found that heart rate 
responsiveness was reduced in women. Vinik and Erbas (2001) also agree that HRV is 
reduced in women. Sloan et al (2009) documented the effect of exercise on cardiac 
autonomic function. De Meersman (1993) compared a group of healthy male runners 
with an age matched sedentary group of males and Goldsmith et al (1992) compared a 
group of healthy endurance trained men with a group of age matched untrained men. 
Both studies found that the men who regularly perform physical exercise had 
significantly higher heart rate variability. They also concluded that long term aerobic 
activity promotes heart rate variability. Levy et al (1992) concluded from a similar 
study the decline seen in parasympathetic activity associated with an increase in age is 
partially reversed with intensive exercise activity and that strenuous activity improves 
heart rate variability. Lucini et al (2002) also demonstrated that active training 
promotes increases in R-R variance and the gain of overall spontaneous baroreflex. 
 
Medication is known to have an effect on studies of heart rate variability. Beta-
adrenergic blocking agents increase heart rate variability (Pagani et al 1986) by 
simultaneously decreasing adrenergic activity and increasing vagal activity (Singer et al 
1995). Anti-arrhythmia drugs depress the parasympathetic nervous system and decrease 
heart rate variability (Anderson 1994). 
 
2.2 Evaluation of Autonomic Function Testing 
 
2.2.1 Assessment of Autonomic Function 
 
A complete assessment of the autonomic nervous system is highly complex due to the 
number of functions it performs. Therefore there is no single test that can provide 
global assessment of autonomic function (Sandroni 1998). Testing usually involves a 
variety of procedures, which are directed towards cardiovascular autonomic function. 
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This is important since postural hypotension is often a presenting symptom (Ravits 
1997).  
 
2.2.2 Calculating Heart Rate Variability Using Electrocardiography 
 
Heart rate is measured in beats per minute. During heart rate variability assessment it is 
important that the time interval between successive heart beats is accurately measured. 
Commonly the interval between the ECG R-waves is used. Accurate wave 
identification can be difficult if there is any artefact present on the ECG trace such as 
signal interference or poor electrode contact. R-wave identification using a rolling 
correlation coefficient technique as described by Buttfield and Bolton (2005) uses an 
archetype signal to identify the QRS pulse on an ECG trace (see figure 2). This 
technique has been proven to accurately identify each heartbeat, improving the 
accuracy of the R-R time interval and is reliable even with noise interference or 
baseline shift of the ECG signal. This technique has been adapted for use with other 
physiological signals, including the automated detection of oesophageal peristaltic 
waves (Perring and Jones 2009). 
 
 
Figure 2 QRS complex, showing R-R interval 
 
The variations in heart rate during autonomic function testing are small, relative to the 
average heart rate. This means that accurate timing between heart beats is imperative to 
ensure that the differences in time between successive beats are related to physiological 
changes and not measurement inaccuracy.  
  
18 
2.2.3 Bedside Testing of Autonomic Function 
 
Autonomic function can be measured non-invasively at the bedside using relatively 
simple provocations. Ewing et al (1973) began using a battery of tests to aid in the 
interpretation of symptoms experienced by diabetics (Ravits 1997). These tests have 
evolved and can now lead to more accurate diagnosis of autonomic neuropathy. 
Because of the involvement of the sympathetic and parasympathetic nervous system 
some of the tests involved in the assessment elicit more prominent responses from one 
branch of the ANS than the other. Increased heart rate and reduced heart rate variability 
in response to deep breathing are primary indicators of parasympathetic dysfunction 
(Shields 2009). Tests such as heart rate and blood pressure responses to standing and 
handgrip are generally accepted as measures of sympathetic activity (Vinik and Erbas 
2001). Most of the autonomic tests are continuous and not dichotomous therefore one 
abnormal result is not indicative of dysfunction. Hence a battery of tests is required for 
complete assessment (Weissler 2002). In 1996 a consensus report by the Therapeutics 
and Technology Subcommittee of the American Academy of Neurology (Low 1996) 
recommended the following tests: 
 
2.2.4 Tests of Cardiovagal Function 
 Heart rate response to deep breathing (Forced breathing) 
 Valsalva ratio 
 Heart rate response to standing 
 
2.2.5 Tests of Adrenergic Function 
 Beat to beat blood pressure recording of the Valsalva manoeuvre 
 Blood pressure and heart rate response to standing 
 
2.2.6 Tests of Sudomotor Function 
 Thermoregulatory sweat test 
 Quantitative sudomotor axon reflex test 
 Sympathetic skin response 
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 Sweat imprint method 
 
The two most important measures commonly included in a battery of tests designed to 
assess autonomic function are the “gold standard” Ewing tests (Ewing et al 1985), the 
response to forced breathing and Valsalva Manoeuvre. These methods have been cited 
in many papers (Low 1996, Ravits 1997, Gerritsen et al 2001) including those 
evaluating cardiac autonomic function in diabetic populations (Ravits 1997 and Braune 
et al 1996). Vinik and Erbas (2001) state that forced breathing is a more sensitive 
measure of parasympathetic attenuation and more useful in detecting early autonomic 
dysfunction and the Valsalva manoeuvre is more useful for sequential long term 
evaluation of severe autonomic dysfunction. Vinik and Erbas (2001) described tests of 
cardiovascular reflexes such as forced breathing assessment as simple, sensitive, non-
invasive and reproducible method of assessing cardio-vagal tone. 
 
2.2.7 Heart Rate Response to Forced Breathing 
 
Wheeler and Watkins introduced the heart rate response to deep breathing (forced 
breathing) test in 1973 (Shields 2009), since then it has become a well-established 
method for assessing cardio-vagal dysfunction particularly in disorders such as diabetic 
autonomic neuropathy, uremic neuropathy and in multi system atrophy and other 
neurodegenerative disorders (Shields 2009). Heart rate response to forced breathing is a 
cyclical shortening and lengthening of the R-R interval (see figure 2) corresponding to 
the inspiratory and expiratory phases of the respiratory cycle i.e. increasing and 
decreasing heart rate (Galletly and Larsen 2001 and Sin et al 2012). The timing of the 
interaction between breathing and heart rate is governed by the respiratory sinus 
arrhythmia (RSA), which is discussed in 2.2.8 (Eckberg 1983).  
 
2.2.8 Respiratory Sinus Arrhythmia (RSA) 
 
Respiratory sinus arrhythmia is achieved through a complex mechanism of the medulla 
oblongata in association with the nucleus of the solitary tract (Khurana 1999). 
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Pulmonary stretch receptors generate afferent nerve impulses that are carried via the 
vagal nerve and interact with the medulla (Tortora 2011). The combination of 
cardioventilatory coupling and RSA forms a complex feedback system. During 
cardioventilatory coupling a heartbeat triggers inspiratory onset (Galletly and Larsen 
2001) and in RSA the breathing cycle modulates heart rate (Hirsch 1981). Although 
coupling primarily influences inspiratory timing, it also affects heart rate variability 
through determining the onset of vagal modulation by RSA. During a coupled or 
cardiac initiated breath, inspiration will occur at a fixed interval after an ECG wave. 
The relationship between the timing of the R wave and onset of inspiration is complex. 
As breathing influences HRV through modulation of RSA it is therefore expected that 
cardioventilatory coupling will contribute to the pattern of HRV (Galletly and Larsen 
1999). 
 
2.2.9 Valsalva Manoeuvre 
 
The Valsalva Manoeuvre (VM) is performed by blowing through a disposable 
mouthpiece, which is attached to an aneroid manometer. After inspiration the subject is 
asked to expire forcefully for approximately 10 seconds. The pressure attained should 
reach 30-50 mmHg (Hamilton et al 1936 and Vinik and Erbas 2001). Within the tubing 
there is a fixed leak forcing the subject to maintain an open glottis (Schuster et al 
2002). The expiration is terminated quickly and the subject resumes breathing at their 
normal resting rate. Instantaneous heart rate (R-wave pulse) is again monitored using a 
three-lead electrocardiograph. 
 
The Valsalva Manoeuvre produces a significant increase in intra-thoracic pressure, 
which in turn elicits a cardiovascular response. This response has been divided into 
four phases (Hamilton et al 1936), (see Figure 3). 
 
1) On forced expiration there is an initial acute rise in both systolic and diastolic 
blood pressure and a variable decrease in heart rate. This is due to increased 
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intra-thoracic pressure blocking venous inflow and compressing the aorta, 
forcing the blood to the periphery. 
2) During the continued forced expiration, mean blood pressure and pulse pressure 
decreases. This hypotension is a result of impaired venous return, which 
stimulates the sympathetic nervous system via baroreceptors. The blood 
pressure then quickly levels and returns to a steady state. This is followed by a 
rise in heart rate.  
3) On termination of forced expiration intra-thoracic pressure drops, relieving 
compression from the aorta. An abrupt decline in blood pressure to normal or 
below normal pressure occurs. This is followed by a small increase in heart rate. 
4) A marked increase in blood pressure and pulse pressure occurs which exceeds 
normal levels; this is due to normal cardiac output meeting a constricted 
peripheral arteriolar bed. As aortic pressure rises, baroreceptors stimulate a 
reflex bradycardia to below basal levels (Benarroch et al 1993). 
 
 
Figure 3 Heart rate during the Valsalva Manoeuvre.  
The four phases of  cardiovascular response to the Valsalva Manoeuvre Cited in Klabunde RE (2007) 
Haemodynamics of a Valsalva Maneuver//cvphysiology.com/ haemodynamics/H014.htm 
 
The Valsalva manoeuvre is often employed as a measure of vagal activity. The 
Valsalva ratio (VR) is calculated by the longest beat-to-beat R-R interval immediately 
after forced expiration divided by the shortest R-R interval during the forced 
expiration. The normal value for Valsalva ratio is >1.21 (Bannister 1988).  
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Analysis of continuous blood pressure and heart rate during the Valsalva Manoeuvre 
can give valuable information regarding the performance of the baroreflex. During the 
Valsalva Manoeuvre a rise in heart rate in response to a rise in intra-thoracic pressure 
when the blood pressure falls suggests that both efferent and afferent pathways are 
intact (Mathias and Bannister 2006). 
 
 
2.2.10 Heart Rate Response to a Change in Posture (Lying to Standing) 
 
Normally a small to moderate rise in heart rate can be measured during postural 
change, not usually exceeding 110 beats per minute. In autonomic dysfunction or 
autonomic failure a substantial fall in blood pressure without a rapid change in heart 
rate is indicative of a baroreflex abnormality. The degree of postural hypotension is 
dependent on a number of factors as described by Mathias (1995) below: 
 
 Speed of positional change 
 Time of day 
 Prolonged recumbence 
 Warm environment 
 Raising intra thoracic pressure (coughing, defecation) 
 Food and alcohol ingestion 
 Physical exertion 
 Manoeuvres and positions 
 Drugs with vasoactive properties 
 
2.2.11 Measurement of Heart Rate Response to Standing 
 
One of the most common methods of assessing and quantifying heart rate changes in 
response to postural change is the 15:30 ratio. On standing, the heart rate increases and 
the time intervals between the beats get smaller. This peaks on the fifteenth beat 
following standing. This is followed by a slowing of the heart rate and is measured on 
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the thirtieth beat. The ratio of the longest to shortest interval should be >1.04 (Mathias 
and Bannister 2006). 
 
2.2.12 Response to Handgrip 
 
Isometric exercise in the form of a sustained maximal handgrip for 10 seconds 
measured using a dynamometer (Takai grip strength meter) gives comparable results to 
those of the tilt table test (Khurana 1996). Heart rate and blood pressure changes in 
response to a sustained handgrip can also be measured over a period of 3-5 minutes at 
30% of the maximal grip (Mathias and Bannister 2006). 
 
2.2.13 Analysis of Handgrip Response 
 
Maximum heart rate measured in beats per minute (bpm) during the handgrip – 
Minimum heart rate (bpm) divided by the average heart rate (bpm) (maximum HR + 
minimum HR)/2. A ratio of 1.1 or higher indicates normal autonomic responses 
(Bannister 1988). 
 
During a sustained 3 minute isometric handgrip, muscle contraction causes an increase 
in diastolic blood pressures and heart rate. A rise of 16 mmHg or more in diastolic 
blood pressure is considered normal, less than 10mmHg is considered a marker for 
autonomic dysfunction (Appenzeller and Oribe 1997 and Vinik and Erbas 2001).   
 
 
2.2.14 Baroreflex 
 
The baroreflex is a complex system involving stretch receptors in the carotid arterial 
walls (carotid sinus) and the aorta (aortic-arch baroreceptors) (Laizzo 2009). It serves 
to maintain a constant blood pressure to the brain and other organs in the body. 
Baroreflex is important in the maintenance of short term blood pressure and moment to 
moment heart rate variability (Vallais et al 2010). Changes in mean arterial blood 
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pressure and pulse pressure trigger a reflex response. A rise in arterial blood pressure 
will initiate the parasympathetic branch of the autonomic nervous system, which will in 
turn decrease heart rate, cardiac contractility, vascular resistance, and venous return. A 
drop in pressure will activate the sympathetic branch and will increase all of the above 
systems (Tortora 2011). Baroreflex provides powerful beat-to-beat negative feedback
 
regulation of arterial blood pressure that minimizes short-term
 
fluctuations in pressure 
(Sherwood 2010). 
 
Respiration can have a significant effect on the influence of the baroreflex (Tiinanen et 
al 2008). Inspiration decreases and expiration increases
 
the cardiac vagal responses to 
baroreflex activation (Eckberg et al 1980 and Fisher et al 2010). A change in the 
breathing pattern, such as during the fixed two minute forced breathing period used in 
this study, may itself affect respiratory sinus arrhythmia,
 
independent of the arterial 
pressure changes accompanying respiration
 
(Calabrese et al 2000).  
 
2.2.15 Pupil Response to Dark (Pupillometry) 
 
The pupil regulates the amount of light transmitted into the retina; the size of the pupil 
is governed by the muscles of the iris. The smooth muscle of the iris is innervated 
entirely by the autonomic nervous system (Appenzeller and Oribe1997). The normal 
pupil is 2.5-5.5mm. It dilates and contracts in response to changes in light and with 
respiration (Appenzeller and Oribe 1997). Pupil size variability has been used to 
estimate autonomic function (Ravits 1997). Changes in pupil diameter are controlled by 
the dilator and sphincter muscles that are influenced by activity in the sympathetic and 
parasympathetic branches of the nervous system. Increased sympathetic activity 
increases the activity of the dilator muscle, prompting dilation, whereas inhibition of 
parasympathetic activity lessens constriction of the sphincter muscle, which also results 
in dilation. Thus, increases in pupillary diameter can be mediated by activity in either 
division of the autonomic nervous system (Steinhauer et al 2004). 
Sympathetic dysfunction causes contraction of the pupil and attenuation of the startle 
reflex in the dark (Lowenstein 1950). Parasympathetic dysfunction causes dilation of 
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the pupil in the dark, attenuation of the light response and pupillotonia (Bremner and 
Smith 2006). The normal pupil is continually changing in size and shows irregular 
movements. During the normal waking state the sympathetic and parasympathetic 
branches are tonically active. They also mediate reflexes depending in part on emotion 
and ambient lighting. Darkness increases sympathetic tone and produces 
pupillodilation. Increased light produces increased parasympathetic tone and therefore 
pupillo-constriction (Reeves and Svenson 2008). The size of the pupil diminishes with 
advancing age and is significantly affected by disease such as diabetes mellitus. 
 
2.2.16 Heart Rate Variability Analysis 
 
Measurement of beat to beat variation in heart rate and / or blood pressure has become 
an important method in the assessment of autonomic function (Gerritsen et al 2001). 
“Variable data such as heart rate can be described not only as a function of time, but 
as the sum of elementary oscillatory components, defined by their frequency and 
amplitude”, i.e. as a function of frequency (Malliani 1999). Heart rate variability 
analysis is usually based on time or frequency domain. 
 
2.2.17 Frequency Domain Measures of Heart Rate Variability 
 
Various spectral density analyses provide the basic information about how variance 
distributes as a function of frequency (power spectrum) (Task Force 1996). The 
methods for the calculation of power spectral density are classified as nonparametric 
e.g. the autoregressive model approach, or parametric e.g. FFT. Nonparametric 
methods have the advantage of having simple algorithms and high processing speed. 
Parametric methods are easier to process and give an accurate estimation of power 
spectral density on a small sample size, making no assumption about the data. 
The two branches of the autonomic nervous system responsible for controlling heart 
rate are active within different frequency ranges. The power spectrum is commonly 
divided into four frequency bands, these are: ultra-low frequency (ULF) (<0.003Hz); 
very low frequency (VLF) (0.003 – 0.04Hz), low frequency (LF) (0.04 – 0.15Hz) 
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reflecting baroreflex feedback loops on both sympathetic and vagal activity and high 
frequency (HF) (0.15 – 0.40Hz) where the major contributor is the effect of the 
respiratory phase on efferent vagal activity (Task Force 1996). The power of the 
different components along with the total power is expressed in absolute units (s
2
). Low 
and High frequency components can also be expressed as normalised units.  
The association between spectral peaks of HRV and the two branches of autonomic 
activity is complex, and interpretation of changes in HRV parameters is not 
straightforward. The High Frequency peak has been shown to correlate with vagal 
activity (Akselrod 1995). The Low Frequency peak has more complex relations with 
the ANS because it is affected by both the sympathetic and parasympathetic activation 
(Toledo 2003). Changes of the LF peak cannot be interpreted independently of the HF 
peak. Therefore, when associating changes in LF and HF peaks to changes in 
autonomic tone, the effect of the sympathetic and vagal activities on the indexes of 
HRV must be considered. A change in vagal activity is reflected by a parallel change in 
both the LF and HF peaks. However, a change in sympathetic activity is reflected 
mainly by a change in the LF peak (Saul 1991). Although the sympathetic and 
parasympathetic systems usually act in opposition, the two systems may work in 
unison. The LF: HF ratio is also commonly used in order to represent the controlled 
and balanced behaviour of the sympathetic and parasympathetic branches of the 
autonomic nervous system (Task Force 1996). Stimulation of the ANS resulting in an 
increase in heart rate can induce either an increase in sympathetic activity or a 
reduction in vagal activity, or both. Similarly, a decrease in heart rate is mediated by 
either sympathetic withdrawal or an increase in vagal activity, or both.  
Toledo (2003) cites changes in HRV parameters indicating a shift in sympatho-vagal 
balance toward vagal enhancement follow one of the following patterns: “1a) LF 
decreases and HF is unchanged or increased, indicates a reduction in sympathetic 
activity; vagal activity is unchanged or increased. 1b) LF is unchanged and HF 
increases, indicating a reduction in sympathetic activity and an increase in vagal 
activity. 1c) Both LF and HF increase, but their ratio is unchanged or reduced, 
indicating increased vagal activity and unchanged or reduced sympathetic activity, 
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respectively. 1d) Both LF and HF decrease and their ratio decreases, indicating 
decreased vagal and sympathetic activities, with a shift in balance toward relative 
vagal enhancement.” 
The changes in HRV parameters indicating a shift in balance toward sympathetic 
enhancement are the converse of the above changes and conform to one of the 
following patterns: “2a) HF decreases and LF increases or is unchanged, indicating a 
reduction in vagal activity and increase in sympathetic activity. 2b) LF increases and 
HF is unchanged, indicating increased sympathetic activity and unchanged vagal 
activity. 2c) Both LF and HF decrease, and their ratio is unchanged, indicating 
reduction of vagal activity without considerable change of sympathetic activity. 2d) 
Both LF and HF increase and their ratio increases, indicating increased vagal and 
sympathetic activities, with a shift in balance toward relative sympathetic 
enhancement.” 
In this research we examine the association of low-grade inflammation with subtle 
changes in HRV using a battery of autonomic tests, including metronome guided 
breathing, where the frequency peak during breathing at six breaths per minute is on 
the threshold of low and high frequency power.  
 
2.2.18 Time (temporal) Domain Measures of Heart Rate Variability 
 
“Time domain measures of heart rate variability are based on either statistical analyses 
of the heart rate or the intervals between successive normal complexes” (Task Force 
1996). The standard deviation of R-R intervals (SDNN) is the simplest variable for 
calculating the statistical time domain measure. The SDNN reflects all the cyclic 
components responsible for variability in the period of recordings. The duration of the 
recordings used to determine the SDNN should be standardised, as it depends on the 
length of the time period. The square root of the mean square differences of successive 
R-R intervals and the number of interval differences of successive R-R intervals greater 
than 50ms (Ewing et al 1985), are the most commonly used measures derived from R-
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R interval differences, and are estimates of high frequency variations of heart rate 
(Task Force 1996).  
 
2.2.19 Photoplethysmography (PPG) 
 
Photoplethysmography is a low cost optical technique that can be used in the 
assessment of cardiac intervals through the measurement of blood volume changes 
(Allen 2007). The technique involves shining a light of infrared or near infrared 
wavelength into peripheral tissue of the body and detecting light that either passes 
through or is reflected back from that tissue. Typically a probe is placed on the finger, 
toe or ear lobe. The light is directed towards the blood flow. Left ventricular systolic 
contraction leads to an arterial pressure pulse and blood flow through arteries into the 
periphery. The blood volume in the finger increases during the systolic phase, and 
decreases in the diastolic phase. The proportion of the light signal that is absorbed or 
reflected back to the sensor represents these changes in blood volume. This produces a 
slow changing signal represented by a waveform identifying the pulse wave (Figure 4), 
which can be used if the ECG signal is distorted.  
 
     
Figure 4 A typical segment of PPG signal. The rising phase is known  
as the anacrotic phase and the falling phase is known as the catacrotic phase.  
In healthy vessels a dicrotic notch can be seen. 
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Figure 5 below displays the same segment of data, with the heart rate calculated using 
the ECG signal (a) and the PPG signal (b). In this instance, the PPG was much more 
reliable for calculating beat to beat heart rate. This is due to the noise on the ECG trace 
at maximum inspiration. 
 
(a) (b)Chest wall movement (breathing)
ECG
Heart rate (calculated using ECG)
Blood pressure (gold) and PPG (purple)
Chest wall movement (breathing)
ECG
Heart rate (calculated using PPG)
Blood pressure (gold) and PPG (purple)
 
Figure 5 The same segment of heart rate variability data with the heart rate calculated using ECG 
(a) and PPG (b).  
The ECG signal is corrupted with noise at maximum inspiration leading to more consistent 
identification of heart beats using PPG. The amplitude of the ECG data (a) has been adjusted to 
display the ECG noise more clearly. 
 
The PPG signal has been used as an alternative to the Electrocardiography (ECG) 
signal to identify heart beats and for estimating heart rate  (Nakajima et al 1996). This 
has particular clinical relevance in heart rate variability studies for testing the 
autonomic nervous system, during which subtle beat to beat variations in heart rate are 
measured. Autonomic function testing is generally performed using the ECG signal to 
measure heart rate but there are situations where the ECG signal can be corrupted. 
Sources of noise on the ECG recording can be electromyography (EMG) signals of 
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nearby muscle groups, baseline drift related to respiration, mains power line 
interference and poor electrode contact (Lu et al. 2009). In cases where the ECG signal 
is poor, using PPG to measure heart rate variability can be a useful alternative. Using 
PPG to measure heart rate variability has been previously investigated during an 
extended resting period, with good correlation found between the techniques (Lu et al. 
2009). 
 
 
2.3 Distinguishing Cardiac Autonomic Neuropathy from Autonomic Imbalance 
 
Typically in cardiac autonomic neuropathy it is documented that there is a reduction or 
loss of parasympathetic autonomic control culminating in abnormal autonomic control 
over heart rate variability (HRV) in response to deep breathing. This loss or reduction 
in parasympathetic tone may not be as significant as first thought and the attenuation in 
autonomic tone may be as a result of early augmentation of sympathetic tone (Vinik 
2011). Measurement of the two branches of the autonomic nervous system is possible 
through spectral analysis (high frequency) of HRV during respiration. HRV derived 
from ECG will give an overall impression of autonomic tone but will not identify 
which branch is activated. “Respiratory analysis can be used in addition to identify 
parasympathetic activity that generates respiratory sinus arrhythmia” (Vinik et al 
2011). Figure 6 shows how the respiratory frequency on the RA spectrum is aligned 
with the respiratory activity on the heart rate spectrum representing vagal activity. 
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Figure 6 Parasympathetic and sympathetic measurement model.  
FRF, fundamental respiratory frequency; HR, heart rate; Lfa, low frequency area; Lfa/Rfa, 
sympathovagal balance; mHR, mean heart rate; RA, respiratory activity; Rfa, respiration frequency area; 
RSA, respiratory sinus arrhythmia. (Taken from: Vinik et al 2011). 
 
 
2.3.1 Neuropathy: Damage to Autonomic Nerve Fibres 
 
Depending on the nerve fibres involved, neuropathy can present in many different 
ways. Small fibre (2-6µm) dysfunction usually precedes large fibre (12 µm) neuropathy 
(Mathias and Bannister 2006) and is usually noted first in the lower limb. It also occurs 
in the autonomic nervous system. Large fibre neuropathy is typically associated with 
muscle wasting and weakness, and loss of proprioception, deep tendon reflexes and 
vibratory sense. Damage to A-Delta fibres can result in numbness; C fibre dysfunction 
can result in burning pain and increased sensation to moderate pain. Vinik (2002) lists 
three stages of neuropathy:  
 
 Functional neuropathy is reversible and without pathology. 
 Structural neuropathy involves loss of structural change and may be reversible. 
 Nerve death occurs in critical disease and is irreversible. 
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2.3.1.1 Diabetes and Nerve Damage. 
 
Diabetic neuropathy is common in the early stages of disease with small nerve fibre 
involvement. The mechanism underlying the development of neuropathy is not fully 
understood but it is known that in insulin dependent diabetes vagal denervation 
becomes increasingly common with lengthening duration of disease. Metabolic 
changes resulting in hypoxia could be important in the development of neuropathy 
Stevens (1995). Guy et al (1984) suggested an immunological mechanism underlying 
neuropathy. Neil et al (1988) suggested symptomatic neuropathy is present in 12% of 
insulin dependent diabetes. Mathias and Bannister (2006) suggest it is more likely to be 
far lower (~1%). 
 
 
2.4 Autonomic Function and Inflammation 
 
2.4.1 The Inflammatory Response and Disease 
 
The physical response to an invasion from pathogens, damaged cells, bacterium or 
irritants starts by the immune system recognising and responding to antigens on the cell 
surface which then triggers an immune cascade and depending on the site of the 
invasion will determine which part of the immune system is activated (Firestein 2011). 
An invasion will trigger a complicated process causing, macrophages, mastocytes, 
dendrites, histiocytes and Kuppfer cells to release inflammatory mediators responsible 
for inflammation and for macrophages to migrate to the site and destroy the pathogen 
or bacteria (Tortora 2011). The phagocytes will also produce cytokines, which act as 
chemical messengers activating other areas of the immune system (Sherwood 2010). 
Inflammation is a protective measure to remove the invading stimuli. The classic signs 
of acute inflammation are redness, swelling, heat, pain, and loss of function (Sherwood 
2010). The primary effect of the inflammatory response is for blood flow to increase to 
the affected area, promoting a heightened immune response. Once the inflammatory 
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response has started it continues until the source of the invasion has been removed 
(Firestein 2011).  
The inflammatory response is primarily governed by the efferent arm of the autonomic 
nervous system, which is initiated by IL-1 binding to glomus cells. Detection of injury 
and infection activates an anti-inflammatory pathway (Tracey 2007).  
 
 
Figure 7  The Cholinergic Anti-inflammatory Pathway and the Vagus Nerve (Tracey 2007) 
Wiring of the cholinergic anti-inflammatory pathway, which balances cytokine production. If the 
cytokine response is unbalanced the same mediators can cause disease. Efferent signals inhibit cytokine 
production and increase HRV. Afferent signals carried to the brain via the vagus can activate the efferent 
response (the inhibitory reflex) 
 
 
Ligands from the immune response activate toll-like receptors and lead to increased 
expression of TNF-α and interleukin-6. “Thus the nervous system is capable of 
initiating a response to tissue injury and inflammation and can per se initiate a pro 
inflammatory response” (Vinik 2012). In Vinik’s paper (2012) he describes in detail, 
autonomic control over inflammation. “The efferent arm of this inflammatory response 
is termed the cholinergic anti-inflammatory pathway”. Acetylcholine interacts with 
immune cells that express nicotinic acetylcholine receptor subunit α7, which has an 
inhibitory role. Acetylcholine activates the Janus kinase and signal transducer and 
activator of transcription pathway (JAK-STAT), affecting the inflammatory responses 
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mediated by Nuclear Factor-KappaB (NF-kB) and initiating the release of 
inflammatory cytokines as a defensive reflex (see Figure 8).  
New research by Martelli et al (2014) supports the theory that inflammation is under 
the control of an inhibitory neural reflex. However, they found in anaesthetised rats, 
sympathetic nerves mediate this reflex rather than the theory put forward by Tracey 
that the parasympathetic and sympathetic systems work together to maintain 
immunological homeostasis. Martelli et al (2014) found that vagotomy caused no 
increase in response from inflammatory mediators and concluded that the “cholinergic-
anti-inflammatory pathway and the vagus nerve do not constitute the efferent arm of 
the inflammatory reflex, when stimulated with moderate or high doses of 
lipopolysaccharide,” although they do not deny that vagal pathways can exert anti-
inflammatory actions in acute inflammation 
 
 
Figure 8 Watkins et al. (1995) discovered that sensory neurons detect the presence of inflammation 
in tissues cited in Vinik (2012). 
 
An inverse relationship between increased serum markers for inflammation such as 
tumour necrosis factor-alpha (TNFα), (Vinik 2012) C reactive protein (CRP) and 
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interleukin-6 (IL6) has been demonstrated in patients with coronary heart disease and a 
reduction in heart rate variability (Aronson et al 2001). The inflammatory process is 
complex, and research by Lampert et al (2008) suggests that inflammatory and 
autonomic processes are almost certainly linked and that the risk factors for coronary 
heart disease may be pro-inflammatory associated with autonomic dysregulation. Vinik 
(2012) states, “autonomic dysfunction and neuropathy have become the most powerful 
predictors of risk of mortality.” In disease states such as Diabetes Mellitus there has 
been a recent increase in the focus on inflammation related to the pathogenesis and 
long term effects on diabetes. Newly diagnosed diabetics (type 2) and pre-diabetics are 
associated with attenuation in parasympathetic tone and an increase in sympathetic tone 
(Lieb et al 2011). Haensel et al (2008) found that heart rate variability is inversely 
correlated with inflammatory markers in healthy individuals as well as in those with 
cardiovascular disease. Lombardi (2004) also found increased measures of 
inflammation such as CRP or IL6 have been proven as risk factors for cardiovascular 
mortality in both healthy subjects and patients with different cardiovascular diseases. 
“Growing experimental and clinical evidence indicates that inflammation plays a 
determinant role in the pathogenesis and progression of atherosclerosis: a finding that 
may well explain the strong epidemiological association between inflammation and 
cardiovascular morbidity and mortality” (Libby et al 2002). Lieb et al (2011) posit that 
inflammation and autonomic function may be intrinsically linked due to dysautonomia 
being associated with an increase in inflammatory cytokines. 
 
A host of research has been published reporting a link between inflammatory disease 
states such as rheumatoid arthritis (Pontet et al 2003), diabetes mellitus, and other 
autoimmune disorders and autonomic impairment (Toussirot et al 1993). In most 
clinical conditions characterized by an increase of inflammatory markers (for example, 
diabetes or acute coronary syndromes), a reduction in heart-rate variability parameters 
is consistently observed in high risk patients, strengthening the connection between 
inflammation and autonomic dysfunction (Lombardi 2004).  
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2.4.2 Mechanism of Inflammation and Autonomic Dysfunction 
 
The mechanisms involved in inflammation and autonomic dysfunction are still not 
fully understood. Infection and respiratory disease can all have a negative effect on 
autonomic tone.  Vassallo and Allen (1997) discuss a link between infection and 
respiratory disorders and a reduction in autonomic function. They referenced Heath et 
al (1982) citing “possible damage to fibres in the terminal bronchioles and alveoli from 
the inflammatory process accompanying pneumonia.” Corrales-Medina et al (2013) 
also discuss the detrimental effect of acute pneumonia on the cardiovascular system. 
It is still unclear the exact mechanism between acute inflammation and temporary 
dysautonomia, however it is likely to be multifactorial. Sajadieh et al (2004) give two 
possible explanations. The first is that autonomic imbalance and inflammation may 
potentiate one another. A direct relationship may exist between heart rate variability 
and inflammation. It is possible that an imbalance of the autonomic nervous system in 
favour of sympathetic activity could influence and increase the inflammatory response. 
Inflammation may in turn influence autonomic tone. “Interleukin-6 has been found in 
the brain and may influence autonomic balance by affecting the hypothalamic-pituitary 
adrenal axis” (Juttler et al 2002). The second explanation could be that reduced heart-
rate variability and inflammation are an additional complication of atherosclerosis. 
Even though the majority of evidence supports the effect of reduced heart-rate 
variability on cardiovascular mortality and morbidity, a direct aetiological relationship 
has not been proven. The mechanisms of activation of inflammation in diabetes 
mellitus, hypertension, obesity, coronary artery disease, mental depression, and other 
states are not clear. Sajadieh et al (2004 page 369) suggests, “Sympathetic over-activity 
or dominance could be a mechanism. Hypertriglyceridaemia; a metabolic consequence 
of sympathetic activity, is seen in many of these situations and is inversely related to 
heart-rate variability. Autonomic imbalance could be secondary to other conditions 
like congestive heart failure, acute myocardial infarction, and stress, as well as a 
primary condition.” Recent studies support the notion that autonomic reflexes may 
control the inflammatory response (Tracey 2009).  
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Tracey (2009) and Vinik (2012) correlate vagal nerve activity and inflammatory 
disease states, suggesting a reflex arc may be involved in inflammation. Vinik (2012) 
implicates the “hypothalamus as the conductor of the endocrine orchestra” and 
estimates that “the earliest detectable changes in diabetes are those of a change in 
HRV.” It may therefore be appropriate to follow-up or screen patients with long-term 
chronic inflammatory conditions (such as cardiovascular disease or diabetes) to assess 
their autonomic status and identify those at increased risk of sudden death associated 
with dysautonomia. Vinik and Erbas (2001) and Vinik (2012) suggest patients with 
type 1 diabetes should be tested for autonomic function after diagnosis and 5 yearly 
thereafter; patients with type 2 diabetes should be tested at diagnosis and yearly 
thereafter. 
 
2.5 Anti-Inflammatory Response  
 
There is a corresponding anti-inflammatory response to every inflammatory process. 
Anti-inflammatory mechanisms are also stimulated in the same way as an 
inflammatory response to host invasion; the anti-inflammatory process exists to 
attenuate inflammation. One of the primary anti-inflammatory interleukins is 
interleukin 10 (IL-10) (De Vries 1995), which is produced by T lymphocytes, some B 
lymphocytes, monocytes and mastocytes resulting in inhibition of t lymphocyte 
proliferation, prevention of macrophage activation and protection against endotoxins. 
IL-10 also reduces the production of inflammatory cytokines by Th1 lymphocytes and 
promotes Th2-type immune response, which is essential in the fight against 
inflammation (Garcia-Moll 2005 page 616). De Vries (1995 page 537) suggests IL-10 
has great potential therapeutic utility in the treatment of diseases, such as chronic 
inflammation, autoimmune diseases; transplant rejection, graft-versus-host disease and 
sepsis. 
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2.6 Influenza Vaccination 
 
In this project we are looking at the effects on autonomic tone resulting from three 
types of low-level inflammatory provocations. The first inflammatory provocation 
investigated for the effects on autonomic tone was the routine influenza vaccination. 
 
2.6.1 The Influenza Virus 
 
Influenza is a highly contagious viral infection resulting in acute respiratory disease 
caused by a ribose nucleic acid (RNA) virus of the orthomyxoviridae family (Cox and 
Subbarao 2000). Influenza typically occurs in winter months in temperate regions and 
is one of the most severe illnesses of the winter season (Centre for Disease Control and 
Prevention 2006). It affects all age groups and is spread in respiratory droplets from 
coughing and sneezing.  
According to the World Health Organisation (2014) annual influenza epidemics affect 
between 5-10 per cent of the adult population. Each year there are between 3-5 million 
cases of severe illness and between 250,000 and 500,000 deaths around the world due 
to influenza or associated complications. In healthy people the disease is usually self-
limiting and usually resolves in 7-10 days. Complications can arise in people with 
underlying cardiopulmonary and other chronic disease, in children less than 2 years, 
pregnant women and all elderly people (Whitley and Monto 2006). 
There are three strains of influenza viruses, type A, B and C. Both strain A and B are 
known to cause illnesses of varying severity in humans (Cox and Subbarao 2000). 
Strain A is likely to be more virulent and is known to have caused all of the influenza 
pandemics to date. The influenza virus is subject to rapid mutation. A mutation in the 
influenza viral strain (antigenic drift) occurs approximately every 10 - 50 years (Potter 
2001). The virus mutates significantly enough to become resistant to known vaccine 
combinations. When a marked change in the influenza virus occurs a pandemic 
inevitably follows.  
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2.6.2 Influenza Vaccination and Chronic Disease 
 
Vaccination programmes and rapid response to potential threats have significantly 
limited the spread of influenza.. According to the Health Protection Agency the number 
of people in the UK vaccinated in 2011/12 increased to 45% compared to the previous 
year. Vaccination can reduce hospitalisation and deaths among adult diabetics by 70% 
(Looijmans-Van Den Akker 2006). According to The Centre for Disease Control and 
Prevention 2006 (CDC), diabetics are three times more likely to die of flu 
complications than people without diabetes and six times more likely to be 
hospitalised. It could be argued that reduced autonomic tone in these already 
compromised patient groups is likely to be further reduced by the inflammatory 
response to the influenza virus. This will consequently place them at far greater risk 
from morbidity and mortality (diabetes.org.uk 2012) and is presumably the reason why 
so many patients are hospitalised as a result. It is therefore vital that annual vaccination 
is encouraged to all those who fall into the “at-risk” groups. 
  
 
2.6.3 The Influenza Vaccine 
 
The Occupational Therapy Department at Poole Hospital NHS Foundation Trust 
administers approximately 1500 influenza vaccines per year within the trust. The aim is 
to vaccinate all front line staff and any staff with pre-existing medical conditions such 
as diabetes or heart disease, which would put them at risk if they contracted influenza. 
The vaccination period in the UK runs from mid-October through to December.  
The World Health Organisation (WHO) makes a decision in February of each year on 
the influenza strains to be included in the following winter’s vaccination for the 
Northern Hemisphere. The prototype viruses (currently 3) originally isolated from 
humans suffering with influenza are propagated in hens eggs to produce larger amounts 
of the virus. The liquid containing the virus is extracted and the viral RNA is 
inactivated and is unable to replicate. The virus is clarified and separated from the 
membrane and the viral core by ultra-centrifugation. The 3 components are combined 
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in the correct proportion and the mixture is filled into syringes of 0.5ml. A syringe 
contains one dose of trivalent vaccine.  
 
Both the vaccine documentation from Solvay Biologicals, who supply the vaccine to 
the hospital and the information from the World Health Organisation list the 
composition of the vaccine for the 2008/09 and 2009/10 flu season. 
 
Influvac
 ® 
Solvay Biologicals 2008/2009 vaccine 
The recommendation from the world health organisation for the composition of 
influenza virus vaccines for use in the 2008/09 season in the northern hemisphere to 
include: 
 Viral strain A / Brisbane/59/2007 (H1N1) like virus 
 Viral strain A / Brisbane/10/2007 (H3N2) like virus 
 Viral strain B / Florida/4/2006 like virus 
 
 
Influvac Solvay Biologicals 2009/2010 vaccine 
The recommendation from the world health organisation for the composition of 
influenza virus vaccines for use in the 2008/09 season in the northern hemisphere to 
include: 
 Viral strain A / Brisbane/59/2007 (H1N1) like virus 
 Viral strain A / Brisbane/10/2007 (H3N2) like virus 
 Viral strain B / Brisbane/60/2008 like virus 
 
2.6.4 Side Effects from the Influenza Vaccine 
 
According to the medicines information product leaflet and the medicines information 
department at Solvay Biologicals who produce the Influvac vaccine which was used in 
this research project, 95% of people vaccinated experience none or very mild side 
effects. The most frequent side effect of vaccination is soreness at the injection site, 
which is intramuscular in the upper arm lasting less than two days.  
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Systemic symptoms can arise after vaccination as part of the body’s immune reaction 
when the body produces interferon. The most frequent symptom would be headache. 
Occasionally fever, malaise, myalgia and other systemic symptoms can occur after the 
vaccination. These reactions are usually mild and begin 6-12 hours post vaccination 
and can persist for 1-2 days. 
 
 
2.6.5 The Immune Response to the Influenza Vaccine 
 
Vaccination with an influenza vaccine such as Influvac stimulates B lymphocytes to 
produce antibodies without causing Influenza. When the body is exposed to the 
antigens in the vaccine the immune response is the same as occurs in an influenza 
infection. These antibodies are specific to the antigens in the vaccine and protective 
immunity occurs within two to three weeks post vaccination and lasts up to twelve 
months. The vaccine is effective in protecting against disease in approximately 70-90% 
of people vaccinated (Stohr 2003). It is well known that inflammatory markers such as 
the liver derived plasma proteins increase in concentration in response to an event such 
as infection (Steele 1994 and Gabay and Kushner 1999). Acute phase reactants C-
reactive protein (CRP) and serum amyloid A protein (SAA) are elevated in the 
common cold and influenza (Whicher 1985 and Miwata et al 1993). Carty et al (2006) 
found that the influenza vaccination resulted in a small but measureable acute phase 
response in men with and without carotid artery disease. However, little information is 
available on the response of these inflammatory markers to influenza vaccination. 
Research by Tsai et al (2005) and Lieb et al (2001) showed transient changes in 
inflammatory blood markers specifically C-reactive protein and plasma lipid 
concentrations at day one and day three after vaccination. These finding suggest that an 
inflammatory response is occurring at a chemical level, which is most significant for 
IL-6 and CRP on days one to three. Posthouwer et al (2004) also found a similar 
response after vaccination with values peaking at two days post vaccination. Tsai et al 
(2005, page 236) quote in their conclusion that “Our findings indicate that influenza 
vaccination, like yellow fever vaccination; can be used as a model to study the 
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response of mild stimulation of the inflammatory system.” We decided to use the 
influenza vaccination as a mild but measureable inflammatory provocation in an 
attempt to establish whether heart rate variability changes as a measure of autonomic 
tone pre and post vaccination. 
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3 Chapter 3: Methods (Influenza Study) 
Chapter 3: Methods (Influenza Study) 
 
3.1 Rationale for Methods Used in this Study 
 
Within the Medical Physics Department, assessment of patient autonomic function is 
routinely performed. A battery of tests including forced breathing and the Valsalva 
manoeuvre is carried out. From clinical experience of autonomic function testing, the 
provocation that consistently produces the most pronounced and reliable measure of 
heart rate response is the forced breathing exercise. The Valsalva manoeuvre produces 
a more dramatic heart rate response when present, but patient capability (particularly in 
the elderly) often determines how successful it is as a measure of autonomic function 
(Mathias and Bannister 2006). Many studies have used deep breathing (forced 
breathing) and / or the Valsalva Manoeuvre as the “gold standard tests” for autonomic 
function (Ryder and Hardisty 1990) (Low 1996). We decided, based on results from 
previous studies and clinical experience that 2 minutes of metronomic guided breathing 
would be the principal provocation used in this study. 
 
Monitoring of chest wall motion during forced breathing as a means of determining the 
degree of co-operation with the procedure in less compliant patients has been adopted 
in the routine assessment technique. We have developed a technique for short-term 
measurement of heart rate (HR) and chest plethysmography with metronome-guided 
breathing for assessment of cardio-ventilatory coupling (Perring and Jones, 2003). In 
previous research, we established that a breathing rate of 6 breaths per minute (0.1 Hz) 
gave optimum amplitude of heart rate variation and optimum correlation between heart 
rate and chest wall movement (Perring and Jones 2003). We have incorporated the six 
breaths per minute breathing rate over two minutes into the routine clinical assessment. 
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3.1.1 Developments to the Current Measurement Technique 
 
Blood pressure (BP) also displays rhythmical and non-rhythmical variations from beat 
to beat. It appears that HR and BP variations at approximately 0.1Hz may reflect 
sympathetic vascular and cardiac autonomic modulation and may be used to obtain a 
measure of Baroreflex Sensitivity (Parati et al, 1995). We now have the capability of 
non-invasive beat-to-beat measurement of blood pressure in the finger using a 
Portapres system. 
 
Photoplethysmography (PPG) has been suggested as a potential measure of autonomic 
function, both as an alternative measure of HR and by assessment of signal amplitude 
(Nitzan et al, 1998). Pulse transit time (PTT) is the time delay between a proximal 
pulse trigger (ECG R-Wave) and a peripheral trigger (characteristic shape in the PPG 
signal). PTT has been suggested as an alternative to measurement of beat-to-beat 
systolic blood pressure in short-term studies (Chiu et al 1991 and Payne et al 2006). 
Davies et al (1999) specifically use metronome guided breathing rate of 6 breaths per 
minute. Other groups have suggested forced breathing at higher rates to avoid a 
breathing component to the HR and BP variability at 0.1 Hz (Fredericks et al, 2000). 
We have implemented both 6 breaths and 10 breaths per minute for a two-minute 
period. 
 
Detailing the relationship between PPG signal, PTT and BP in healthy participants and 
patients with autonomic neuropathy, which has been documented by established 
techniques, is difficult, particularly the derivation of timing information in a relatively 
slow changing signal like the PPG signal. We have applied the technique of rolling 
correlation coefficient (Buttfield and Bolton, 2005) to accurate timing of a variety of 
physiological signals including ECG and oesophageal manometry for timing 
oesophageal peristalsis (Perring and Jones 2009). We have used this technique to 
establish the effectiveness of PPG measurement for HR variability studies. This is 
continuing work that will be concluded by another researcher within the department. 
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3.1.2 Evaluating the Measurement Techniques by Examining an Inflammatory 
Response to the Influenza Vaccine 
 
Researchers have shown a temporary fall in cardiovascular autonomic responses 
following pneumonia using simple autonomic reflex testing and posit an inflammatory 
link to autonomic failure (Vassallo and Allen 1997). Corrales-Medina et al (2012) 
reported a high incidence of cardiac complications during the course of community 
acquired pneumonia and have shown these events are independently associated with 
increased mortality. It is also known that HRV is reduced in patients during ventilator 
weaning (Shen et al 2003). Pontet et al (2003) established reduced HRV in patients 
with rheumatoid arthritis, and also in separate research into sepsis. Von Kanel et al 
(2008) identified a link between decreased HRV and atheroma. Lieb et al (2011) found 
reduced HRV before the advent of inflammation in diabetes. Lee et al (2006) found 
changes in autonomic tone in gastro-oesophageal reflux.  
This study looks at the short-term effects on autonomic function of an inflammatory 
provocation. The cohort we examined were normal healthy participants having a 
routine influenza vaccination. Work has been published on the variation of 
inflammatory markers following the influenza vaccination, but initial research suggests 
that no one has assessed autonomic responsiveness variation in a similar fashion 
(Posthouwera et al 2004). Using the measurement techniques discussed above (PPG, 
PTT and BP) we assessed the mild and short term effects of the inflammation from the 
influenza vaccine on autonomic tone.  
 
3.2 Study Design 
 
A descriptive, cross sectional, pre-test / post-test design was used to assess the effect of 
the Influenza Vaccination on heart rate variability (autonomic function) in 71 healthy 
volunteer’s pre and post vaccination. 
 This study assessed the degree of loss of autonomic control over heart rate variability 
in healthy volunteers and whether the novel measurement regime described, proved to 
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be a more sensitive measure of the degree of attenuation of autonomic control than the 
methods presently used. 
 
3.3 Recruitment 
 
Seventy one healthy participants, age 18 to 80 years, who elected to have the annual 
vaccination for influenza, which is routinely offered and administered by the 
Occupational Health department within Poole Hospital, were recruited. Participants 
were selected on the basis that they were having the vaccination because of their 
occupation, rather than for health reasons. Therefore all of the participants were 
hospital employees or voluntary workers within the hospital. We assessed their 
autonomic function between one and five days prior to the vaccination and between 
two and five days after the vaccination. 
 
Initial application to Dorset REC was for 35 volunteers in the study. Recruitment was 
extremely successful and it was decided to further increase the number of participants. 
The protocol was subject to a successful application for a substantial amendment to 
increase numbers to 50 volunteers. Analysis of  data suggested in some cases that there 
were differences in autonomic tone pre and post vaccination. Based on results from a 
post vaccination questionnaire we subdivided the total cohort into two symptomatic 
groups and have found that we needed to increase the data to give more power to the 
statistics. We reapplied to the Ethics committee to further increase the participant 
numbers to 100. We continued recruitment in October – December 2009 during the 
Influenza vaccination period to further improve the statistics. 
 
We recruited participants using either a direct approach or by placement of posters 
around the hospital. We talked with the Poole Occupational Health Department and 
established that they were happy to help with the recruitment process by displaying one 
of our posters in the department. When the Occupational Health Department advertised 
the availability of the Flu vaccine we asked them to display the recruitment poster. 
Each year the occupational health department place posters around the hospital offering 
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the flu vaccine and advertises the list of session dates in the hospital magazine. We 
submitted our recruitment poster to the hospital magazine along with an invitation to 
participate to coincide with the announcement of the availability of the vaccine. We 
established that the occupational health department expected to vaccinate 
approximately one thousand people in a two month period leading up to the “flu 
season.”  
There were a large number of people potentially available to take part in our study. 
Members of staff were encouraged to sign up for the vaccination sessions in advance. 
We asked the Occupational Health Team to send out an “Invitation to take part in the 
research” and the participant information sheet. This meant that confidentiality of the 
people signing up for the vaccination was maintained. They were left to decide whether 
they wanted to make contact with our department.  
 
We also approached members of staff known to us in other departments around the 
hospital including the many elderly volunteer staff. They were left with the information 
sheet about the research project and it was up to them to contact us if they wanted to 
participate. 
 
3.3.1 Inclusion Criterion: 
 
1) Healthy participants between the ages of 18 – 80 years. 
2 All participants filled out a health questionnaire and did not suffer from any of 
the listed inflammatory conditions. 
3) Members of staff / voluntary staff offered the flu vaccine at Poole hospital. 
4) Other participants eligible to take part such as the healthy partners of people 
visiting the hospital. 
5) People able to fully consent to taking part. 
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3.3.2 Exclusion Criteria 
 
A health questionnaire was given to each participant. Anyone who had any of the 
following pre-existing conditions or who were unable to fully consent were excluded:  
 
 Diabetes Mellitus  
 Degenerative disease, such as: Alzheimer’s disease 
 Heart disease 
 Arthritis 
 Gastrointestinal disease (see section 7.2.2). 
 Respiratory disease 
 Allergies, hives or anaphylaxis 
 Lupus 
 Multiple Sclerosis 
 Tuberculosis 
 Chronic Cholecystitis 
 Chronic Prostatitis 
 Glomerulonephritis 
 Pelvic Inflammatory Disease 
 Vasculitis (phlebitis, arteritis) 
 Vascular disease 
 Any patients taking the following medications: 
1. Alpha Blockers 
2. Beta Blockers 
3. ACE Inhibitors 
4. Calcium Channel Blockers 
5. Tri-Cyclic Antidepressants 
6. Opiates 
7. Anticholinergics 
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3.4 Instrumentation 
 
3.4.1 Procomp Infiniti Biosignal Recorder. 
 
A ProComp Infiniti (Thought Technology Ltd) was used to collect ECG, PPG and 
chest plethysmography signals. This is a microprocessor controlled encoder unit with 8 
recording channels, which receives signals from the sensors. These signals are then 
digitised, encoded and transmitted to a TT-USB interface unit. A fibre optic cable is 
used for transmission of the signals from the ProComp Infiniti unit to the TT-USB 
interface, which converts the data from optical form to USB format, thereby electrically 
isolating the subject from the electrical mains supply. 
 
3.4.1.1 ECG 
 
Patients were connected to a 3 lead ECG. The ECG lead was connected to a ProComp 
Infiniti a multiple biosignal detector. The ECG pulse was sampled at 2048Hz. Heart 
rate was captured in real time using a thresholding technique using the peak of the QRS 
complex as the trigger, a schematic of instrumentation is shown in Figure 10. The data 
is displayed in real time (see Figure 9). Recording software was written in Microsoft 
Visual Basic V6.0 (Microsoft Corp, Redmond, Washington).  
 
3.4.1.2 PPG 
 
A ProComp Infiniti PPG sensor was positioned and secured against the palmar surface 
of the left index finger. PPG was sampled at intervals of 2048Hz. Blood volume pulse 
or PPG is a relative measure, it did not have a standard unit. 
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3.4.1.3 Chest Plethysmography 
 
Chest wall movement was detected using a ProComp Infiniti respiration-flex/pro 
sensor. The sensor consists mainly of a long strap that was stretched around the 
patient’s chest. The sensor was placed during a full expiration and quickly fastened 
with just a small amount of tension. The sensor should not be loose when breathing out 
completely. The sensor was placed on top of clothing, if not too bulky. The sensor is 
sensitive to stretch during expansion and contraction of the ribcage during breathing; it 
is however, not a strain gauge.  
 
The respiration signal is a relative measure of chest expansion. The ProComp Infiniti 
does not generate standard units of measure for respiration. From the raw signal 
waveform, the Infiniti software is able to calculate the respiration rate and relative 
breath amplitude. Chest movement voltages were sampled at intervals of 256Hz and 
the data recorded to disk.  
 
The breathing channel was displayed on screen in real time as a graphical display with 
an overwrite period of 20 seconds (see Figure 9). The breathing cycles were monitored 
to ensure that the amplitude of the breaths were approximately the same for each cycle. 
The rate and depth of breathing were carefully monitored since the maximum change in 
heart rate has been demonstrated at frequencies between 5.5 and 7.0 cycles (breaths) 
per minute and at a maximum voluntary depth (Freedman 1993). 
 
Expiration to inspiration ratio (E: I ratio) was determined by dividing the mean value 
for longest R-R interval during each expiration, by the mean value for shortest R-R 
interval during each inspiration. Normal limits proposed are equal to or greater than a 
ratio of 1.1 (Bannister 1988). This method is dependent on heart rate variability in beats 
per minute and can be used regardless of resting heart rate.  
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3.4.2 Portapres Beat to Beat Blood Pressure Measurement. 
 
The Portapres® is the ambulatory Finapres technology solution from FMS, (Finapres 
Medical Systems). The Portapres model-2® (TNO-TPD Biomedical Instrumentation 
2001) offers the ability to perform continuous non-invasive ambulatory finger blood 
pressure monitoring via equipment incorporating an air pressure control valve, a 
pressure transducer, an infrared cuff, and a photo-diode amplifier and is carried at the 
wrist. The data can be directly transferred from the flash card via a serial port to a PC, 
onto which the beat-to-beat analyses can be run (Figure 11). 
 
Non-invasive blood pressure in the finger is measured using the clamp volume method, 
which was originally described by Penaz (1973). A finger cuff is placed around a 
finger, which incorporates an inflatable bladder, an infrared light emitting diode (LED) 
and an infrared photodiode. The desired arterial diameter is the unloaded diameter, the 
point where the pressure inside the artery equals the pressure in the finger cuff (zero 
transmural pressure). This can be calculated by applying periods of constant cuff 
pressure and observing the PPG signals during this time. The arterial diameter is 
measured using PPG, the pressure required to keep the diameter constant is then 
recorded. This pressure mirrors the intravascular pressure.   
 
During measurement periods, the unloaded diameter is unlikely to remain constant. The 
Portapres uses an algorithm called Physiocal (Wesseling et al 1995) to assess the 
amplitude and shape of the PPG signal during periods of constant cuff pressure to 
ensure that the correct unloaded diameter is being used. A calibration is performed at 
frequent intervals (after every 10
th
 heartbeat) at the start of a measurement period and 
as the measurements stabilise, this interval increases. 
 
To correct for any hydrostatic differential from finger placement and therefore attempt 
to approximate the systemic blood pressure, a height correction unit is used. This 
consists of a liquid filled tube with one end, placed at heart level, containing a very 
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compliant plastic bag and the other end connected to a pressure transducer, placed on 
the finger (TNO TPD Biomedical Instrumentation). 
 
The systolic and diastolic blood pressure data recorded using the Portapres was 
transmitted to the laptop via a RS232 serial comport.  
 
An automated blood pressure monitor (Microlife BP 3AC1) was used at the end of each 
procedure to measure systemic blood pressure. 
 
Figure 9 shows a typical recording in real time displaying the chest plethysmography 
signal, raw ECG signal, beat to beat heart rate calculated using a thresholding 
technique identifying the peak of the QRS complex, beat to beat finger blood pressure 
and Photoplethysmography signal. After recalculation of the heart rate using the 
technique described in section 3.9 the data are processed and compared with age 
matched normal values.  
 
 
Figure 9 Typical autonomic recording showing chest plethysmography signal, ECG, beat to beat heart 
rate, finger blood pressure, and PPG blood volume. 
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3.4.3 Schematic for Instrumentation 
 
Figure 10 Schematic for Instrumentation showing connections between the patient and the equipment 
 
3.4.4 Parameters Measured 
 
The parameters measured included ECG, PPG, beat-to-beat BP, chest plethysmography 
and pupil reaction to light and dark. ECG, PPG, BP and chest plethysmography were 
measured by simple non-invasive sensors placed on the chest and on the fingers. The 
recording devices were commercial units, which are CE marked and connected to the 
recording PC using opto-isolated connections. Pupil reaction to light and dark was 
assessed using a pair of goggles incorporating two infrared cameras.  
 
Time taken for each visit was 20 minutes. All measurements were completely non-
invasive. 
 
Autonomic function testing was performed on healthy participants within one to five 
days prior to and between two and five days following the influenza vaccination. The 
optimum timing was two days post vaccination. This is mainly due to the evidence 
emerging from a number of studies which suggest the optimal time for assessment of 
mild inflammation when looking at C-reactive protein responses is most significant at 
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two days post vaccination (Posthouwera 2004). Other research suggests testing for CRP 
inflammatory markers at one and three days post vaccination (Tsai 2005). The 
volunteer recorded the degree of adverse reaction to vaccination on a “Vaccine 
Evaluation Centre Questionnaire” (Scheifele 1990), see appendix 16.2.  
 
3.4.5 Preparations required for the investigation:  
 
 No food for three hours prior to testing.  
 No caffeine or nicotine for at least three hours prior to testing. 
 The test was performed (where possible) at the same time of day, thus 
avoiding diurnal variation. 
 A health questionnaire was issued to exclude anyone with any of the listed 
diseases. 
 
Informed consent was obtained. Volunteers were given the opportunity to ask 
questions. 
 
The volunteer’s date of birth and the date of the initial visit and the date of the 
vaccination were written on the consent form. Each volunteer was issued with a 
sequential “V” number, which made him or her anonymous on the computer. The only 
piece of personal data linking them to the “V” number was their date of birth. 
 
A record of the gender of each volunteer was assigned to the “V” number for the 
purposes of sorting the data for statistical analysis. 
 
 The clinical room used during the study was maintained using climate control at an 
ambient temperature of between 22 and 23 degrees Celsius as suggested by Low and 
Pfeiffer (1997). Lighting was set at a normal level; variable control over this was not 
possible. Adequate time was given to those volunteers with cold hands and a poor PPG 
and BP signal due to vasoconstriction of the peripheral vasculature. 
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The room was quiet and subjects were familiarised with the equipment and the 
environment (Bloomfield 2001). Subjects were asked to read through the health 
questionnaire and declare that they were not affected by any of the diseases listed. They 
were given the opportunity to ask any questions about the test and then asked to sign a 
consent form. If participants answered yes to any of the questions on the questionnaire 
they did not have to disclose any health information and could declare themselves 
exempt from the research project while maintaining their privacy.  
 
 
Figure 11. Equipment used in this research 
 
 
3.5 Autonomic Assessment 
 
Volunteers were positioned on the examination couch in a supine position and 
connected to the equipment (see Figure 11c).  
 
 A rest period of at least 2 minutes was given to eliminate the effects of anxiety 
or anticipation (white coat syndrome) (Owens et al 1999).  
 
 2 cycles of slow deep breathing were performed to establish the correct 
breathing pattern and technique at 6 breaths per minute. 
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 The Valsalva Manoeuvre was performed making sure an airway pressure of 
approximately 30mmHg was obtained. This was held for 8 -10 seconds. 
 
 A maximal hand grip was performed using a grip strength meter. The hand grip 
was sustained for 10 seconds. Grip strength (kg) was recorded 
 
 An on-screen digital timer was used to pace the breathing cycle. The subject 
was required to inhale for a count of 5 seconds and exhale for a count of 5 
seconds. The breathing rate thus obtained corresponded to 6 breaths per minute. 
This was performed for two minutes. 
 
 A breathing pattern corresponding to 10 breaths per minute for two minutes was 
also paced using a digital metronome. The subject was required to inhale for a 
count of 3 seconds and exhale for a count of 3 seconds. This breathing rate is 
more similar to normal spontaneous breathing and generally easier to maintain. 
 
 The breathing exercises were always performed in the same order for consistency.  
 
An automated brachial blood pressure was taken using a digital blood pressure device. 
The left arm was always used for this unless there was a clinical reason for not 
performing it for example in the case of mastectomy. In this instance the opposite arm 
was used. 
 
At the end of this period the data collection was complete. Subjects were asked to 
remain still for a short period of time to allow them to overcome any ill effects of the 
breathing exercises.  
The final measurement was dynamic pupillometry. The volunteer was asked to wear 
Medical Physics designed and built infrared goggles. Images were taken of the right 
eye while the volunteer was sat in a completely darkened room. After 30 seconds in the 
dark a light was flashed into the left eye and the response of the Iris in the right eye was 
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recorded, after another 30 seconds in the dark another flash occurred in the same eye. 
The response was again recorded.  
 
3.6 Statistical Analysis 
 
Data were analysed using Kwikstat Winks SAS 4.62 statistical analysis software 
(Texasoft 1991-2001).Parametric and non-parametric statistical analysis was performed 
as appropriate. The parametric statistical analysis are known as parametric because they 
require estimation of the parameters that define the underlying distribution of the data 
which for a paired t-test is the standard deviation and the mean (Whitley and Ball 
2002). A paired t-test is an example of a repeated measures design used for testing 
differences by comparing the means for two variables for a single group, where each 
individual in a group is their own control giving a smaller error term and larger t-value. 
Repeated measure t tests often benefit from needing fewer subjects to give statistical 
power however they give n-1 degrees of freedom, meaning a higher t-value is needed 
for significance to be reached.  
The non-parametric tests make no assumption about the data. Non parametric statistical 
comparison used in the study was the Wilcoxon signed rank test, which was used for 
comparison of two independent groups. Non parametric tests are often used to analyse 
ordered categorical data. Analysis may lack statistical power compared with parametric 
analysis and are generally geared towards testing a hypothesis rather than estimation of 
effect.  
For correlation analysis of data a Pearson’s product moment correlation coefficient was 
used for parametric data and a Spearman’s rank correlation coefficient was used for 
non-parametric data. Correlation is a measure of the statistical strength of linear 
association between two variables. However, one disadvantage with correlation 
analysis is that it gives no indication of causality. 
Analysis of variance (ANOVA) was used to analyse the difference in mean values over 
successive visits. ANOVA can test hypotheses that a t-test cannot by examining what 
the variation is within groups then examines how the variation translates into variation 
between groups taking into account the number of degrees of freedom (Moore and 
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McCabe 2003). ANOVA assumes the data is normally distributed and that the standard 
deviation in each data set is similar. A limitation of using ANOVA is that it will only 
determine that there is a difference between at least one group from at least one other. 
It will not identify which group or how many groups differ statistically. In this instance 
multivariate analysis of variance (MANOVA) would be appropriate to measure 
multiple dependant variables simultaneously which will reduce the incidence of 
statistical errors from repeated testing where the ANOVA allows for only one variable. 
Fishers Exact was used to determine whether there was a significant difference between 
the two vaccination periods with respect to the gender of participants by measuring the 
association between the variables. Fishers exact can be used for small sample sizes in 
place of a chi-squared test. 
Study results are displayed in tables with mean, standard deviation, T values and P 
values. Correlational data is represented as scatter plots with line of best fit, tabular 
results of correlation data give p and r values, for the significant results the slope is also 
given. Statistically significant results are displayed as either histograms including 
standard error bars or box and whiskers plots which show a summary of a large amount 
of data by displaying  minimum, first quartile, median, third quartile and maximum 
values. The exact values and distribution of results are not retained in a boxplot; 
however it is a visually effective way of presenting data allowing a graphical display of 
distribution of results and provides an indication of the degree of asymmetry in the 
distribution of data. 
 
3.7 Ethical Considerations 
 
Approval for the study protocol was granted by the East Dorset Local Research and 
Ethics Committee and Poole Hospital Trust (see appendix 16.4.1) 
 
3.8 Data Security  
 
Unique study identification was established at the time of taking consent. All pro-forma 
data and study information stored on computer were identified only by this number. No 
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further patient-specific information was held in connection with this project. Consent 
forms were kept securely in a locked filing cabinet. Pro-forma data and automated 
analysis data were held on the secure hospital shared network. All recorded data were 
held in accordance with the Data protection act of 1998 and in conjunction with the 
hospital policy on data security. 
 
3.9 Heart Rate Analysis 
 
Raw ECG, PPG and chest wall motion data was captured using the ProComp Infiniti 
hardware and capture and analysis software written in Visual basic version 6. 
Raw ECG data was processed and instantaneous heart rate recalculated using the visual 
basic Autonomic analysis software after the rolling correlation technique of Buttfield 
and Bolton (2005) was applied (See Figure 12). 
 
 
3.9.1 Rolling Correlation Coefficient Technique 
 
A suitable archetypal QRS complex within the ECG signal was identified as typical 
and used as a template to define the shape of the QRS complex for each volunteer. The 
most obvious segment of data to select as the archetype signal is the R-wave. A single 
point is selected within the signal, and then the data 0.2 seconds prior to and following 
the mouse click is used as the archetype. QRS pulses in the data were identified in the 
raw ECG data by a strong positive correlation with the archetypal ECG template. 
Precise timing of the ECG complex was defined by a maximum of the correlation 
coefficient. Nearly all heart rate artefacts (erroneous data) were removed from the 
recording trace in this way. The beat to beat (b-b) instantaneous heart rate was 
calculated for each adjacent heartbeat from the time of onset of each QRS complex 
identified using Buttfield and Bolton technique, which is shown in Figure 12. This 
method was not used in real-time during acquisition, but implemented in software and 
used to process the data prior to analysis. During data acquisition, a threshold 
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measurement is used to identify R-waves, with a heartbeat being identified when the 
ECG signal exceeds a threshold value. 
 
 
Figure 12. Principle of Buttfield and Bolton technique 
 
For automated analysis of segments of the heart rate data train e.g. frequency analysis 
and fractal dimension analysis, a cubic spline interpolation was used to re-sample the 
instantaneous heart rate to a regular sample interval of 8 samples per second. The chest 
wall movement breathing data was also re-sampled to match the regularised heart rate 
data. Any additional artefactual instantaneous heart rate data due to ECG noise or 
ectopic beats were manually removed and substituted with interpolated heart rate data 
using a cubic spline interpolation technique.  
 
Fast Fourier Transform (FFT) is a computational calculation using an efficient 
algorithm for time frequency analysis to determine the frequency of a discreet signal. 
Analysis was performed both in the temporal domain, and in the frequency domain 
following Fast Fourier Transform. 
 
Raw ECG 
Archetypal QRS Template 
Moved through data 
stream 
Resulting correlation curve 
Precise timing of QRS pulses obtained 
from maxima of correlation curve 
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3.9.2 Fractal Dimension Analysis 
 
The analysis of heart rate variability is a well-established technique for the 
investigation into cardiac autonomic dysfunction. In recent years non-linear parameters 
obtained from heart rate variability data analyses have given an alternative insight into 
the interpretation of heart rate variability. Fractal behaviour of heart rate variability can 
be assessed by extracting fractal dimension using Higuchi’s algorithm. This method has 
been quoted by Addio et al (2007) as allowing better fractal estimation, eliminating the 
errors due to the indirect estimation of fractal dimension from spectral power. 
Fractal analysis assesses the relationship between heart rate variability and the scale at 
which this variation is reviewed (see Figure 13). When the data is sampled at a lower 
resolution, smaller scale variations are overlooked and the total variation in heart rate 
falls. By plotting Log of the total variation measured against Log of the resolution, a 
graph representing the fractal characteristics of the HRV is obtained. The gradient of 
the graph is the fractal dimension, which ranges from 1-2 (see Figure 14).  
 
Fractal dimension   =    Log (measured length at resolution) 
                                       Log (total variation) 
         
              = 1 for straight line 
                    = 2 for plane 
         = between 1 and 2 for variable plane 
If there is random noise the fractal dimension ≈ 2 
If there is a sine wave the fractal dimension ≈1.6 
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Figure 13. Illustration of sampling during fractal analysis 
 
 
Figure 14. Calculating fractal dimension 
 
3.10 Measurement Parameters Used 
 
3.10.1 Ewing Analysis 
 
The Ewing measures of heart rate variability are generally time domain measures, 
which assess variations in instantaneous heart rate secondary to provocations such as 
Heart Rate (bpm) 
Heart Beat 
Length sampling every 1 sample points = L1 
Heart Rate 
Heart Beat 
Number 
Length sampling every n sample points = Ln 
Line of best fit 
Heart Rate Length sampling every n sample points = Ln 
(n even bigger, Ln even Shorter) 
Heart Beat 
Log(L) 
Log(n) 
Line of best fit 
Gradient=fractal 
dimension 
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the Valsalva manoeuvre. These measurements allow assessment of changes in heart 
rate variability governed by different branches of the ANS, for example heart rate 
response to deep breathing is under parasympathetic control, hand grip under 
sympathetic control and Valsalva Manoeuvre mediated by both branches of the ANS 
(Kimattila et al 1997). 
 
The following calculations were made for provocations undertaken as recommended by 
Ewing (1985) 
 Slow breathing. Maximum to minimum heart rate during 1 cycle of a slow 
breathing regimen (6 breaths/min). 
 Maximum to minimum heart rate ratio during performance of the Valsalva 
manoeuvre 
 Maximum to minimum heart rate ratio during maximal hand grip. 
 
3.10.2 Frequency Domain 
 
Frequency domain measurement of heart rate variability is an alternative method of 
assessment. Various spectral methods have been used in the analysis of the HRV. 
Power spectral density (PSD) analysis provides the basic information about how 
variance distributes as a function of frequency, however only an estimate can be 
obtained by mathematical algorithms (Task Force 1996).  
 
Frequency analysis of heart rate data during resting can be used to determine the effect 
of the branches of the ANS.  
 
 High Frequency (HF) represents vagally (parasympathetic) mediated autonomic 
tone associated with respiration,  
 Low frequency (LF) related to sympathetic autonomic control. 
 HF/LF Ratio can be used to represent the balance between the two branches of 
the ANS. 
 Fractal dimension analysis (see section 3.9.2) 
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 Short-term maximum to minimum heart rate difference during resting 
 Spectral Power (see Figure 15). 
 
The total spectral power of the Heart Rate Variation was measured in the following 
frequency ranges: 
 
Very Low Frequency – 0.01-0.04 Hz 
Low Frequency   – 0.04-0.15 Hz 
High Frequency  – 0.15 – 0.4 Hz 
LF/HF ratio 
 
 
Figure 15. A representation of a typical spectral power curve for heart rate variability.  
The resulting spectral power values that can be obtained are labelled very low frequency power 
(VLFP), low frequency power (LFP), and high frequency power (HFP). 
 
 
3.10.3 Metronome Guided Breathing Period 
 
A set of heart rate variability measurements were made over a period of 2 minutes 
during which, breathing was controlled by a metronome. This enabled us to tightly 
control breathing and assess the short term effects of breathing on autonomic tone. The 
parameters measured are detailed overleaf. 
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3.10.4 Temporal Domain 
 
3.10.4.1 Mean Amplitude of Heart Rate Variation (A) 
 
The amplitude of heart rate variation was measured for each cycle of heart rate change 
from maximum to minimum instantaneous heart rate as indicated in Figure 16. The 
mean value was calculated, the resulting parameter we have labelled (A). Standard 
deviation of heart rate (±SD) was also calculated. 
 
 
Figure 16. Diagram showing the parameter Average Amplitude 
 
 
3.10.4.2 Maximum Correlation of Heart Rate to Chest Wall Motion (CORR) 
 
In order to establish the maximum correlation in synchronicity between breathing and 
heart rate, the heart rate curve was shifted in time by 0.125 s intervals within the range 
+/- 5 seconds to find the optimum shift required to maximise correlation of heart rate 
and chest wall movement during breathing (see Figure 17). This was automated 
through the autonomic analysis software. The maximum correlation coefficient 
obtained was labelled CORR, (this is shown in Figure 17).  
 
In previous research by Perring and Jones (2003) the technique of shifting the heart rate 
data was used to determine the maximum correlation between heart rate and breathing 
Heart Rate (HR) (bpm) 
 
Time (mins) 
A = Average amp 
SD = Standard deviation HR 
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cycle for both normal and diabetic groups. There did not appear to be any difference in 
time shift values obtained for normal or diabetic group and the time shift necessary to 
maximise correlation between heart rate and chest wall movement was not related to 
age. 
 
We would expect a time delay when assessing the phase relationship between heart rate 
and measurement of chest wall movement using plethysmography as a first 
approximation of breathing as we are not measuring changes in internal thoracic 
pressure or pulmonary stretch. It is valid to shift the heart rate data to correlate 
maximally with the breathing curve. 
 
 
Figure 17. Optimum shift to achieve maximum alignment of HR and breathing 
 
 
3.10.4.3 Comparison of Spirometry and Chest Plethysmography 
 
In a previous study by Perring and Jones (2003), eight healthy volunteers were asked to 
perform 2 minutes of metronome guided breathing using the chest plethysmography 
system while breathing into a spirometer system (Morgan Benchmark). The tidal 
breathing curve obtained from the spirometer was compared with the chest wall 
movement curve produced by the chest plethysmography system. Correlation between 
the breathing cycle measurements using spirometry and plethysmography was 
HR(bpm) 
Breathing 
Time (mins) 
Original HR curve Best fit HR curve 
CORR = best fit correlation 
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consistently good (mean correlation coefficient 0.94 ± 0.03). This comparison of the 
two techniques gives confidence in the chest wall measurement. 
 
3.10.5 Frequency Domain Measures 
 
The result of power spectral density (PSD) analysis provides the basic information 
about how variance distributes as a function of frequency. The nonparametric 
calculation for PSD is fast Fourier transform (FFT). The result of FFT was a graph of 
the variation of spectral power with frequency. In periods of metronome breathing, the 
frequency spectrum was dominated by the spectral peak at the frequency corresponding 
to the rate of respiration (see Figure 18). 
 
The spectral power within the peak corresponding to the breathing frequency was also 
measured as the log of the integral of the breathing peak in the frequency spectrum. 
This was labelled LPP (Log peak power) (see Figure 18). 
 
 
Figure 18. Peak power within the frequency peak corresponding to breathing 
 
The spectral power curve for heart rate variation was also compared with the spectral 
power curve for chest wall movement and the correlation coefficient calculated. This 
was labelled FCORR (see Figure 19). As for breathing heart rate correlation in the time 
domain, there was no evidence of any decay of correlation with age. 
 
HR Spectral Power 
Frequency 
Spectral power peak 
corresponding to breathing 
LPP=Ln (integral of breathing 
peak) 
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Figure 19.The FFT Correlation parameter represents the correlation coefficient between the 
values of the two spectral power curves shown above for heart rate and breathing variation,  
 
We have published the results of previous research on a sample of 44 normal healthy 
volunteers (age range 20-77 years SD+/- 13.6) using chest plethysmography and 
metronome guided breathing at 6 breaths per minute (Perring and Jones 2003). Using 
this original normal data we have established an age-matched normal range for the 
temporal and frequency parameters described below. 
 
We established the lines of best fit with age and the standard deviation from this line of 
best fit for each parameter as below. 
 
 CORR = 0.765. Standard deviation from line of best fit = 0.104 
 A = 22.9 - 0.2297 *Age (years). SD from line of best fit = 5.467 
 SD = 9.04 – 0.094*Age (years). SD from line of best fit = 1.851 
 LPP = 7.715 – 0.0233*Age (years). SD from line of best fit = 0.4553 
 FCORR = 0.922. SD from line of best fit = 0.149 
 
We then obtained an overall deviation from the age-matched normal range by adding 
the number of SD’s from the norm of each parameter. We obtained a standard 
deviation for this parameter in order to quote a total deviation from the age matched 
norm for all parameters combined (labelled DEV, the unit being the number of standard 
HR Spectral Power 
Breathing Spectral 
Power 
Frequency 
FCORR = correlation coefficient 
HR/ Breathing spectra 
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deviations from the normal age matched range). This gives a good indication of overall 
parasympathetic or vagal tone compared to an age matched normal range. 
 
3.10.6 Parameter Labels (Overview) 
 
The amplitude of heart rate variation was measured for each cycle of heart rate change 
from maximum to minimum instantaneous heart rate as indicated in Figure 16. The 
mean value was calculated, the resulting parameter we have labelled (A).  
 
Standard deviation of heart rate (SD) was also calculated. 
 
The spectral power within the peak corresponding to the breathing frequency was also 
measured as the log of the integral of the breathing peak in the frequency spectrum. 
This was labelled LPP (see Figure 18). 
 
The heart rate curve was shifted in time by 0.125 s intervals within the range +/- 5 
seconds to find the optimum shift required to maximise correlation of heart rate and 
chest wall movement during breathing. The maximum correlation coefficient obtained 
was labelled CORR (see Figure 17). 
 
The spectral power curve for heart rate variation was also compared with the spectral 
power curve for chest wall movement and the correlation coefficient calculated. This 
was labelled FCORR (see Figure 19). 
 
For each of these parameters, the value was expressed as a number of standard 
deviations away from the (age match if required) normal value. An overall deviation 
from the age-matched norm was established by adding the number of standard 
deviations from the norm of each parameter. A standard deviation for this parameter 
was obtained in order to quote a total deviation from the age matched norm for all 
parameter combined (DEV). 
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3.10.7 Blood Pressure Analysis (Baroreflex Sensitivity) 
 
Continuous blood pressure monitoring was performed during these investigations using 
the Portapres system. The systolic blood pressure (BP) was obtained for each beat 
where it was recorded during the metronome guided breathing period. A cubic spline 
interpolation was then performed in order to produce a continuous dataset of systolic 
BP at 8 samples per second. Frequency spectra were then produced for both heart rate 
and systolic BP using FFT and the peak corresponding to the 6 breaths/minute 
metronome breathing rate. The integrated peak power was then calculated for the 
breathing peak in both heart rate and BP spectra and the ratio of the integrated peak 
power for HR/ BP was calculated (see Figure 20. This represented a measure of the 
baroreflex sensitivity. 
 
 
Figure 20 A typical screen shot of blood pressure and heart rate date (baroreflex) 
Heart rate and blood pressure are shown in the lower panel of this figure detailing the 
relationship between the coupling of the physiological signals. The spectral power of the 
signals is shown to the right and the correlation coefficient is displayed. In this trace it is clear 
that heart rate and blood pressure remain coupled. 
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3.10.8 Pupillometry 
 
3.10.8.1 Instrumentation 
 
Pupillometry was performed using medical physics designed and built goggles. These 
comprised of a standard adult diving mask. The Perspex lenses were removed and 
replaced with metal plates to fill the spaces. Housed within each eyepiece was a 
Phillips SPC200NC web camera. The infra-red filters were removed and approximately 
280 pictures per minute / four frames per second (4Hz) were captured while the 
volunteer sat in the dark. While this was not a particularly fast capture rate, it was 
sufficient to show changes in sympathetic tone in the autonomic nervous system.  
 
Software was written in Visual basic 6 using XVideo OCX image capture software. 
The goggles are connected to a laptop via USB connection. 
 
3.10.8.2 Pupillometry Method 
 
We assess pupillometry by placing infrared goggles comfortably against the face by the 
volunteer. The driver for the right eye is selected on the pupilometry programme and 
the eye is displayed in real time on the screen. The position of the eye is checked to 
make sure it is in the centre of the field of view. It is important to be able to clearly 
define the margin of the iris and the pupil in the vertical plane. The lights are switched 
off and the patient is allowed to acclimatise to the darkness. It is vital that extraneous 
light is eliminated from the room.  
The recording period is started via the software. One eye is filmed. After filming in the 
dark for 30 seconds a one second flash of light is shone into the contra-lateral eye, a 
period of 30 seconds in the dark follows and then another one second flash, followed 
by 30 seconds of darkness. The response to the flash is seen in the eye that is being 
filmed.  
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3.10.8.3 Pupillometry Measurement 
 
The pupilometry measurement software is written in Visual basic 6. The volunteer file 
is selected. The image with the largest pupil size is identified, corresponding to a point 
at which the eyes are fully accommodated to darkness (see Figure 21). This can be 
manually adjusted if a better image is required. The patient’s date of birth is entered to 
allow for result to be compared with the age matched normal range database. 
Pupil response to dark adaptation was measured in a manner described by Smith and 
Dewhirst (1986). The software prompts to identify the left and right margins of the 
pupil and then the left and right margins of the iris see (Figure 21). The diameter of the 
pupil and iris were measured and the pupil/iris ratio calculated. The result is 
automatically compared against an age-matched normal range which was established 
by a previous unpublished normal sample performed in Poole, and is embedded in the 
analysis software.  
 
 
Figure 21 Pupillometry software showing the margins of the iris and pupil. 
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3.10.9 Summary table of autonomic function testing 
 
Table 1 Summary table of autonomic function testing.  Provocations used for testing HRV and the 
branch of the ANS that is activated. 
Test Name Summary ANS Branch 
Resting Spontaneous heart rate changes during extended resting period 
are recorded. The maximum and minimum heart rate rise is 
identified in a typical 20 second period. The percentage 
change is quoted. >6% is normal.  
Gives an 
indication of the 
balance between 
the two branches 
of the ANS 
Valsalva 
Manoeuvre 
The Valsalva manoeuvre consists of respiratory strain that 
increases intra-thoracic and intra-abdominal pressures and 
alters hemodynamic and cardiac functions. Heart rate during 
the Valsalva Manoeuvre is recorded and a ratio of the fastest 
heart rate to the slowest is calculated as a way of 
noninvasively quantifying the procedure. The result is  >1.2 
Multimodal 
(parasympathetic 
and sympathetic 
branches) 
Hand grip Isometric exercise increases heart rate. The Maximum HR in 
BPM and the minimum are identified. The result is age 
matched and displayed as a ratio (>1.1) 
Sympathetic 
Lying  / 
standing 
 
Blood pressure 
response to 
lying standing  
Heart rate recorded the ratio of the 15:30 beat after standing is 
recorded. 
 
 
Blood pressure recorded at rest and after 2 minutes of standing 
 
Parasympathetic 
 
 
 
Sympathetic 
BP response to 
5 minute 
Sustained hand 
grip 
Persistent muscle contraction causes blood pressure and heart 
rate to increase. The mechanism involves the exercise reflex, 
which withdraws parasympathetic activity and increases 
sympathetic activity. This test requires the patient to apply and 
maintain grip at 30% maximal activity for up to 5 minutes; the 
diastolic blood pressure should rise more than 16 mm Hg 
Sympathetic 
2 minute 
metronome 
guided 
The variation of heart rate with respiration is known as sinus 
arrhythmia and is generated by autonomic reflexes. Inspiration 
increases heart rate, and expiration decreases it. The variation 
is primarily mediated by the vagus innervation of the heart. 
Parasympathetic 
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breathing Pulmonary stretch receptors as well as cardiac 
mechanoreceptors and possibly baroreceptors contribute to 
regulating the heart rate variation. It increases with slower 
respiratory rates and reaches a maximum around 5 or 6 
respirations per minute 
Pupillometry Measurement of iris: pupil ratio in the dark compared with age 
matched normal values 
Sympathetic and 
parasympathetic 
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4 Chapter 4: Results: Influenza Study 
Chapter 4: Results (Influenza Study) 
 
This chapter will examine the results of the influenza study, including addressing 
demographics of the study population, the decision to separate the cohort into 
subgroups, examining the mild inflammatory effect of vaccination on resting heart rate, 
the effect of handgrip strength on HRV, breathing depth analysis, the gold standard 
Ewing measurements of autonomic function and HRV during two minutes of 
metronome guided breathing. All or some of the assessments may be used depending 
on the physical ability and compliance of the individual. Each component of the test 
will stress either of the two branches of the ANS; these are listed in section 3.10.9. 
 
4.1 Relevant Study Information 
 
4.1.1 Statistical Assessment 
 
Prior to analysis, all data was checked to see whether or not it fitted a normal 
distribution. Software called OpenStat was used to assess this and the test used within 
this software was a Lilliefors test for normality. Following this the data were analysed 
using Kwikstat Winks SAS 4.62 statistical analysis software (Texasoft 1991-2001). 
Parametric and non-parametric statistical analysis were performed as appropriate.  
 
4.2 Demographic and Lifestyle Factors  
 
The age of participants in this study ranged from 23 – 73 years which closely reflects 
the working age of the hospital population and volunteers. Data were analysed for the 
healthy volunteers collected over the two vaccination periods (2008/09 and 2009/10). 
The demographics for the groups were assessed to establish whether they are evenly 
matched between the two years. Data for age was analysed from the two vaccination 
periods using an unpaired t-test. There was no significant difference between the two 
cohorts (P=0.47). 
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The data was disproportionately weighted in favour of females over males (3:1). This 
was unintentional but is likely to reflect the ratio of female to male employees within 
the hospital. We have performed statistical analysis using Fishers Exact on the number 
of men and women in each cohort from each vaccination year and there is no 
statistically significant difference between the two cohorts (p=0.961).  
Resting heart rate (beats per minute) was established prior to vaccination for males (63 
±19.5) and females (72.9 ±11.1) to determine whether there is a difference in heart rate 
related to gender. Our results show that female participants in general have a higher 
resting heart rate than males. However, analysis using an unpaired t-test found there 
was no statistical difference between the data (p=0.061). 
 
Table 2. Table showing the age and gender distribution for the two vaccination periods.  
 Recruitment numbers Mean Age (±SD) Age Range 
Vaccination 
period 
2008/09 2009/10 2008/09 2009/10 2008/09 2009/10 
Male 12 6 45.8 (14.4) 47.8 (6.6) 20 – 64 37- 55 
Female 35 18 51.1 (11.8) 47 (12.1) 23 - 73 23- 63 
Total Group 47 24 49.8  (12.6) 47.2 (10.8) 20 - 73 23 - 63 
Mean (±SD) values for males, females and the total group. The data indicates a distribution skewed towards 
females in both vaccination periods with a similar distribution of age for each cohort for both vaccination 
periods with a similar distribution of age for each cohort for both vaccination periods. P value was calculated 
using an unpaired t-test with no significance between visits. 
 
4.2.1 Drop-out rate 
 
Data for two subjects were not used in the study (2.8%). One volunteer’s ECG trace 
contained erroneous HR data, which could not be substituted using the PPG data. The 
second failed to attend the post vaccination assessment.  
 
4.2.2 Sub-grouping of the Volunteers According to the Post Vaccination 
Symptom Questionnaire 
 
The total group (N=71) was divided into two major categories; volunteers who reported 
no symptoms after vaccination, these were termed category A (N=31) and volunteers 
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who reported various degrees of symptoms after receiving the vaccine, called category 
B (N=40) This symptomatic category was further subdivided into two sub-groups 
according to the extent and severity of their symptoms in response to the vaccination; 
Category B, subgroup 1 (N=25) consisted of volunteers with only mild symptoms and 
Category B, subgroup 2 (N=15) consisted of volunteers who experienced more 
significant symptoms than subgroup 1 as demonstrated in table 3. 
 
 
Table 3. Groupings of the volunteers based on post vaccination symptom questionnaire.  
Group Number Symptoms 
Full cohort N=71 Total group post vaccination 
Category A N=31 Asymptomatic  
Category B N=40 Symptomatic 
Sub group 1 N=25 
Volunteers reporting mild symptoms after vaccination. Typically sore arm 
lasting less than 24 hours. 
Sub group 2 N=15 
Significant symptoms. Including sore arm, headache, malaise and raised 
temperature, lasting > 24 hours 
Table showing the number of participants in the full cohort and subgroups according to post vaccination 
symptom questionnaire. Symptoms have been listed for each subgroup. 
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Figure 22. Flow chart showing grouping of participants 
This schematic shows the recruitment of participants to the study. The number of participants  
in each vaccination period and in each subgroup according to symptom questionnaire. 
 
 
 
 
22 Symptomatic 
  Category B 
6 Asymptomatic 
  Category A 
25 Asymptomatic 
  Category A 
18 Symptomatic 
  Category B 
7 with most significant 
symptoms 
8 with most significant 
symptoms 
(Category B):   
Sub-group 2 
Most significant 
symptoms (N= 15) 
(Category B):   
All symptomatic volunteers 
(N=40) 
11 mild 
symptoms 
(Subgroup 1) 
14 mild 
symptoms 
(Subgroup 1) 
2008/2009 Vaccination 2009/2010 Vaccination 
N= 47 N= 24 
Total group 
(N=71) 
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4.3 The Effects of Vaccination on Physiological Measurement Parameters 
 
This study examined the effect of the influenza vaccination on physiological measures 
such as resting heart rate, blood pressure, measures of breathing depth analysis and 
spontaneous breathing rate. Results of analyses are shown in the following sections. 
 
4.3.1 Finger Blood Pressure Measures 
 
Beat to beat finger blood pressure was measured continuously throughout the 
autonomic assessment. Systolic and diastolic blood pressure (mmHg) pre and post 
vaccination was recorded. For both systolic and diastolic blood pressure, pre and post 
vaccination the percentage difference (v1 – v2) was reduced for all groups, the largest 
percentage change was for category B subgroup 2 (systolic -6.8%). There were 
statistically significant differences noted in the full cohort for both systolic and 
diastolic blood pressure, which decreased (see Table 4). The reason for this is unclear 
however it may be related to the inflammatory process following the vaccination. There 
were no statistical differences seen in either of the subgroups pre and post vaccination 
despite the percentage changes noted (see Table 4). 
 
Table 4. Systolic and diastolic blood pressure pre and post vaccination.  
 Total Group 
N=71 
Category B 
N=40 
Category B 
Sub-group 2 N=15 
Mean Systolic (mmHg) Pre vaccination (±SD) 124.1 (30.1) 131.2 (19.5) 124.1 (26.8) 
Mean Systolic (mmHg) Post Vaccination (±SD) 117.8 (32.2) 128.5 (18.1) 115.6 (24.6) 
% Difference Systolic BP (V1-V3) -5.07 -2.05 -6.8 
P Value 0.103 0.390  0.225 
Mean Diastolic (mmHg) Pre vaccination (±SD) 82.01 (8.6) 82.32 (7.67) 82.8  (9.79) 
Mean Diastolic (mmHg) Post Vaccination (±SD) 79.1 (12.3) 80.47 (9.23) 82.06 (11.06) 
% Difference Diastolic BP (V1-V3) -3.55% -2.22% -0.89% 
P Value 0.02  0.07  0.69 
The systolic and diastolic blood pressure (mmHg) measures pre and post vaccination for the total group and 2 
symptomatic subgroups are shown in the table below. Mean (±SD) values and percentage difference (V1-V3) are 
given for all participants’ pre and post vaccination. P values were calculated using a paired t-test. Significant 
values (p=<0.05) are shown in bold. 
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4.3.2 Breathing Depth Analysis Pre and Post Vaccination 
 
Two minutes of breathing data was recorded for each participant before and after 
vaccination, each set of data was tightly controlled using a metronome to guide the 
timing of each breath cycle. Measurements were made taking the amplitude of the 
waveform from peak to trough for each breath cycle during the two minutes. The 
measurement represents average chest wall movement in arbitrary units. Analysis of 
breathing depth was performed before and after vaccination to assess whether 
participants had performed the breathing provocation differently between visits. The 
mean percentage difference between the two visits was -1.08% showing the breathing 
depth was slightly reduced after vaccination. However, there was no significant 
statistical difference in performance of the metronome-breathing task between the 2 
visits (P=0.853), (see Table 5). 
 
  Table 5 Breathing depth analysis for the full cohort.  
 Pre vaccination 
(SD) 
Post vaccination 
(SD) 
% Difference  
(V1- V2) 
P Value 
Mean (+/-SD) 111.3 (64.4) 110.1 (69.5) -1.08 0.853 
Breathing depth measured in arbitrary units for the full cohort. Mean breathing depth and SD are shown 
for pre and post vaccination visits. Analysis was performed using a t-test. No significant difference was 
seen between the visits.                                   
      
4.3.3 Measures of Spontaneous (resting) Breathing Rate Pre and Post 
Vaccination 
 
Measures of breathing rate during an extended period of rest were made for each 
participant pre and post vaccination. The number of breaths (defined by the peak of the 
chest wall waveform) was counted for the resting period and an average compared pre 
and post vaccination (see Table 6). There was a 2% reduction observed between visit 1 
and visit 2, however there was no significant difference in spontaneous breathing rate 
between the resting investigation period prior to and following vaccination (p=0.85) 
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(resting breathing rate (mean +/-SD) cycles/min prior to and cycle/min following 
vaccination. 
 
Table 6 Measures of Spontaneous (resting) Breathing Rate Pre and Post Vaccination 
 Pre vaccination 
(SD) 
Post vaccination 
(SD) 
% Difference  
(V1- V2) 
P Value 
Mean Breaths 
per minute 
 (+/-SD) 
16.4 +/- 3.9 16.08 +/-3.3 -1.95 P = 0.85 
Table showing mean, +/-SD, % difference (V1-V2) for resting breathing rate cycles/min prior to and 
cycle/min following vaccination. 
 
4.4 Results of the “Gold Standard” Ewing Assessment of Autonomic Function 
 
During assessment of autonomic function pre and post influenza vaccination the 
standard beat to beat Ewing measurements were made along with other provocations. 
The data were analysed to see if differences in heart rate variability exist pre and post 
vaccination. The percentage difference between data for visit 1 and visit 2 shows a drop 
in nearly all parameters post vaccination, particularly for subgroup 2 where all HRV 
measures were reduced (see Table 7). Despite this, the results of paired t-test show that 
there are no significant statistical changes to the parameters as a result of the influenza 
vaccination apart from the resting parameter for subgroup 2 (p=0.05).  It could be 
argued that, I) the sample size was too small to discern a difference in heart rate 
changes using the Ewing measures for all parameters other than resting or II) that no 
differences actually exist between pre and post vaccination measures due to the weak 
inflammatory effect of the vaccination, or III) the Ewing measures are insufficiently 
sensitive to the small changes that we might expect as a result of this study.  
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Table 7. Autonomic function testing using Ewing assessments pre and post vaccination.  
 Total Group (N=71) Category B (N=40) Sub-group 2 (N=15) 
 Mean 
V1 
(±SD) 
Mean 
V2 
(±SD) 
% 
Diff 
v1-v2 
P 
Val 
 
Mean 
V1 
(±SD) 
Mean 
V2 
(±SD) 
% 
Diff 
v1-v2 
P 
Val  
 
Mean 
V1 
(±SD) 
Mean 
V2 
(±SD) 
% 
Diff 
v1-v2 
P 
Val 
Resting 
(%) 
9.2  
(5.7) 
8.5 
(4.4) 
-7.6 0.34  
 
9.6 
(5.9) 
8.09 
(3.2) 
-15.7 0.09  
 
9.67 
(5.55) 
7.4 
(3.09) 
-23.5 0.05 
Forced 
Breathing 
(bpm) 
19.5 
(0.6) 
19.7 
(10.3) 
1.03 0.82 19.9 
(10.5) 
19.7 
(10.4) 
-1.01 0.82  19.9 
(9.3) 
18.9 
(10.2) 
-5.03 0.47  
Insp/Exp 
Diff 
(bpm) 
14.17 
(7.7) 
14.05 
(7.8) 
-0.85 0.84  
 
14.68 
(8.0) 
14.2 
(7.8) 
-3.27 0.46  
 
14.76 
(7.58) 
13.35  
(7.47) 
-9.55 0.15  
Valsalva 
(ratio)  
1.32 
(0.2) 
1.33 
(0.2) 
0.76 0.76  
 
1.32 
(0.2) 
1.34 
(0.2) 
1.52 0.55 
 
1.33 
(0.24) 
1.31 
(0.19) 
-1.5 0.68  
Hand 
grip 
(ratio) 
1.17  
(0.1) 
1.16 
(0.1) 
-0.85 0.79 1.17 
(0.1) 
1.17 
(0.1) 
0 0.55 
 
1.15 
(0.07) 
1.14 
(0.05) 
-0.87 0.54  
Mean (±SD) values and % difference (v1-v2) for HRV parameters for the total group and symptomatic 
subgroups pre and post vaccination. P values calculated using a paired t-test. Significant values 
(p=≤0.05) are shown in bold. 
 
4.5 Two Minutes Metronome Guided Breathing at 6 Breaths Per Minute 
Breathing Heart Rate Variability Pre and Post Vaccination. 
 
Results from the total group were first analysed using Pearson’s correlation coefficient 
to determine whether there was an inverse correlation between Age and Frequency 
Domain Parameters. We saw a moderate but statistically significant negative 
correlation between age and three heart rate variability parameters (A, SD and LPP) for 
all volunteers breathing at six breaths per minute over two minutes (see Table 8).  
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Table 8. Correlation between Age and HRV Parameters for all volunteers during metronome 
guided breathing at six breaths per minute.  
Parameters measured 
Pearson's Correlation 
 Coefficient 
 
t-value  
 
P value 
A (bpm) -0.5239 5.07 P= <0.001 
SD (bpm) -0.4948 4.69 P =<0.001 
CORR (unitless) -0.1318 1.1 P= 0.277 
LPP (unitless) -0.5241 5.07 P =<0.001 
FCORR (unitless) -0.1059 0.88 P= 0.383 
Correlation was performed using Pearson’s correlation coefficient. P values were calculated at 
P=<0.05 significance level. The significant results are shown in bold. HR Parameters shown are listed 
in 3.10.6. 
 
Secondly data collected during two minutes of metronome breathing at 6 breaths per 
minute were analysed to determine whether there was a difference in the total cohort 
and the 2 subgroups (pre and post vaccination). There was a percentage change 
between the two visits for most of the HRV parameters for the full group, however no 
statistically significant difference resulting from the influenza vaccination in any of the 
parameters during the 2 minute metronome breathing period in the full sample group 
were observed. This also included the overall deviation composite score (DEV) (see 
Table 9). The percentage difference in heart rate data between the two visits reduced 
for the two subgroups for all of the HRV parameters. The results of statistical analysis 
using a paired t-test for the two symptomatic groups are of particular interest and 
results are displayed in Table 9. In Category B (n=40) where volunteers experienced a 
symptomatic response to vaccination there is some evidence of deterioration in heart 
rate variation as a response to metronome breathing. In two parameters, SD (p=0.029) 
and LPP (p=0.028) the fall in heart rate response was statistically significant although 
this deterioration was not sufficient to display a significant drop in the composite 
overall deviation score (DEV), (see Table 9). By contrast in subgroup 2 (N=15) a 
significant deterioration in all heart rate variability frequency parameters apart from the 
FCORR was observed. This was reflected clearly in the composite overall deviation 
score (DEV) (see Table 9 and Figure 23). 
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Table 9. Comparison of HRV parameters pre and post influenza vaccination for two minutes of 
metronome breathing at 6 breaths per minute.  
 Total Group (N=71) Category B (N=40) Sub-group 2 (N=15) 
 Mean 
V1 
(±SD) 
Mean 
V2 
(±SD) 
% Diff 
V1-V2 
P 
Val 
Mean 
V1 
(±SD) 
Mean 
V2 
(±SD) 
% 
Diff 
V1-V2 
P Val Mean 
V1 
(±SD) 
Mean 
V2 
(±SD) 
% Diff 
V1-V2 
P Val 
CORR 
(unitless) 
-0.28 
(1.8) 
-0.37 
(2.1) 
-32 0.48 -0.22 
(2.1) 
-0.34 
(1.9) 
-54.5 0.71 0.17 
(1.7) 
0.09 
(2.23) 
-47.1 0.01 
A (bpm) 0.33 
(1.0) 
0.34 
(1.1) 
3.03 0.41 0.37 
(1.1) 
0.31 
(1.2) 
-16.2 0.07 
 
0.44 
(1.3) 
0.39 
(1.43) 
-9.3 0.02 
 
SD (bpm) 0.63 
(1.1) 
0.53 
(1.1) 
-15.8 0.16 0.67  
(1.2) 
0.38  
(1.2) 
-43 0.029 
 
0.43 
(1.4) 
0.18 
(1.47) 
-58.1 0.02 
 
LPP 
(unitless) 
0.65 
(0.8) 
0.55 
(1.0) 
-15.4 0.28  0.66 
(0.9) 
0.53  
(1.1) 
-11.7 0.028 0.69 
(1.0) 
0.15 
(1.27) 
-78 0.01 
 
FCORR  
(unitless) 
-0.10 
(1.2) 
-0.07 
(1.3) 
30 0.36 -0.09 
(1.3) 
-0.04 
(1.2) 
-55.6 0.80 
 
-0.12 
(1.1) 
-0.13 
(1.75) 
-8.3 0.193 
 
DEV  0.29 
(1.2) 
0.25 
(1.2) 
-13.8 0.35 0.33 
(1.3) 
0.14 
(1.2) 
-57.6 0.19 0.26 
(1.5) 
0.18 
(1.52) 
3-0.7 <0.001 
 
Mean (±SD) results for the full cohort and symptomatic subgroups are shown. Analysis was performed 
using Wilcoxon’s signed rank. Significant P values calculated at P=≤0.05 significance level. Results that 
differed significantly from the starting value are shown in bold. Parameters shown in section 3.10.6. 
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Figure 23 Graphs showing HRV parameter (DEV) after 2 minutes of metronome breathing pre 
and post vaccination.  
Pre-vaccination is shown as visit 1 and post vaccination is shown as visit 2. The (DEV) HRV parameter 
for Category B, subgroup 2 for each visit is shown in graph (A) A statistically significant difference was 
seen for this parameter (p=≤0.001) between visits. The mean value for each group is shown 
Graph (B) shows the (DEV) parameter for the total group, Category B, and Subgroup 2 pre and post 
vaccination at the 6 breaths per minute breathing rate. The mean DEV value is shown for each group. 
There is a statistically significant difference (p=≤0.001) between visits in the DEV parameter for 
subgroup 2 
 
 
4.6 Analysis of Raw HRV data 
 
In order to confirm the validity of our HRV measures we assessed changes in the raw 
HR data for each parameter from which the alternative aged matched deviation data is 
based. When analysing the heart rate data, the raw data was used in place of the 
standard deviation from the line of best fit for each parameter during two minutes of 
forced breathing at 6 breaths per minute for the full cohort and for subgroup 2, (see 
Table 10). No statistical difference was found when comparing the raw heart rate data 
for the full group (N=71). However, some of the raw heart rate data for spectral 
Composite Score (DEV) for the most symptomatic N=15 cohort 
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-5
-4
-3
-2
-1
0
1
2
3
4
0 1 2 3
Visit
S
t
a
n
d
a
r
d
 D
e
v
ia
t
io
n
s
DEV Pre Vaccine
DEV Post Vaccine
Mean
Overall deviation from the mean pre and post 2008/09 vaccine 6 breaths 
per minute forced breathing in total cohort and 2 symptomatic subgroups
-1.5
-1
-0.5
0
0.5
1
1.5
2
1 2
pre and post
d
e
v
.n
o
r
m
 (
S
D
's
)
n=70
n= 40
n=15
A B 
isit Pre and Post vaccination (visit) 
 
Overall Deviation from the mean pre and post accination during 
m tro ome guided breathing at 6 breaths per minute for the total 
cohort and the two symptomatic groups 
  
86 
parameters in subgroup 2 (N=15) were significantly different before and after the 
influenza vaccination.  
 
Table 10.  Raw HRV data from metronome guided breathing at 6 breaths per minute rate.  
Parameter Full Group (N=71 volunteers) Subgroup 2 (N=15 volunteers) 
 t value P value t value P value 
SD (bpm) 0.75 0.4535 1.829 0.088 
A (bpm) 0.09 0.921 2.471 0.026 
LPP (unitless) 0.99 0.3771 3.626 0.002 
CORR (unitless) 0.43 0.6668 2.739 0.016 
FCORR (unitless) 0.39 0.6965 0.964 0.351 
The raw heart rate data was analysed for the full group and subgroup 2 pre and post vaccination. 
Parameters shown are described in section 3.10.6. HR data was analysed using a paired t-test. 
Significant results are shown in bold. 
 
4.7 Summary of Resting HRV prior to and post vaccination 
 
The data was analysed to determine the percentage change in values between visit one 
and two for the full group and subgroup 2. For the full group, the percentage change in 
HR values is variable with a reduction in systolic blood pressure, fractal dimension and 
LF/HF ratio (see table 11). For subgroup 2, the results were again variable with the 
largest percentage change for PNN50 (28.06%). The same number of parameters for 
this group showed a percentage reduction post vaccination.  
Analysis of resting HRV was performed using a paired t-test. A table of results (Table 
11) summarises the differences between measures of resting heart rate variability and 
blood pressure prior to and following influenza vaccination for the full volunteer group 
of 71 volunteers and the 15 volunteers who subsequently reported significant post-
vaccination symptoms. Other measures include Fractal dimension as defined by 
Higuchi’s algorithm. SDNN = Standard deviation of RR interval. PNN50 = percentage 
of RR intervals where the gap between adjacent intervals is greater than 50ms. LF/HF 
ratio = ratio of integrated spectral power of the portions of the heart rate frequency plot 
in the low frequency (0.04-0.15 Hz) and high frequency (0.15 – 0.4 Hz) bands. There 
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were no statistically significant differences between any measures pre and post 
vaccination for the full cohort or for subgroup 2. 
 
Table 11 Summary of the differences between measures of resting heart rate variability and blood 
pressure prior to and following influenza vaccination for the full group, and Category B subgroup 
2.  
Parameter Pre-vaccination 
Mean (±SD)  
Post-vaccination  
Mean (±SD) 
% diff 
(V1-V2) 
P value 
Full group (71 volunteers) 
**Resting Heart Rate (bpm) 73.45 (10.91) 74.34 (10.45) 1.21 0.285 
*Systolic Blood Pressure (mmHg) 124.1 (30.1) 117.8 (32.2) -5.08 0.103 
Fractal Dimension 1.39 (0.12) 1.36 (0.19) -0.03 0.166 
SDNN (ms) 46.66 (25.84) 57.45 (59.46) 23.12 0.137 
PNN50 (%) 8.80 (11.61) 8.87 (11.63) 0.8 0.960 
LF/HF Ratio 1.07 (0.08) 1.05 (0.14) -1.87 0.341 
Category B, Subgroup 2 (15 volunteers) 
Resting Heart Rate (bpm) 76.90 (13.65) 76.86 (14.56) -0.05 0.977 
Systolic Blood Pressure (mmHg) 124.1 (26.8) 115.6 (24.6) -6.85 0.225 
Fractal Dimension 1.390 (0.09) 1.43 (0.12) 2.88 0.176 
SDNN (ms) 42.60 (24.69) 46.61 (19.68) 9.39 0.551 
PNN50 (%) 8.09 (9.09) 10.36 (13.88) 28.06 0.459 
LF/HF Ratio 1.37 (0.66) 1.36  (0.61) -0.73 0.703 
Fractal dimension as defined by Higuchi’s algorithm. SDNN = Standard deviation of RR interval. 
PNN50 = percentage of RR intervals where the gap between adjacent intervals is greater than 50ms. 
LF/HF ratio = ratio of integrated spectral power of the portions of the heart rate frequency plot in the 
low frequency (0.04-0.15 Hz) and high frequency (0.15 – 0.4 Hz) bands.* BP taken with automated 
device. ** Over extended resting period 
 
 
4.8 Frequency Domain Parameters during 2 Minutes Metronome Guided 
Breathing at 10 breaths per Minute Breathing Rate Pre and Post 
Vaccination. 
 
A two minute breathing exercise at a fixed rate of 10 breaths per minute was also 
performed. There are fewer participants in the group for the 10 breaths per minute 
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protocol, as this particular test has not been performed for all participants at the start of 
recruitment and data collection.  
Firstly the HRV results during breathing at 10 breaths per minute were correlated 
against age. The results show an inverse correlation for all of the parameters with age 
(see Table 12), which is in keeping with the 6 breaths per minute results and with 
previously, published research (Perring and Jones 2003). All parameters show a 
statistically significant deterioration with age; including CORR and FCORR at 10 
breaths per minute (see Table 12). By contrast CORR and FCORR showed no 
significant decay with age at 6 breaths per minute, (see Table 8). 
 
 
Table 12 Correlation between Age and HRV Parameters for all volunteers during metronome 
guided breathing at 10 breaths per minute.  
Parameter Pearson's Correlation Coefficient t-value  P value 
SD (bpm) -0.5149 4.8 P = 0.001 
A (bpm) -0.5569 5.36 P = 0.001 
LPP (unitless) -0.5267 4.96 P = 0.001 
CORR (unitless) -0.3101 2.61 P= 0.011 
FCORR (unitless) -0.3083 2.59 P= 0.012 
Correlation was performed using Pearson’s correlation coefficient. Parameters shown are explained in 
section 3.10.6. Significant values are shown in bold. 
 
 
Secondly we did not see significant differences between many of the frequency 
parameters before and after the vaccination however, analysis shows a statistically 
significant result in the full group for LPP (P=0.03) and category B, subgroup 1 
(P=0.01) for LPP, which showed a decay greater than would be expected as a result of 
random fluctuations at the 5% level. The reasons for this are unclear; however it is 
likely that the 10 breaths per minute breathing rate is not enough of a provocation to 
promote large changes in HRV. No parameters showed any significant deterioration as 
a result of the influenza vaccination in Category B, subgroup 2.  
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Table 13. Table showing comparison of HRV parameters pre and post influenza vaccination for 
two minutes of metronome breathing at 10 breaths per minute. 
 Total Group  
N=66 
Category B  
N=38 
Category B, Sub-group 2  
N=14 
SD (bpm) P=0.217  P=0.058  P = 0.226 
A (bpm) P = 0.325  P=0.127 P = 0.351 
LPP (unitless) P=0.029 P =0.009 P = 0.091 
CORR (unitless) P=0.958 P=0.894 P = 0.665  
FCORR (unitless) P=0.665  P= 0.838 P = 0.613 
A paired t-test was performed for HRV data for the full group and two subgroups. P values were 
calculated at P=<0.05 significance level. The significant results are shown in bold. There is no 
statistically significant difference between results. Parameters shown are described in section 3.10.6 
 
 
4.9 Iris/pupil response to dark pre and post vaccination 
 
The right eye was photographed while in the dark using infrared goggles. The pupillary 
adjustment to dark and to a flash of light in the contra-lateral eye was recorded. The 
iris: pupil ratio was calculated using the medical physics pupillometry computer 
programme. The result is compared to an age matched normal range and the number of 
standard deviations from the normal range is quoted. The iris: pupil ratio was 
calculated for all of the volunteers. The percentage change in iris: pupil ratio was 
calculated between visit one and two. The largest percentage change was seen in 
Category B (N=40), which was reduced by 46.15% (see table 14).  
The pre and post vaccination values were statistically analysed using a paired t-test. 
The results show there was no evidence of a statistically significant decrease in the 
pupil response to darkness in the full sample (N=71) and in Subgroup 2 (N=15), despite 
a 23.9% and 34.7% reduction. Interestingly enough there was statistically significant 
difference (P=0.027) in pupil/iris responses was seen in Category B (N=40) (see Table 
14 and Figure 24). Subgroup 2 was too small to show a significant difference pre and 
post vaccination. This is discussed further in chapter 5. 
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Table 14. Iris/pupil response to dark pre and post influenza vaccination for all volunteers 
 Mean 
(standard 
deviation from 
normal mean) 
Pre vaccination 
(±SD)  
Mean 
(standard 
deviation from 
normal mean) 
Post 
vaccination 
(±SD) 
% Diff  
(V1-V2) 
P Val 
Total Group  
N=71 
-0.46 (1.32) -0.57 (1.44) -23.9 P = 0.171 
Category B 
N=40 
-0.39 (1.47) -0.57 (1.35) -46.15 P = 0.027 
Category B  
Sub-group 2  N=15 
-0.46 (1.3) -0.62 (1.4) -34.7   P= 0.237 
Mean and SD data for the full cohort and symptomatic subgroups. Analysis was performed. P  
values were calculated using a paired t-test. Significant results (P=≤0.05) are shown in bold. 
 
 
Figure 24. Mean difference in Iris/pupil response to dark pre (visit 1) and post (visit 2) vaccination 
for the symptomatic group B (N=40).  
Mean values are shown for visit one and two, there is a significant statistical difference between the 
pupillometry data (p=≤0.0273)This graph shows the mean difference in the number of standard 
deviations above or below the age matched normal range for iris:pupil ratio measures for subgroup 
category B (N=40) pre and post vaccination. 
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4.9.1 Inter-operative Variability for Assessment of Iris/Pupil Ratio 
Measurements 
 
The pupillometry data from the original cohort of volunteers from the first vaccination 
period (n=45) were assessed to establish age matched mean prior to and post 
vaccination with a view to investigating inter-operator variability. The same assessment 
was performed by two independent assessors for the same data to determine the 
repeatability of the technique. The standard deviation results were then compared to 
determine whether there was variability between assessors. There is no significant 
statistical difference between the assessors for the data for either of the visits (p=0.62 
and 0.61 respectively). (The results are shown in Figure 25). 
 
     
Figure 25. Graph showing inter-operative variability for assessment of Iris/pupil ratio 
measurements.  
Graph showing pupillometry results for 2 independent reviewers assessing the same 45 participants for 
visit one. There was no statistical difference between reviewers the mean of the data for both assessors is 
shown. 
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4.9.2 Factors Affecting the Outcomes of the Influenza Study: 
 
There were a number of factors affecting the outcome of the study. These are examined 
in turn in the following segments. 
 
A: Reliability (reproducibility) of the data 
 
In order to assess the reliability (reproducibility) of our collected data, we conducted 
repeat autonomic function testing on thirteen healthy volunteers separated by 2-5 days, 
where no vaccination was given. The percentage change for all measures of AF was 
variable with the majority of parameters reducing between visits. The results of 
statistical analysis show that the resting parameter and LPP were statistically different 
pre and post vaccination. 
 
Table 15 Results for autonomic function testing on 13 healthy volunteers tested and retested 2-5 
days apart.   
Parameter  V1 Mean (±SD) V2 Mean (±SD) % Diff 
(V1-V2) 
P Val 
Ewing Measures 
Resting (%) 8.8 (5.0) 10.7 (5.37) 21.59 0.05 
Forced breathing (%)  23.3 (10.8) 22.7 (11.7) -2.58 0.72 
I/E Diff  (bpm) 16.66 (7.14) 15.63 (7.2) -6.16 0.47 
Valsalva (ratio) 1.39 (0.17) 1.38 (0.24) -0.72 0.55 
Handgrip (ratio) 1.16 (0.09) 1.17 (0.1) 0.86 0.51 
Metronome breathing 
SD (bpm) 1.31 (1.66) 1.2 (1.49) -8.4 0.36 
A (bpm) 1.08 (1.62) 0.99 (1.51) -8.3 0.11 
CORR (unitless) -0.038 (1.06) -0.028 (1.55) 26.3 0.83 
LPP (unitless) 0.87 (0.96) 0.71 (1.08) -18.4 0.01 
FCORR  (unitless) 0.09 (0.42) 0.1 (1.26) 11.1 0.24 
DEV  0.92 (1.24) 0.71 (1.43) -22.8 0.16 
Mean, SD, and % difference for the 13 volunteers for repeat visits. Analysis performed using a paired t-
test (P=<0.05) Significant values are shown in bold. Parameters are described in section 3.10.6. 
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B: Validity 
I Comparison of normal data from influenza study and previous normal range 
data  
 
In order to fulfil the second aim of the project, the autonomic function data collected 
from 71 healthy individual’s pre vaccination was compared with previous data 
collected for 44 healthy volunteers to validate our existing normal range. After 
statistical comparison, there was no statistically significant difference between 
parameters for the full group n=71 compared to the previous normal range data (n=44) 
apart from the SD parameter (p=0.007) (see Table 16).  
 
We conclude that: 
 The calculations used to generate the overall deviation (DEV) parameter appear 
to be valid. 
 The correlation coefficient for all parameters measured for the 6 breaths per 
minute provocation appears to be similar in the new dataset compared to the 
original normal dataset. 
 The automated calculation is valid based on the original normal dataset for 
future normal and patient studies. 
 
Table 16. Comparison of present normal (pre-flu) sample (N=71) with past normal data (n=44)  
Parameter Original normal group N=44 
(SD’s from age-matched 
norm) 
New normal group N=71, 1
st
 
visit (SD’s from age-
matched norm) 
t value P value 
A (bpm)  0+/- 1.0 0.373 +/-1.032 1.69 0.093 
SD (bpm) 0+/- 1.0 0.631 +/-1.122 2.75 0.007 
CORR (unitless) 0+/- 1.0 -0.289 +/-1.799 1.13 0.259 
LPP (unitless) 0 +/- 1.0 0.652 +/-0.837 0.89 0.375 
FCORR  (unitless) 0 +/- 1.0 -0.104 +/-1.192 0.43 0.668 
DEV  0 +/- 1.0 0.292 +/-1.188 0.45 0.654 
SD from age matched normal value is shown for the original group (N=44) and the pre vaccination influenza 
group (N=71). Statistical analysis was performed using a student’s t test for unpaired data. Significant results 
in bold. 
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Figure 26 Graphs representing HRV parameters showing the line of best fit for each parameter and +/- two 
standard deviations from the age matched normal range obtained from the original study in 2003.  
Graph (A) showing Maximum Correlation (CORR) between HR and chest wall plethysmography breathing. Graph 
(B) showing Average peak to trough HR amplitude (BPM). Graph (C) showing standard deviation heart rate 
variation (±SD). Graph (D) showing Log amplitude of peak of the frequency power curve (LPP) following FFT. 
Graph (E) showing Correlation of breathing and HR following FFT (FCORR). 
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C:   Type of Influenza Vaccine Used 
 
The response to the vaccination was assessed in terms of the level of symptoms 
experienced. We noted 46% of volunteers in the first vaccination period (2008/09) 
experienced a degree of symptoms from the vaccination, 17% of these were significant 
symptoms. Compared with the 2009/10 vaccination, where 75% experienced 
symptoms, 29% of which were more significant symptoms (see Table 17). Statistical 
analysis of the data using Fishers Exact did not show any difference in the number of 
symptomatic volunteers between the 2 vaccinations (P> 0.05).  
 
Table 17. Number of volunteers experiencing symptoms after influenza vaccination.  
 2008/09 
Vaccination 
2009/10 
Vaccination 
Number of volunteers in each cohort 47 24 
Number of volunteers experiencing any symptoms post 
vaccination and percentage of total in each group 
22 (46%) 18 (75%) 
Number of volunteers experiencing the most significant 
symptoms and percentage of total in each group 
8 (17%) 7 (29%) 
Participant numbers in each vaccination period and the percentage of the total in each period. Sub 
groups of the total shown with definition of the level of symptoms experienced after vaccination 
 
 
D:   Time Delay between Administration of Influenza Vaccination and Assessment 
of Autonomic Function Testing 
 
The mean time delay between the vaccination and follow up visit was 2.6 days (+/- 
1.07).  51% of the volunteers were seen on day two and 84% were seen between day 
one and three (see Table 18). 
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Table 18. Time delay (days) between vaccination and autonomic function testing 
Number of days between 
vaccination and assessment 
1 2 3 4 5 
% of  total group seen within 
specific time 
5.6% 51% 27% 14% 2.8% 
Table showing the number of days between vaccination and Autonomic assessment and the percentage of 
participants who had the autonomic function assessment on each day post vaccination. 
 
E. Age and Gender 
 
Analysis of the ages in both the 2008/09 and 2009/10 cohorts and have shown that 
there is no significant difference between the cohorts in the two groups (p=0.471) (see 
Table 2). 
 
There was an inverse relationship between HRV parameters at 6 and 10 breaths per 
minute and increasing age, the results are displayed in Table 8 and Table 12. 
 
There was no significant statistical difference between the male and female subjects for 
resting heart rate (BPM), however we did not look at all HRV parameters with respect 
to gender because of the small male sample and bias towards females. 
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5 Chapter 5: Discussion (Influenza Study) 
Chapter 5: Discussion (Influenza Study) 
 
5.1 The Choice of the Influenza Vaccination and the Outcome of the Study 
 
Data was collected over a two year period incorporating two flu vaccination periods. 
The trivalent vaccine used during both vaccination periods was produced by the same 
pharmaceutical company. The vaccine differed slightly in the composition in 
accordance with the World Health Organisation guidelines. Both contained the same 
viral A strain. However the Viral B strain in the 2008/09 vaccine was the 
Florida/4/2006. Whereas the viral B strain in the 2009/10 vaccine was 
Brisbane/60/2008. This is in accordance with extrapolation of the evidence for the 
strain most likely to be most virulent in the forthcoming year. 
 
We noted 46% of volunteers in the first vaccination period (2008/09) experienced a 
degree of symptoms from the vaccination, 17% of these were significant symptoms. 
Compared with the 2009/10 vaccination where 75% experienced symptoms, 29% of 
which were more significant symptoms (see Table 17). Despite these findings statistical 
analysis of the data using Fishers Exact did not show any difference in the number of 
symptomatic volunteers between the 2 vaccinations (P> 0.05).  
 
The protocol for administration of the vaccine was the same for both periods and the 
personnel in the Occupational Health department were the same. None of the 
volunteers who were vaccinated in the first year were recruited during the second year.  
 
The flu vaccine was the chosen provocation necessary to induce a mild inflammatory 
response in the volunteers. We chose it primarily because of the availability within the 
research setting and logistically it was relatively easy to recruit volunteers, as hospital 
staff were asked to sign up for the vaccination sessions in advance. This project also 
had to be approved by the ethics committee and this would have been less likely if we 
had tried to incorporate a more deleterious provocation. We could have used a travel 
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vaccination such as yellow fever, in place of the influenza vaccine. Tsai et al (2005) 
suggest yellow fever is a similar model to study the response of mild stimulation of the 
inflammatory system. One problem with using the yellow fever vaccination is that it is 
not routinely administered to large numbers of people at one time in the UK in the 
same way the influenza vaccination is administered and it tends to be given in the 
community setting by a practice nurse.   
In order to increase our recruitment numbers we had to accept that performing the 
research over two years would mean that the composition of the vaccine was likely to 
be different for each year. Using two slightly different vaccines did not affect the 
results because we were not directly comparing the vaccines for any differences; we 
were comparing heart rate variability for each participant before and after a 
vaccination.  
 
 
5.2 Demographic Factors  
 
Large variation in heart rate variability has been described in healthy volunteers by 
Molgaard et al (1994). Both age and gender have been identified as primary factors, 
excluding disease, which may affect autonomic function. Increasing age has been 
shown to have an attenuating effect on autonomic tone in healthy subjects (Bigger et al 
(1995) and confirmed in Perring and Jones (2003) and in the present study (see Table 8 
and Table 12). 
 
There is research to suggest that gender bias is present for autonomic tone with men 
displaying higher values of heart rate variability (Cowan et al 1998). We did not see 
any significant differences between the gender groups for resting heart rate. This might 
be due to a small sample size of the study and to the large number of female 
participants in the study. 
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The group was not ethnically diverse. There was a significant bias as more than 95% of 
volunteers were Caucasian. A literature search does not suggest any evidence relating 
ethnicity to heart rate variability.  
 
Where possible autonomic function assessments were performed at the same time of 
the day to avoid diurnal variation. This was in practice slightly difficult in the work 
place setting as we were limited with the timing of the vaccination and when the 
autonomic function testing could be performed but where possible we adhered to the 
protocol. 
 
Repeatability was addressed by assessing thirteen healthy volunteers on two occasions, 
separated by 2-5 days who did not have the influenza vaccination (see Table 15). 
Autonomic function testing was performed on each occasion. The protocol for testing 
was the same as per section 3.4.5. After statistical analysis there are two parameters 
that show significant differences between visits, resting heart rate and LPP (see Table 
15). It could be argued the difference in the resting parameter between visits (see Table 
7) could simply be due to the way in which the analysis was performed. The percentage 
change in resting heart rate is calculated using a single point to determine a minimum 
heart rate and a single point to determine a maximum heart rate selected from one heart 
rate cycle. In a healthy normal trace the heart rate changes are quite marked and it is 
down to the operator to choose a maximum and minimum point from one cycle in an 
extended resting period (see Figure 27). Where the markers are positioned may make a 
difference to the overall percentage change and therefore although both results may 
have been above the normal threshold, which is 6%, it is possible that markers were not 
positioned on the cycle with the highest heart rate, as the differences can be subtle 
when performing the analysis. In the clinical setting it is accepted that this parameter is 
quite variable and we do not place much emphasis on the resting heart rate result. On 
the other hand the LPP result is more difficult to explain, however this is likely to be an 
anomaly, which may be due to a relative small sample size.  
There were no significant differences in the other heart rate variability parameters 
between repeated autonomic function testing (separated by two to five days) for healthy 
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volunteers who did not have the influenza vaccination. This suggests that the technique 
is reproducible. 
 
 
Figure 27 Screenshot of resting heart rate data with markers for minimum and maximum heart 
rate. 
 
5.3 The Choice of Technique in Assessment of Autonomic Function and the 
Effect on the Outcome of the Study, 
 
5.3.1 Holter Measurements 
 
Many studies assessing heart rate variability have previously used extended 24 hour 
Holter measurement (Stein et al 1994, Nada et al 2001). There are several problems 
surrounding the use of this method. Essentially there is no control over the primary 
effector parameter on heart rate during the extended measurement period i.e. breathing 
and no concomitant recording of that parameter measuring any variation during the 
measurement period. Also there is no control on the other parameters likely to affect 
heart rate variability i.e. exercise or emotional state.  
 
We opted to use a short sampling time instead of longer Holter measurements. The 
advantages of short recording periods are that the collection and analysis time is shorter 
and the data can comply with the assumption made during data analysis that the signal 
(breathing rate) does not change with time. Short term recordings such as the two 
minute metronome guided breathing are ideal for following disease progression. One of 
the problems associated with short recordings is that they only record data on short 
term reflex responses and they do not include very low frequency (VLF) data. Using 
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the LF/HF ratio reflects the balance between the two branches of the ANS. This 
sympatho-vagal balance in a healthy adult is usually between 1 and 2. It was felt that 
the benefits of controlled metronome guided breathing outweighed the effects on VLF 
power for the purpose of this project, and that a short sampling time was on balance 
advantageous. 
 
5.3.2 Limitations of Heart Rate Variability Testing 
 
A limitation of standard heart rate variability testing is that it relies on normal sinus 
rhythm. Performing autonomic function testing on patients with arrhythmias, frequent 
ectopic heart beats or significant tremor is often very difficult and may result in an 
unsatisfactory study. PPG signal can be used in place of ECG where artefact or noise is 
a limiting factor but may not offer an alternative in all circumstances. 
 
It is indicative that autonomic neuropathy is not universal over all systems uniformly 
and that assessment of multiple systems in the clinical setting is necessary to ensure 
best diagnostic power. 
 
5.3.3 Pupillometry 
 
We performed pupillary dark adaptation measures on all volunteers before and after 
vaccination. During analysis a significant difference was demonstrated in category B 
(n=40), with respect to the standard deviation of iris/pupil ratio compared to an age 
matched normal range pre and post vaccination. This difference was not evident in 
category B, subgroup 2 with the most significant symptoms (n=15) (See Table 14). 
Possible conclusions that we can draw from this are:  
 
 The sample size for subgroup 2 is too small.  
 That the sympathetic branch of the autonomic nervous system controlling 
the pupil response is less affected by the vaccine and no statistical 
difference exists between the pre and post vaccination. 
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 Or that the measurement technique is not sufficiently sensitive to 
determine low level changes in autonomic tone.  
 
We will continue to collect these data clinically as it is a useful indicator of reduced 
autonomic tone in patients with more significant autonomic dysfunction and not 
susceptible to errors as a result of ectopic or erroneous heart rate data. 
 
5.3.4 Heart Rate Variability Findings    
 
We can infer that the mild inflammatory response to the influenza vaccination is 
associated with a change in HRV between the two visits and had a significant effect on 
short measures of heart rate variability during metronome guided breathing in the 
subgroups of symptomatic participants (as shown in Table 9). This is in keeping with 
work by Lanza et al (2011) who found significant correlation between reduced C-
reactive protein (CRP) levels and increased HRV parameters after the administration of 
atenolol, suggesting a patho-physiological link between inflammation and autonomic 
regulation. 
 
Analysis of the raw HR data (pre and post vaccination) (shown in Table 10) for 
subgroup 2, results in significant differences in all metronome guided breathing 
parameters except for FCORR which does not significantly differ for either the raw 
heart rate data or the standard deviation data. This may be due to the correlation of the 
frequency power curves being significantly affected by low level changes in heart rate 
and the resulting power being spread either side of the signal peak. Care needs to be 
taken when interpreting the statistical significance of multiple parameters as the 
likelihood of one reaching the threshold for significance is additive. However, in this 
case multiple parameters display significant difference pre and post vaccination and we 
are confident that this is not due to chance.   
 
Analysis of extended period of resting heart rate variability was assessed for the full 
Influenza group and subgroup 2 prior to and following influenza vaccination. Other 
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measures include Fractal dimension, SDNN = Standard deviation of RR interval. 
PNN50 = percentage of RR intervals where the gap between adjacent intervals is 
greater than 50ms. LF/HF ratio = ratio of integrated spectral power of the portions of 
the heart rate frequency plot in the low frequency (0.04-0.15 Hz) and high frequency 
(0.15 – 0.4 Hz) bands. There were no statistically significant differences between any 
measures pre and post vaccination for either group. 
 
We also re-established that the 6 breaths per minute breathing rate is a greater heart rate 
provocation than spontaneous free breathing during the resting period or breathing at a 
fixed rate of 10 breaths per minute and resulted in more significant results pre and post 
vaccination (see Table 9). This is in keeping with previous research performed by 
Perring and Jones (2003). Several other studies have also documented that the scale of 
respiratory related fluctuations of HRV significantly changes according to breathing 
rate, exhibiting the highest response 0.1 Hz and a progressive decrease of the gain as 
the respiratory frequency increases above this value (Brown et al 1993, Hirsch et al 
1981, and Saul et al; 1991).  
 
We have established that there is no statistically significant difference between our 
previous normal range published in 2003 and the new data collected from healthy 
volunteers during this study (see Table 16). New normal volunteer data was collected 
from volunteers who did not have the vaccination. Data analysis suggests the technique 
is reproducible with no statistical difference between the initial visit and a second visit. 
However we still need to further refine the normal age matched values during 
metronome breathing and to establish the reproducibility of these measures. 
 
5.4 Inflammation and Heart Rate Variability 
 
This study showed that acute inflammation in response to the seasonal influenza 
vaccination lead to statistically significant changes in heart rate variability parameters 
prior to and post vaccination in the subgroups of symptomatic participants, particularly 
subgroup 2 (n=15) where participants experienced the most marked symptoms in 
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response to the vaccination (see Table 9). In keeping with our research, a host of other 
research has been published reporting a link between other inflammatory disease states 
and autonomic impairment, Sajadieh et al (2004) found reduced HRV in patients with 
subclinical inflammation, Libby et al (2002) with atherosclerosis, Vinik (2012) and 
Lombardi (2004) with Diabetes, Addio et al (2007) with COPD, and Chakraborty et al 
(1989) with GORD. 
Our research found a significant difference in HRV in a subgroup of the most 
symptomatic participant’s i.e. those assumed to have the highest level of inflammation, 
which is in keeping with other research in the field. We question what physiological 
mechanisms are involved in this process. It is known that increasing age, medications, 
infection, and respiratory disease can all have a negative effect on autonomic tone. 
Corrales-Medina (2012 and 2013) and Vassallo and Allen (1997) discuss a link 
between infection and respiratory disorders and a reduction in autonomic function. 
Vassallo and Allen reference Heath et al (1982) citing “possible damage to fibres in the 
terminal bronchioles and alveoli from the inflammatory process accompanying 
pneumonia.” It is still unclear the exact mechanism linking acute inflammation and 
temporary dysautonomia, however it is likely to be multifactorial. Evidence from 
Tracey (2007), suggests the presence of the “cholinergic anti-inflammatory pathway” 
where the vagal nerve is implicated in a “hard wired” connection between nervous and 
immune systems (Czura and Tracey 2005), with consequent association between heart 
rate variability and inflammation (Thayer 2009). Stimulation of the vagal nerve 
attenuates the production of pro-inflammatory cytokines and inhibits the inflammatory 
process (de Jonge and Ulloa 2007). New research by Martelli et al (2014) supports the 
theory that inflammation is under the control of an inhibitory neural reflex. However, 
they refute that parasympathetic and sympathetic systems work together to maintain 
immunological homeostasis and conclude that the “cholinergic-anti-inflammatory 
pathway and the vagus nerve do not constitute the efferent arm of the inflammatory 
reflex,” although they do not deny that vagal pathways can exert anti-inflammatory 
actions in acute inflammation.  
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In clinical conditions characterized by an increase in inflammatory markers, for 
example diabetes, rheumatoid arthritis, sepsis and acute coronary syndromes, a 
reduction in heart rate variability is consistently observed in high risk patients, 
strengthening the connection between inflammation and autonomic dysfunction 
(Lombardi 2004), this is also in keeping with our findings that showed a decline in 
HRV in response to the influenza vaccination (Perring and Jones 2012). The 
connection between inflammation and reduced HRV suggests that potentially many of 
the inflammatory diseases may be diseases of autonomic dysfunction (Czura and 
Tracey 2005). We know from previous research (Tsai et al 2005) that after vaccination 
there is a corresponding increase in inflammatory markers e.g. CRP. Although we did 
not measure inflammatory markers directly in this project we can infer that the known 
and published inflammatory response to the influenza vaccine from Tsai et al’s work 
(2005) affected autonomic tone temporarily. 
 
Research by Ziegler et al (1992) suggests regardless of glycaemic control, all patients 
with diabetes are at risk from developing autonomic complications. Chronic disease 
such as diabetes results in permanent loss of autonomic tone. The exact cause of this is 
unknown but it is believed to be a product of demyelinating polyneuropathy (Sharma 
2002). It is not clear at what point diabetic dysautonomia is temporary and therefore 
reversible and at what point it becomes permanent. We do know that short-term 
changes in autonomic tone were seen in the influenza study (see Table 9 and Table 11). 
The heart rate changes related to inflammation from the vaccine would be expected to 
be transient and peak at two days post vaccination and would rapidly diminish, we can 
therefore measure temporary and reversible changes in HRV related to acute 
inflammation which may be an important development in the assessment and 
progression of other inflammatory disease. In the case of diabetes it is chronic disease 
and poor glycaemic control that is thought to lead to irreversible damage. If assessed 
and managed early the consequences of the disease to the patient could be potentially 
reversed or minimised. 
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Other inflammatory diseases such as asthma, reflux oesophagitis, arthritis, and 
inflammatory bowel disease may all lead to a temporary reduction in autonomic tone. 
We have assessed reflux oesophagitis and heart rate variability and the response to 
proton pump inhibitor therapy, the details are discussed in chapter six. 
 
 
5.5 The Implications of this Study on Routine Clinical Assessment 
 
Spectral analysis of metronome guided breathing at a rate of six breaths per minute for 
2 minutes has shown the most significant difference before and after vaccination. We 
did not find that other measures were sensitive enough to detect such low level 
changes. This does not mean that they should be excluded from routine clinical use. 
Ewing et al (1982) suggested a battery of five tests 3 predominantly parasympathetic 
(Valsalva Manoeuvre, Deep “forced” breathing and 30:15 ratio after standing) and two 
sympathetic tests, (blood pressure response to standing and sustained handgrip (30% 
maximum for 5 minutes). O’Brien et al (1986) suggest a similar regime but with less 
repetition of provocation making it quicker to perform. Ewing et al (1982) used one 
normal range regardless of age, which gave false negative results among younger 
patients and false positives among the elderly patients. O’Brien et al (1986) used an age 
match normal range to overcome this problem. They suggested maximum-minimum 
heart rate during single deep breath, maximum – minimum heart rate during Valsalva 
Manoeuvre, (taking the maximum after the Valsalva has been performed) and heart rate 
ratio on standing at 15 and 30 beats after standing. In 1996 The Task Force of the 
European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology defined and published standards for clinical use and interpretation of 
heart rate variability “Time domain, geometric measures and frequency domain 
constitute the standard clinically used parameters.”  
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5.6 Limitations of the Study 
 
Breathing was measured indirectly through first approximation of chest wall movement 
measured by changes in a pressure band worn around the chest. Direct measurement of 
tidal breathing was not measured due to unavailability of equipment and the chest cuff 
was not calibrated prior to use. The measurement of chest wall movement as an 
approximation of patient breathing was a limiting factor in this project. To investigate 
accurately the relationship between Heart Rate and Breathing, a more accurate measure 
of instantaneous air flow and ideally intra-thoracic pressure would be needed. However 
as we are looking at heart rate changes relating to controlled cyclical deep breathing, 
absolute measures of lung function are not necessary and for assessment of autonomic 
function (heart rate variability) this technique is adequate.  
 
We assessed volunteers prior to the vaccination and as close to two days post 
vaccination as possible. The occupational health department vaccinated approximately 
one thousand members of staff on eight set dates over approximately 4 weeks and we 
tried to fit in around their schedule. Some of the “flu clinics” were drop in clinics, 
where booking was not required and the other sessions were pre-booked in advance. It 
was the pre-booked people we were able to contact prior to the vaccination 
appointment. Vaccination takes approximately two minutes. Our study took 
approximately 20 minutes on each visit so we were unable to see the volunteers at the 
same rate as the occupational health department. We struggled to cope with the number 
of volunteers recruited. On the days following the flu clinics, we were performing 
autonomic function studies in 20 minute sessions from 8am. This was on top of routine 
clinical commitments. We also had a problem when the flu clinics fell on a Thursday or 
Friday as it meant patients wouldn’t be seen again for the second assessment until 
Monday which would put the timing beyond the optimum 2 day follow up. We 
therefore could not include people vaccinated on Thursday and where possible avoided 
recruiting people vaccinated on Friday. 
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We acknowledge a significant drawback for this study was the lack of provision in the 
protocol to take blood samples for inflammatory markers. The project was performed 
on a minimal budget and there was no financial provision made for such testing. We 
did not have staff competent in phlebotomy techniques within the immediate 
department, or storage and analysis equipment for blood samples, which would have 
incurred further costs. We also thought that it would be more difficult to recruit if blood 
samples were part of the protocol. If this study is repeated in the future it would be the 
first amendment that would be made to the protocol. 
 
5.7 Future Work 
 
Vassallo and Allen (1997) identified that patients often remain non-specifically ill for a 
significant period following pneumonia and recovery takes much longer than would be 
expected. Mr Middleton, Consultant Orthopaedic surgeon spoke at a post graduate 
research meeting about hip replacement and he observed that there appears to be a 
distinct group of patients who undergo total hip replacement, who do not seem to 
recover as quickly as might be expected which may be related to a drop in autonomic 
tone and we posit that we could potentially identify those patients by autonomic 
screening prior to surgery. A consultant in elderly medicine at Poole hospital has 
recently contacted our department to discuss a similar phenomenon involving patients 
under his care. He has noticed anecdotally that elderly patients with pre-existing co-
morbidities often seem to take much longer to recover from influenza than would be 
expected. He has noted that the non-specific ill health cited by Vassallo and Allen 
following inflammatory response to influenza seems to last for considerably longer 
than expected but usually resolves before the next follow up appointment several weeks 
later where the patient reports an improvement. We would like to be involved in the 
clinical assessment of HRV in this group of patients. 
 
I intend to perform a small study to establish whether changing the shape of the 
respiratory curve makes any difference to heart rate variability. This is on-going. 
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There is a need to further refine our age matched normal ranges of autonomic heart rate 
variation based on metronome guided breathing and simultaneous measurement of 
chest plethysmography. 
 
This project has been written up and has been published in: Clinical Physiology and 
Functional Imaging 2012. A copy of the published document is included in the 
appendices (see appendix 16.1). 
A longer term study following up the most symptomatic volunteers at set periods after 
the vaccination would have been useful to establish when the autonomic tone returns to 
its pre vaccination state. This was not in the ethics protocol for this study and was not 
performed. 
 
The influenza vaccination and heart rate variability project looked at the influence of an 
acute inflammatory response triggered by the influenza vaccination on the autonomic 
nervous system. It is suggested that this inflammatory state is temporary and blood 
markers suggest it peaks at two days and diminishes rapidly thereafter. I will look at the 
data and reanalyse it according to the number of days post vaccination, days 2-5.  
 
The next phase of this research was to look at the effects of a more chronic 
inflammatory state. The provocation chosen for the next research project was erosive 
oesophagitis related to gastro-oesophageal reflux disease. It is established in previous 
research that the presence of erosive oesophagitis significantly reduces autonomic tone. 
This will be discussed in more detail in chapter 6. 
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6 .Chapter 6 Evaluation of the Effects of Proton Pump Inhibitors on Autonomic Tone in Patients with Erosive or Non 
Erosive Oesophagitis. 
Chapter 6: Evaluation of the Effects of Proton Pump 
Inhibitors on Autonomic Tone in Patients with Erosive or 
Non Erosive Oesophagitis.  
 
6.1 Autonomic Nervous System and the Gastrointestinal System 
 
It has been suggested that there is a link between gastroesophageal reflux disease 
(GORD) and impaired cardiovascular autonomic function, assessed by heart rate 
variability measurement. Chen (2006) found that the autonomic function appears to 
differ significantly between patients with and without erosive oesophagitis. Lee et al 
(2004) suggested that it is the structural state of the oesophagus and not the 
symptomology, which dictates the autonomic function status. 
 
This study will examine heart rate variability in two patient groups, those with mild 
erosive reflux (oesophagitis) disease (ERD) and those with non-erosive reflux disease 
(NERD). It will also assess symptom severity and the change in autonomic tone in the 
two groups after an eight week healing dose of proton pump inhibitor therapy. 
 
6.2 Gastro-Oesophageal Reflux Disease and Erosive and Non Erosive 
Oesophagitis  
 
6.2.1 Terminology 
 
Interchangeable terms are frequently used to describe gastro-oesophageal reflux disease 
and are often abbreviated to either GORD or GERD, the former is English, the latter is 
the American spelling but both are commonly used to mean the same thing. 
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6.2.2 GORD: What are the Causes and Symptoms of Acid Reflux? 
 
There are several theories as to the causes of reflux. It is generally thought that the 
muscle of the lower oesophageal sphincter becomes weak or is prone to Spontaneous 
Transient Lower Oesophageal Sphincter Relaxations (TLOSR’s) (Bredenoord et al 
2006)). Several other contributory factors can also promote acid reflux, such as 
smoking, or drinking too much alcohol. Being overweight or wearing tight clothing can 
also increase the upward pressure on the gastro-oesophageal junction between the 
oesophagus and the stomach (Ayazi et al 2007). Some people will notice that certain 
foods promote reflux, particularly acidic, rich, spicy or fatty foods. In some cases acid 
reflux is associated with the presence of a hiatus hernia, which prevents the muscle at 
the base of the oesophagus from functioning (Sontag 1999). 
Symptoms of gastroesophageal reflux disease (GORD) are very common, affecting 9% 
to 17% of the population of Europe, 20% in North America, 12% to 15% of Australia, 
and 2% to 5% of Asia once a week (Fass 2005). Acid reflux causes a range of 
symptoms including a burning sensation in the upper abdomen and lower chest, 
sometimes moving up into the throat. The oesophagus does not have the same 
protective lining as the stomach and therefore the acid and other digestive enzymes 
normally produced by the stomach can cause a burning sensation. It is often worse at 
night or when supine or can be brought on by bending or physical exercise, particularly 
after a meal. This sensation or discomfort is most often referred to as heartburn. Other 
typical symptoms associated with reflux are epigastric pain, retrosternal pain, belching, 
dysphagia, and regurgitation. 
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6.2.3 Reflux Oesophagitis 
 
If the lower oesophageal sphincter (LOS) is weak or relaxes inappropriately, stomach 
contents flow into the distal oesophagus causing irritation and inflammation (De Vault 
et al 1999). Oesophagitis is inflammation of the lining of the oesophagus. In most 
people this is caused by the digestive enzymes in the stomach, repeatedly moving 
upwards into the lower oesophagus. The oesophageal mucosa becomes inflamed and 
has a blistered appearance (Sontag et al 2006).  
 
6.2.3.1 Grading Erosive Oesophagitis. 
 
When the oesophagus is assessed using endoscopy, the practitioner looks for evidence 
of reflux oesophagitis and the severity? Oesophagitis is graded according to its severity 
to improve consistency of reporting among clinicians. The Los Angeles Classification 
for diagnosis and grading of reflux oesophagitis was published in 1999 (Dent 2008) 
and then further recommended in a paper by Katz et al (2013.). 
 
6.2.3.2 Erosive Oesophagitis: Los Angeles Classification 
 
Grade A  
One (or more) mucosal break no longer than 5 mm that does not extend between the 
tops of two mucosal folds 
 
Grade B  
One (or more) mucosal break more than 5 mm that does not extend between the tops of 
two mucosal folds 
 
Grade C 
One (or more) mucosal break that is continuous between the tops of two mucosal folds 
but which involves less than 75% of the circumference 
 
Grade D 
One (or more) mucosal break, which involves at least 75% of the oesophageal 
circumference. 
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6.2.3.3 Non Erosive Oesophagitis (endoscopy negative reflux disease). 
 
The number of patients presenting with symptoms of typical gastro-oesophageal reflux 
disease (GORD) but do not have any endoscopic evidence of erosive oesophagitis is 
actually higher than those with reflux oesophagitis (Fass 2005). Compared with 
patients with erosive oesophagitis, the non-erosive reflux disease (NERD) patients tend 
to be younger, female, and lack a hiatus hernia (Fass 2006). The lack of endoscopic 
evidence of reflux in the non-erosive group does not mean that these patients are not 
experiencing GORD. Further assessment via 24 hour pH and impedance measurement 
often reveals a high level of acid reflux outside of physiological limits. 
 
 
6.2.3.4  Erosive and Non Erosive Oesophagitis and the Effect on Autonomic 
Function 
 
Historically the link between Gastroesophageal reflux disease (GORD) and impaired 
cardiovascular autonomic function has been examined in research by Chakraborty et al 
(1989). Recent research by Chen (2006) has looked at the differences in autonomic 
function in patients with and without erosive oesophagitis; assessed by clinical 
symptoms, endoscopy, and 24hr pH measurement. Research showed that autonomic 
tone was reduced in the erosive oesophagitis patients. Chen (2006) found that the 
symptoms severity scoring was the same regardless of the presence or absence of 
erosive oesophagitis but the autonomic function appears to differ significantly between 
the two groups, with spectral analysis of heart rate variability significantly reduced in 
the high frequency power band in patients with erosive oesophagitis (neurogenic 
inflammation) (Maggi and Meli 1988). Lee et al (2004) also found reduced autonomic 
tone in patients with erosive oesophagitis (even in patients without symptoms) 
compared with the non-erosive group. Chakraborty (1989) and Cunningham (1991) 
both demonstrated reduced autonomic tone in patients with erosive oesophagitis and 
abnormal ambulatory 24 hour pH measurement.  
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There is an established link between oesophageal motility and reduced autonomic tone. 
Autonomic neuropathies constitute disorders of extrinsic innervation. These may affect 
both the sympathetic and parasympathetic systems or may selectively involve 
cholinergic or adrenergic function (Khurana 1988). Oesophageal acid exposure is 
generally associated with a decrease in autonomic tone. A predominant 
parasympathetic fluctuation during sleeping and a superimposed sympathetic 
interaction during waking dictate diurnal characteristics of autonomic regulation (Lee 
et al 2006). 
 
Cunningham et al (1991) studied the prevalence
 
of and relations between autonomic 
nerve dysfunction (as assessed
 
by cardiovascular reflex tests) and oesophageal transit, 
oesophageal
 
motility, gastric emptying, and endoscopic grade of oesophagitis.
 
They 
concluded that in gastro-oesophageal reflux disease there
 
is a high prevalence of 
parasympathetic nerve dysfunction, which
 
relates to delayed oesophageal transit and 
abnormal peristalsis
 
and may therefore be of pathogenic importance. They report that 
there is no correlation between the presence of autonomic dysfunction and the 
endoscopic grade of oesophagitis. 
 
6.2.4 Proton Pump Inhibitor (PPI) Therapy 
 
Proton Pump Inhibitor (PPI) therapy is a common treatment for GORD related 
symptoms. PPI therapy has been commercially available since the 1980’s and is some 
of the most widely prescribed medication in the world. Caro et al (2001) performed a 
Meta-analysis of 53 studies involving acute PPI therapy and maintenance PPI therapy. 
These studies looked at the PPI healing rates for erosive oesophagitis at eight weeks. 
All PPI’s showed a greater degree of healing oesophagitis at eight weeks than 
ranitidine (H2-receptor antagonist) or placebo and all maintained similar rates of 
symptom control. Chiba et al (1997) show that 4 – 12 week PPI therapy heals 
oesophagitis twice as fast as Histamine receptor antagonists (H2RA’s) peaking at 6 
weeks and determined that PPI’s irrespective of dose or duration of treatment provided 
the greatest overall symptom relief. Dean et al (2004) suggest healing at 4 weeks may 
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not show full therapeutic gain in patients with NERD and that the trend of symptom 
improvement may well takes at least eight weeks. We opted to follow up patients in 
this study eight weeks after commencing PPI therapy to allow for complete healing. 
 
6.2.4.1 PPI Therapy and the Autonomic Nervous System. 
 
An extensive literature and Internet search has found no evidence to suggest that PPI 
therapy has any known effect on the autonomic nervous system. The Medicine 
Information Department at Astra Zeneca could not find information on any known 
effects of Proton Pump Inhibitors on the Autonomic Nervous System. 
 
6.3 Rationale 
 
The first part of this PhD research explored the acute inflammatory effects of the 
influenza vaccine on autonomic function. We were able to perform experimental 
research on healthy volunteers collecting pre-test and post-test data, looking at subtle 
and temporary changes in autonomic tone in response to the vaccination provocation. 
The influenza vaccine allowed us to study a relatively large number of volunteers in a 
controlled hospital setting, assessing HRV before and after vaccination.  
 
The results of the preceding influenza study suggest a temporary reduction in 
autonomic tone with respect to temporal and frequency measures of heart rate 
variability post vaccination. This is particularly significant in a small sub-group of 
participants (n=15) who reported the most notable symptoms after the vaccination (see 
Table 9).  
 
Another group of patients we are interested in studying are those with gastro-
oesophageal reflux disease. We routinely provide a range of GI physiological 
assessments and work closely with endoscopy, gastroenterology and surgery. A paper 
by Farmer et al (2013) recently discussed the role of the autonomic nervous system 
during oesophageal intubation and the relationship of stress to intubation.  We know 
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that the gut is driven by the autonomic nervous system (Olsson and Holmgren 2011), 
and hypothesize in a similar fashion to Chen et al (2006) that the presence of erosive 
oesophagitis and associated inflammation caused by gastroesophageal reflux disease 
(GORD) may be enough to cause a change in HRV, particularly for those with erosive 
oesophagitis. This was also investigated by Lee et al (2004), who concluded autonomic 
tone was lower in the erosive oesophagitis group than for the non-erosive oesophagitis 
group. Although previous research has shown a relationship between inflammation 
(oesophagitis) and reduced HRV, none have demonstrated whether or not it is a 
reversible process. We posit any resulting attenuation in autonomic function may be a 
temporary process, which is reversible after healing of the inflammation from eight 
weeks of PPI therapy. We aim to establish whether there is a measureable difference in 
autonomic tone through measurement of heart rate variability (HRV) prior to, and after 
eight weeks of PPI therapy which research by Caro et al (2001) suggests should result 
in complete healing of erosive oesophagitis caused by GORD. After healing of the 
oesophagitis has occurred we would expect an improvement in autonomic tone 
(increase in HRV) compared to the baseline visit. This will be supported by the GERD 
Impact Scale scores, which will be collected before and after eight weeks of PPI 
treatment for both the NERD and ERD groups, where we expect a significant decrease 
in symptom scores relating to an improvement in symptoms. Other research in this field 
has not looked at changes in HRV in this way. 
 
There is also controversy surrounding the non-erosive oesophagitis group with 
conflicting results relating to the effect of inflammation on HRV in this particular 
group. We would also like to examine whether there is any change in autonomic tone in 
patients symptomatic of GORD who are identified endoscopically as having non-
erosive reflux disease (endoscopy negative), but have other markers for GORD such as 
a hiatus hernia or lax lower oesophageal sphincter. In this instance, we would posit that 
i) autonomic performance in the non-erosive group would be the same prior to and after 
eight weeks of PPI therapy and ii) In the erosive oesophagitis group we would expect 
differences in autonomic function before and after eight weeks of PPI therapy.  
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6.4 Aims 
 
The main aims of this part of this study were to: 
 
1. Discern whether there was a difference in autonomic tone between 
patients with non-erosive oesophagitis disease (NERD) and erosive 
oesophagitis reflux disease (ERD) 
2. Investigate the effects of an 8 week course of anti-reflux treatment (PPI) 
on autonomic tone in both patient groups. 
3. Establish whether the level of response to PPI treatment according to the 
GERD Impact Scale was associated with the level of improvement in 
autonomic tone. 
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7 Chapter 7 Methods (GORD Study) 
Chapter 7: Methods (GORD Study) 
 
7.1 Study Design 
 
A descriptive, cross sectional, pre-test / post-test design was used to assess the effect of 
erosive and non-erosive reflux disease and the effect of eight weeks of PPI therapy on 
autonomic performance. 
Routine endoscopic investigation was performed by Consultant Gastroenterologist / 
Surgeon/ Endoscopist who made a clinical judgement regarding the inclusion / 
exclusion criteria for recruitment for the research project. 
 
 
7.2 Recruitment 
 
Patients were referred for endoscopic investigation and diagnosis of symptoms 
associated with GORD. Endoscopic examination was performed in the normal way. If a 
patient was identified as a suitable candidate for the research project and fulfilled the 
inclusion / exclusion criterion (see section 7.2.1) they were approached prior to their 
discharge. A patient invitation letter was given to the patient introducing them to the 
study along with the patient information leaflet. If sedation had been used during the 
endoscopy procedure the patients could not be recruited to the study on the same day 
and were asked to contact us if they wished to take part on a future date. 
 
Patients were informed that taking part in the research project would not be part of their 
routine care and that they did not have to take part if they did not wish to do so. They 
were also assured that any decision they made about taking part would not affect their 
treatment and continuing care in the hospital. 
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7.2.1 Inclusion Criteria: 
 Heartburn 
 Retrosternal pain 
 Regurgitation 
 Epigastric pain 
 Non cardiac chest pain 
 Patients to be prescribed PPI 
 Grade (A) and (B) oesophagitis 
 Hiatus hernia 
 Lax lower oesophageal sphincter 
 
7.2.2 Exclusion Criteria: 
 
Exclusions remain as per section 3.3.2. The following are related to this study: 
 
GI related exclusions:  
 Oesophageal varices,  
 Grade (C) and (D) reflux oesophagitis,  
 Barrett’s oesophagus,  
 Achalasia,  
 Upper GI pathology apart from oesophagitis,  
 Recent upper GI surgery,  
 Dysphagia,  
 Long term use of PPI 
 
7.2.3 Description of Population under Study 
 
Patients aged 18 – 80 years were recruited by Gastroenterologists, nurse endoscopist 
and a GI Surgeon. Patients were assigned to two distinct groups based on the 
endoscopic findings; the erosive oesophagitis group or the non-erosive oesophagitis 
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group. Aside from reflux disease we recruited an otherwise healthy group of 
participants with no pre-existing co morbidities. 
Statistical power calculations performed by a statistician in the research and 
development unit at Bournemouth University, suggested that recruitment of thirty 
patients would provide enough data for the results to be statistically reliable (see 
appendix 16.3).  
 
 
7.2.4 Patient Pathway 
      
                  
 
         Figure 28. Algorithm to determine route through research pathway. 
 
 
 OGD + Symptoms  
Autonomic Function Testing + 
Symptom Questionnaire 
Grade 1 and 2 Erosive 
Oesophagitis Reflux Disease  
(ERD)  
Non Erosive Reflux Disease 
(NERD) 
GP referral to Consultant 
 PPI Prescribed by GP/ Consultant 
      (8 weeks course)  
 Repeat Autonomic Function Testing on PPI 
 +   
 GERD Symptom Questionnaire 
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7.3 Instrumentation 
 
Full details of instrumentation are discussed fully in sections 3.4. The same protocol 
was followed for this study.  
 
 
7.4  Preparations Required for the Investigation:  
 
The general preparations for this assessment are as listed in section 3.4.5. The 
following additional preparations are specific to this study: 
 If the patient’s GP has previously prescribed a course of PPI treatment this 
was continued as normal after the initial autonomic function testing has 
been performed. 
 If the patient had not already been prescribed a PPI by the GP the 
Consultant prescribed an eight week course of PPI treatment.  
 Patients were reassessed at approximately eight weeks post endoscopy 
while still taking PPI medication. Repeat autonomic function testing was 
performed in the medical physics department. 
 A second “GERD Impact Scale” questionnaire was completed after eight 
weeks of treatment with PPI (see Figure 29). 
 
7.4.1 GERD Impact Scale 
 
The GERD Impact Scale (Figure 29) is a simple method of scoring reflux symptom 
severity. The symptoms are rated from 1-4 (1) =never (4) =daily. The best possible 
score would be 9 relating to no reflux symptoms. The worst possible score would be 36 
representing daily symptoms. 
  
122 
 
Figure 29 GERD Impact Scale 
 
 
7.5 Ethical Approval  
Ethical approval was sought and approved by Hampshire Research Ethics Committee 
(10/H0504/31) see appendix 16.4.2  
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Chapter 8: Results (GORD Study) 
 
8.1 Recruitment and Characteristics of the Study Group 
 
This chapter will present the results of the GORD study, including addressing 
demographics of the study population, examining the mild inflammatory effect of non-
erosive and erosive oesophagitis on HRV during autonomic assessment including two 
minutes of metronome guided breathing and the effect of eight weeks of PPI therapy on 
autonomic tone.  
 
We recruited 20 participants in total, 12 in the NERD group and 8 in the ERD group; 
the average age was 50.6 years ±12.2. The average age for the ERD group was slightly 
higher than the average age for the NERD group however the difference between the 
two groups was not statistically significant. The recruitment numbers, age and gender 
of the participants for this study are shown in Table 19.  
 
The age of this cohort was compared with the age of the previous normal range 
collected from the influenza study (mean 48.6± 11.9) using an unpaired t test. There 
was no statistically significant difference between the ages of the two groups (P=0.52, 
t=0.64). 
 
Recruitment was unpredictable and more difficult than expected. We initially recruited 
23 patients into the trial. An additional 12 patients were identified but they either 
declined to take part in the project or were sedated during the gastroscopy and did not 
contact us. The dropout rate was 13%. Despite best efforts to encourage a repeat visit 
some of the participants did not attend for follow up. 
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Table 19. Gender and age for all participants in the GORD project.  
 Numbers Mean Age (yrs.) SD 
Total Group 20 50.6 12.2 
NERD Group    
Total 12 50.58 13.67 
Female 5 52.2 9.2 
Male 7 49.8 16.3 
ERD Group  
Total 8 52.5 10.12 
Female 4 50.5 9.2 
Male 4 53.7 11.8 
Mean and standard deviation for age of the males, females and total for the NERD and ERD group. 
 
 
8.2 Relating the GERD Impact Scale Scores to severity and frequency of 
symptoms 
 
All participants completed a GERD impact scale questionnaire at both visits. In the 
ERD and NERD group there was a relationship between a decrease in symptom scale 
scores and a decrease in the severity or frequency of the symptoms, suggesting after 
eight weeks of medication the patients experienced less frequent and less severe 
symptoms related to GERD. Table 20 shows the percentage decrease in symptom 
scores between the first visit and after eight weeks of PPI treatment.  
Analysis of the results for the GERD Impact scale using a paired t-test shows a 
statistical difference (p=<0.001) in the scores for the ERD, and NERD groups between 
visits one and two, after eight weeks of PPI therapy. The patients reported less frequent 
and less severe symptoms. The improvement in symptoms are reflected in a lower 
score on visit 2 representing a reduction of 26.4% and 26.7% in ERD and NERD scores 
respectively (see Table 20). 
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 Table 20 GERD Impact Scale Scores and percentage reduction in scores for the ERD and NERD 
groups pre and post 8 week PPI therapy.  
 Mean V1 
(±SD) 
Mean V2 
(±SD) 
% Difference in GERD 
Impact scores between visit 1 
and 2 (±SD) 
P Value  
ERD 32.6 (4.3) 24.0 (4.9) 26.4% (7.3) P= <0.001  
NERD 30.3 (4.9) 22.2 (4.8) 26.7% (14.2) P= <0.001  
Mean (±SD) are given for each group with the analysis performed using a paired t-test. The results are 
given at (P=0.05) confidence level (in bold). Minimum GERD Impact Scale score = 9 (indicating no 
reflux symptoms); maximum GERD Impact Scale score = 36 (indicating severe daily symptoms). 
 
 
8.3 Comparison of GERD Impact Scale scores for ERD and NERD groups for 
visit one and visit two respectively. 
 
Sub-group analysis showed a statistical difference in scores relating to symptoms pre 
and post eight week PPI therapy (see Table 20). A lower overall point score on visit 
two for both groups related to a better outcome i.e. less frequent or less severe 
symptoms experienced after eight weeks of PPI treatment compared to the initial visit 
where patients were either not taking their PPI (as per gastroscopy protocol) tablets or 
had not yet started the course of PPI therapy. 
 
Comparison of the GERD Impact scale scores at baseline for the ERD and NERD 
group was performed using a Mann Whitney U test. There is no statistical difference 
between the ERD (32.6 ±4.4) and NERD (30.3 ±4.9) scores collected for visit one 
(p=0.42). This suggests that neither the ERD nor NERD group were experiencing 
greater or lesser symptoms than the other. 
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8.4 Comparison of Baseline Heart Rate Variability for the ERD and NERD 
Groups with Normal Range Data (N=71) 
 
Heart rate variability at baseline (visit 1) for the ERD and NERD groups was compared 
with heart rate data from a healthy normal range to establish if HRV is attenuated in 
either group compared with the healthy normal range (currently used in our medical 
physics laboratory as normal standard reference values for similar age and gender). The 
percentage difference between the sets of data is clear, with attenuation in all ERD 
heart rate variability parameters compared with the normal heart rate data. An unpaired 
t-test was used to analyse the data. Results show that there are some statistically 
significant differences between heart rate measures for the ERD group and the normal 
reference values for the healthy data; in particular, resting (p=0.05), Valsalva (p=0.001) 
and CORR (p=0.03) as shown in Table 21.  
 
However, the outcome is less clear with the NERD data, as there is either a decrease in 
half of the HRV parameters or no change in the other half when compared with the 
normal reference values. Furthermore, there were no statistical differences between 
NERD data and the normal range data (see Table 21).  
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Table 21 Comparison of Baseline ERD (N=8) and NERD (N=12) HRV with Normal Range HRV 
Data (N=71) 
 Normal 
Mean 
(±SD) 
ERD  
V1 
(Mean 
(±SD) 
% 
Diff 
P  
Val 
Normal   
Mean 
(±SD) 
NERD V1 
Mean  
(±SD) 
% 
Diff 
P  
Val 
Ewing Measures 
Resting (%) 9.2  (5.7) 5.3 (2.9) -42.4 0.05 9.2  (5.7) 7.0 (4.9) -23.9 0.20 
Forced Breathing 
(%)  
19.5 (0.6) 13.9 (9.1) -29.1 0.16 19.5 (0.6) 20.6 (14.6) 5.1 0.78 
Insp/Exp (bpm) 14.17 (7.7) 9.3 (5.2) -34.4 0.08 14.17 (7.7) 13.5 (8.9) -4.7 0.77 
Valsalva (ratio) 1.32 (0.2) 1.2 (0.1) 24.2 0.001 1.32 (0.2) 1.4 (0.3) 6.0 0.79 
Hand grip ratio 
(ratio) 
1.17  (0.1) 1.1 (0.1) -5.9 0.3 1.17  (0.1) 1.2 (0.1) 2.56 0.13 
Metronome Breathing 
SD (bpm) 0.63 (1.8) -0.34 (1.6) -153 0.71 0.63 (1.8) 0.89 (1.5) 41 0.5 
A (bpm) 0.33 (1.0) 0.16 (1.4) -51.5 0.6 0.33 (1.0) 0.69 (1.5) 109 0.37 
LPP (unitless) 0.63 (1.1) 0.1  (1.0) -84 0.09 0.63 (1.1) 0.68 (1.0) 7.9 0.90 
CORR (unitless) -0.37 (0.8) -1.91 (1.9) -416 0.03 -0.37 (0.8) -0.84 (1.8) -127 0.42 
FCORR (unitless) -0.10 (1.2) -0.95 (2.1) -850 0.07 -0.10 (1.2) -0.09 (0.6) -10 0.36 
DEV 0.29 (1.2) -0.46 (1.6) -258 0.10 0.29 (1.2) 0.27 (1.1) -6.9 0.74 
Mean (±SD) for HRV parameters for the NERD and ERD group and the HRV data from the healthy 
normal range are shown. Percentage difference is shown between the normal values and the ERD/ 
NERD values. Analysis using an unpaired t-test was performed (P=<0.05). The significant results are 
shown in bold. Parameters shown are described in section 3.10.6. 
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8.5 HRV Parameters for Ewing assessment and during metronome guided 
breathing for the ERD and NERD Groups 
 
The Ewing tests were performed at baseline and after eight weeks of PPI therapy for 
the NERD and ERD groups. There was a generalised increase in (i.e., improvement) in 
HR values for the ERD and NERD group between the two visits indicating an 
improvement (recovery) in autonomic tone after eight weeks of PPI. Analysis of the 
results showed no statistically significant differences between the HRV for the ERD 
group before and after 8 weeks of PPI therapy. There is however an overall trend in the 
data showing an increase in the mean HRV values, in particular for forced breathing, 
(see Table 22).  
The same observation is also applicable to the NERD group, as we did not see any 
statistically significant differences in HRV measures in the NERD group. However, 
there was again evidence of a trend in the data showing an improvement in HRV before 
and after eight weeks of PPI therapy (see Table 22). 
 
Metronome guided breathing was performed for two minutes at 6 breaths/minute rate. 
Mean values for the ERD group for certain parameters show a trend toward a recovery 
in autonomic tone after eight weeks of PPI therapy with a percentage improvement in 
four of six parameters. However, analysis of the heart rate data showed a statistically 
significant difference only in the DEV parameter (P=0.05) before and after eight weeks 
of PPI therapy (see Table 22 and Figure 30).  
On the other hand, although certain parameters from the NERD group data also show a 
trend toward some improvement in autonomic tone after eight weeks of PPI therapy, 
there were no significant statistical differences in the frequency parameters for the 
NERD group. 
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Figure 30 Graph showing the DEV parameter for the ERD group.  
Box and whiskers plot showing the DEV parameter before (visit 1) and after eight weeks of PPI (visit 2) 
for the ERD group. Statistical analysis shows a significant (p=0.05) difference between visits with a 
higher DEV score (improved HRV) after eight weeks of PPI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Visit 
D
E
V
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Table 22 Result for all HRV parameters during Ewing assessment and metronome guide breathing 
for the ERD and NERD group pre and post eight week PPI therapy.  
 ERD Group (N=8) NERD Group (N=12) 
 V1  
Mean 
(±SD) 
V2 
(Mean 
(±SD) 
% 
Diff 
P  
Val 
V1  
Mean 
(±SD) 
V2 
Mean  
(±SD) 
% 
Diff 
P  
Val 
Ewing Measures 
Resting (%) 5.3 (2.9) 5.4 (3.8) 1.89 0.91  7.0 (4.9) 10.0 (8.4) 42.9 0.12  
Forced Breathing 
(%) 
13.9 (9.1) 19.6 (9.7) 41 0.06 20.6 (14.6) 22.7 (13.6) 11.17 0.32  
Insp/Exp (bpm) 9.3 (5.2) 12.1 (6.1) 30.1 0.08  13.5 (8.9) 14.6 (9.5) 8.15 0.30  
Valsalva (ratio) 1.2 (0.1) 1.3 (0.2) 8.3 0.12 1.4 (0.3) 1.4 (0.23) 0 0.27  
Hand grip (ratio) 1.1 (0.1) 1.1 (0.1) 0 0.35 1.2 (0.1) 1.2 (0.08) 0 0.18  
Lying / Standing 
(ratio) 
1.0 (0.1) 1.1 (0.1) 10 0.14 1.1 (0.16) 1.0 (0.38) 9.1 0.71  
Metronome Breathing 
SD (bpm) 0.34 (1.6) 0.47 (1.7) 38.2 0.55  0.89 (1.5) 0.99 (1.5) 11 0.58  
A (bpm) 0.16 (1.4) 0.13 (1.5) -18.7 0.39  0.69 (1.5) 0.6 (1.5) -13 0.81  
LPP (unitless) 0.1  (1.0) 0.07 (1.1) -30 0.44  0.68 (1.0) 0.61 (1.0) 10.3 0.62  
CORR (unitless) -1.91 (1.9) -1.65 (2.2) 13.6 0.80 -0.84 (1.8) -0.61 (1.8) 27 0.62  
FCORR (unitless) -0.95 (2.1) -0.64 (2.0) 32 0.49  -0.09 (0.6) -0.15 (1.3) -66 0.38  
DEV -0.46 (1.6) -0.37 (1.6) 19.57 0.05 0.27 (1.1) 0.36 (1.4) 33 0.34  
Mean (±SD) for HRV parameters for each group are shown. Analysis using a paired t-test was 
performed (P=<0.05). The significant results are shown in bold. Parameters shown are described in 
section 3.10.6. 
 
8.6 Summary of Resting Heart Rate Variability Prior to and following eight 
weeks of PPI therapy 
 
The extended resting heart rate values for both groups were compared before and after 
PPI therapy. There was an increase in all values between visits apart from SDNN for 
the ERD group. For the NERD group there was a marginal increase in all values apart 
from LF/HF ratio. Statistical analysis of the extended period of resting heart rate 
variability was assessed for the ERD and NERD group. A table of results (Table 23) 
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summarises the differences between measures of resting heart rate variability prior to 
and following eight weeks of PPI therapy for the ERD and NERD groups. Other 
measures include Fractal dimension as defined by Higuchi’s algorithm. SDNN = 
Standard deviation of RR interval. PNN50 = percentage of RR intervals where the gap 
between adjacent intervals is greater than 50ms. LF/HF ratio = ratio of integrated 
spectral power of the portions of the heart rate frequency plot in the low frequency 
(0.04-0.15 Hz) and high frequency (0.15 – 0.4 Hz) bands. There were no statistically 
significant differences between any measures pre and post PPI therapy for either group. 
 
 
Table 23 Summary of the differences between measures of resting heart rate variability prior to 
and following PPI therapy for the ERD and NERD group.  
Parameter Mean (±SD)  
Visit 1 
Mean (±SD)  
Visit 2 
% Diff 
(V1-V2) 
P value 
ERD group (N=8) 
*Resting Heart Rate (bpm) 76.9 (12.3) 77.8 (11.65) 1.2 0.89 
Fractal Dimension -1.29 (0.06) -0.98 (0.87) 24.0 0.36 
SDNN (ms) 32.1 (4.07) 30.9 (10.7) -3.74 0.36 
PNN50 (%) 1.66 (1.8) 2.86 (3.6) 72.3 0.34 
LF/HF Ratio 2.29 (1.07) 3.55 (1.8) 55 0.12 
NERD (N=12) 
*Resting Heart Rate (bpm) 73.8 (13.2) 74.5 (10.91) 0.95 0.28 
Fractal Dimension -1.24 (0.05) -1.23 (0.06) 0.8 0.92 
SDNN (ms) 66.4 (47) 68.6 (72.6) 3.3 0.27 
PNN50 (%) 2.7 (2.07) 2.8 (2.7) 3.7 0.15 
LF/HF Ratio 3.55 (1.6) 2.93 (1.3) -16.9 0.28 
Mean and SD values for extended resting HR measures. Fractal dimension as defined by Higuchi’s 
algorithm. SDNN = Standard deviation of RR interval. PNN50 = percentage of RR intervals where the 
gap between adjacent intervals is greater than 50ms. LF/HF ratio = ratio of integrated spectral power of 
the portions of the heart rate frequency plot in the low frequency (0.04-0.15 Hz) and high frequency 
(0.15 – 0.4 Hz) bands. *Over extended resting period 
 
 
 
  
132 
8.7 Pupillary dark adaptation response. A comparison of standard deviation 
from the age matched normal range for the ERD and NERD group. 
 
Pupillometry was performed for each volunteer. The pupillary dark adaptation response 
increased between visit one and visit two, (after eight weeks of PPI therapy) with a 
percentage rise in both the ERD and NERD group. Analysis of results using a paired t-
test show a statistically significant difference (p=0.037) when comparing the number of 
standard deviations from age matched normal values for the ERD group (see Table 24). 
This suggests that with healing of inflammation (erosive oesophagitis) in the ERD 
group the pupillary dark adaptation response improved with a mean value of 0.43 
standard deviations above age matched normal values. For the NERD group there was 
not such a statistically significant difference, however, pupillometry values at baseline 
were already higher for this group than the ERD group and rose to a mean value of 0.16 
standard deviations below normal age matched values. The subsequent percentage 
improvement after PPI therapy for the NERD group was half that of the ERD group 
(70.9% compared to 144.4%).  
 
 
Table 24 Pupillary dark adaptation response for the ERD and NERD Groups.  
Group Mean SD Visit 1  
(+/- SD) 
Mean SD Visit 2  
(+/- SD) 
% Diff (V1-V2) P Value 
ERD (n=8) -0.97 (1.07) 0.43 (1.38) 144.3 0.037 
NERD (n=12) -0.55 (1.09) -0.16 (1.48) 70.9 0.086 
A comparison of standard deviation from the age matched normal range for the ERD and NERD group. 
Mean (±SD) values for pupillometry for each group are shown. Comparison using a paired t-test was 
performed. Significant results (P=<0.05) are shown in bold. 
 
 
8.8 Analysis of Blood Pressure Measurements Pre and Post PPI Therapy  
 
A blood pressure measurement was taken at the end of each study using a microlife 
automated brachial blood pressure monitor to ascertain whether there were any changes 
between the two visits. Continuous beat to beat measurement was also taken 
throughout each study using the Portapres. Looking at the percentage difference in 
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values between visit one and two, the automated measure of systolic blood pressure for 
both groups reduced. For the other measures all values increased slightly between visits 
for both groups. Statistical comparison of automated brachial BP and Portapres finger 
BP at visit one and visit two was performed using a paired t-test for both the ERD and 
NERD group. Analysis of the blood pressure measures between the first and second 
visits for both groups showed there was no statistical difference in systolic or diastolic 
blood pressure between visits using either measurement technique apart from the 
Portapres measure of diastolic blood pressure for the ERD group (p=0.04) (see Table 
25). 
 
Table 25 Comparison of automated blood pressure and Portapres finger blood pressure for visit 1 
and visit 2 for both the ERD and NERD groups.   
 ERD Group  (N=8) NERD Group  (N=12) 
 V1 Mean 
(±SD) 
V2 Mean 
(±SD) 
% 
Diff 
 P 
Val 
V1 Mean 
(±SD) 
V2 
Mean 
(±SD) 
 % 
Diff 
P  
Val 
Systolic automated 
mmHg 
142.5 
(22.2) 
141.0 
(22.3) 
-1.05 0.56  
 
137.6 
(17.3) 
137  
(16.2) 
-0.44 0.61 
 
Diastolic 
automated mmHg 
87.5  
(12.2) 
88.6  
(13.1) 
1.26 0.64 
 
83.5  
(8.8) 
84  
(7.4) 
0.6 0.34 
 
Systolic 
(Portapres) mmHg 
116.6 
(23.5) 
132.8 
(31.3) 
13.9 0.14 
 
114.4 
(20.5) 
120.7 
(21.0) 
5.5 0.16 
 
Diastolic 
(Portapres) mmHg 
65.1  
(8.9) 
81.3  
(7.5) 
24.8 0.04 
 
64.3  
(12.6) 
65.4  
(10.1) 
1.7 0.36 
 
Mean (±SD) for each visit for the ERD and NERD groups. Analysis performed using a paired t-test 
(P=<0.05). There were no significant changes in blood pressure between visits for either measurement 
technique. 
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9 Chapter 9: Discussion (GORD Study) 
Chapter 9: Discussion (GORD Study) 
 
9.1 Demographic Factors and their Effects on Heart Rate Variability 
 
In this study we compared heart rate variability in two distinct groups of patients 
selected via endoscopic assessment for GORD and associated erosive and non-erosive 
oesophagitis. Patient HRV was reassessed after an eight week healing dose of PPI 
therapy to assess for changes in autonomic tone. We recruited 11 males and 9 females 
with an average age of 50.6yrs (+/-12). For this study this was a lower number of 
participants recruited than initially intended. The issues surrounding recruitment are 
discussed in section 9.9.  
Research suggests that gender bias is present for autonomic tone with men displaying 
higher values of heart rate variability (Cowan et al 1998). We did not assess male and 
female results separately for this study because splitting the data into two more groups 
would have decreased the sample size further. 
Participants in this study were asked to complete a health questionnaire to ascertain 
whether there were any co-morbidities that would affect the study. The patients 
included in the study were essentially healthy with no history of inflammatory disease, 
cardiac disease or diabetes. The only disease present at the time of testing was gastro-
oesophageal reflux (with or without the presence of grade one or grade two 
oesophagitis). 
 
 
9.1.1 Diversity of the Study Cohort 
 
The study group was not ethnically diverse. There was a significant bias as all study 
volunteers were Caucasian.  
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9.1.2 Study Protocol 
 
The autonomic assessment protocol was the same as per the previous influenza study 
(see section 3.6.3), with the exception of the 10 breaths per minute metronome 
breathing provocation. Volunteers were asked to re-attend following eight weeks of 
prescribed PPI therapy. All patients were followed up within the eighth week for 
autonomic assessment. 
 
 
9.2 Comparing Baseline Measurements of Autonomic Function in the ERD and 
NERD Groups with a Healthy Normal Range 
 
Heart rate variability for the ERD and NERD groups at baseline was compared against 
healthy normal range reference values to examine whether there were significant 
differences in HRV parameters for either group. There was a marked difference in the 
percentage change in HRV values for both groups, with all parameters for the ERD 
group showing attenuation, (see Table 21). Using an unpaired t-test we saw significant 
differences between some heart rate parameters; suggesting that in an otherwise disease 
free cohort, heart rate variability in the erosive oesophagitis group was compromised at 
baseline. This is in contrast with the NERD group, where despite noting attenuation in 
heart rate variability between baseline data and the normal range, there were no 
statistically significant differences identified. It could therefore be argued that 
autonomic tone in the NERD group deviates only minimally to that of the normal 
healthy range. However, these findings should be interpreted with caution due to the 
small sample size of the study group. 
 
9.3 Ewing Measures of Heart Rate Variability in the ERD and NERD Groups  
 
Our previous research found that the inflammatory process associated with the 
Influenza vaccination was not powerful enough to provoke a significant change in 
autonomic tone assessed using the Ewing measures (except in a small subgroup with 
more significant post-vaccination symptoms).  
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Analysis of the heart rate data for the ERD group showed that there was a modest 
percentage increase in all HRV data (i.e. some recovery in autonomic functions) after 8 
weeks of PPI treatment. It is important to note here that although there were no 
statistically significant differences in all HRV collected data (pre and post PPI therapy), 
measures of forced breathing and lying/standing parameters in this particular group (i.e. 
ERD group) were in fact approaching significance (p=0.06 and p=0.08) (see Table 22).  
The NERD group also showed some improvement in HRV data (pre and post PPI 
therapy) however; there were no statistically significant differences between all data 
collected during the two visits. We suggest this may firstly be due to the fact that 
baseline HRV data for the NERD group –from the outset- were not statistically 
different from that of the normal range reference values used in our lab, and secondly 
there was no evidence of endoscopic inflammation in this NERD group. Dobrek et al 
(2004) “not only found autonomic dysfunction in patients with inflammatory changes, 
(ERD group) but also the presence of dysfunction in patients without any 
morphological changes (the NERD group) during OGD.” Our study does not agree 
with this research at the current time, as we did not identify statistically significant 
differences despite a generalised percentage improvement in HRV, (see Table 22). The 
sample size of both groups in our study is small and may not be large enough to 
adequately address this particular issue (i.e., the presence or absence of structural 
endoscopic inflammatory changes in the ERD and NERD groups and their effects on 
autonomic function), using the Ewing tests. 
 
Analysis of an extended period of resting heart rate was performed for the ERD and 
NERD group. Assessment of resting heart rate, fractal dimension, SDNN, PNN50 and 
LF/HF ratio measures were made prior to and after eight weeks of PPI therapy. There 
was an increase in most measures of resting heart rate between visits, which was only 
marginal for the NERD group but there was no statistically significant improvement 
with the intervention of PPI therapy for either group (see Table 23). This suggests that 
the effect of inflammation (associated with erosive oesophagitis in the ERD group) was 
not potent enough to elicit measureable changes in resting heart rate in either the 
sympathetic or parasympathetic branches of the ANS. Rather this suggests an initial 
reduction in the vegetative balance of the two branches (visit one), leading to a 
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generalised improvement in responsiveness after PPI therapy (visit 2). For the NERD 
group the values are only marginally changed between visits, which may be due to the 
absence of any erosive oesophagitis (inflammation) in this group. 
 
 
9.4 Heart Rate Variability Measures during Metronome Guided Breathing in 
the ERD and NERD Groups after 8 weeks of PPI therapy 
 
For heart rate measures during two minutes of metronome guided breathing there was a 
noticeable improvement in four of the six HRV parameters for the ERD group post PPI 
therapy. Results of statistical analysis of paired data collected during metronome 
guided breathing suggest there is a statistically significant difference in the DEV 
parameter between the baseline and follow up visit for the ERD group (see Table 22 
and Figure 30). This finding is in keeping with research, by Lee et al (2004) who found 
a difference in autonomic tone in the ERD group compared with the NERD group. 
Chen (2006) also found that autonomic function appears to differ significantly between 
the two groups, with spectral analysis of heart rate variability significantly reduced in 
the high frequency power band in patients with erosive oesophagitis. We suggest that 
the presence of inflammation linked to erosive oesophagitis in this group may be the 
cause of the attenuated heart rate variability at baseline and may be the cause of I) the 
attenuation observed in our HRV data when compared to a healthy normal range 
reference values (see Table 21) and II) may be the reason why in this particular group 
we see a reversal (improvement) in autonomic tone (DEV parameter) after an eight 
week healing dose of PPI therapy, (see Table 22). However, the sample size is small 
(N=8) and more data will need to be collected to establish this relationship further.  
For the non-erosive reflux disease (NERD) group there was also an improvement noted 
in the heart rate data between visits one and two for metronome guided breathing 
parameters. However, there were no statistically significant changes relating to 
autonomic tone pre and post PPI, despite a good symptomatic response to the PPI 
therapy as measured by the GERD impact scale. However, we would not necessarily 
expect to see a significant improvement in autonomic tone in this particular group, as 
the baseline heart rate data was not significantly different –from statistical point of 
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view- to that of a healthy normal range, (see Table 21). Furthermore, it could also be 
argued that any inflammatory process in the NERD group is so weak to the extent that 
it is not enough to influence or to cause attenuation in the autonomic function of this 
particular group.  
 
9.5 The Effect of Erosive Oesophagitis and Associated Inflammation on Heart 
Rate Variability 
 
The heart rate variability findings discussed in the preceding sections (9.3 and 9.4) are 
in keeping with our previous research, which suggested that the presence of 
inflammation related to the influenza vaccination (in a subgroup of the most 
symptomatic participants) was associated with significantly reduced heart rate 
variability (Perring and Jones 2012).  
All patients recruited to the ERD group were classified as having either grade A or B 
Mild to moderate oesophagitis. Chakraborty et al (1989) found heart rate variability 
was related to the grading of oesophagitis. We did not specifically assess this due to the 
small sample size. Cunningham (1991) states “The high prevalence of parasympathetic 
cardiovascular dysfunction, which was unrelated to the grade of oesophagitis, 
indicates that the vagal nerve impairment in GERD is not a secondary phenomenon” 
The results of this study agree that autonomic tone is attenuated during metronome 
guided breathing in patients with mild to moderate erosive oesophagitis prior to starting 
eight weeks of PPI therapy with subsequent augmentation in autonomic tone after the 
inflammation has healed (see Table 22).  
 
In keeping with research by Chen et al (2006), it could be argued that the small but 
measureable changes in heart rate variability seen in the ERD group may be associated 
with the inflammatory changes in the oesophagus resulting from erosive oesophagitis. 
However, research by Dobrek et al (2004) suggests that autonomic tone is disturbed in 
both NERD and ERD patients. Results from our research do not support these findings. 
We saw a generalised trend in heart rate data for the NERD group suggesting an 
increase in heart rate variability post PPI, but this did not reach statistically significant 
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levels. This may have been due to I) the small sample size or II) the absence of any 
erosive oesophagitis related inflammation in this particular group.  
At present there is a suggestion that the initial reduction and subsequent reversal 
(improvement) of autonomic tone in the ERD group may be linked to healing of 
inflammation post PPI. However, there is not enough data to conclusively ascribe the 
HRV changes solely to the inflammatory process associated with erosive oesophagitis 
and will continue to recruit more patients to the study to increase statistical power.  
 
 
9.6 Autonomic Tone in the ERD and NERD groups after eight weeks PPI 
therapy and GERD Impact Scale Scores. 
 
The GERD impact scale was used to ascertain the frequency and severity of reflux 
related symptoms prior to and after eight weeks of PPI therapy. There are many 
validated reflux questionnaires available, some of which may give more in-depth 
information relating to specific aspects of symptom relief. This scale was used as a 
simple and quick way to gauge the extent of symptoms and more generalised 
symptomatic improvement.  
For both the ERD and NERD groups there was a significant percentage decrease in 
“GERD impact scale” questionnaire scores indicating an improvement in symptoms 
after PPI therapy, (see Table 20). There were statistically significant differences in 
symptom frequency and severity prior to and after eight weeks of PPI in both groups 
(P=0.001). Research has shown that eight weeks of PPI therapy is enough time to heal 
erosive oesophagitis (Caro et al 2001). We saw a statistically significant improvement 
in autonomic tone in the ERD group (pre and post PPI therapy) during two minutes of 
metronome guided breathing. This is associated with significant improvement seen in 
the GERD impact scale scores. 
 
 Long and Orlando (2007) suggest PPI’s are the most effective agent for the treatment 
of NERD but are less effective in providing symptom relief than for patients with 
erosive oesophagitis. We did not see this in our relatively small cohort and the degree 
of response to PPI was assessed as being the same for both (ERD and NERD) groups 
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(see Table 20). Chen (2006) found that the symptoms severity scoring was the same 
regardless of the presence or absence of erosive oesophagitis but the autonomic 
function appears to differ significantly between the two groups, with spectral analysis 
of heart rate variability significantly reduced in patients with erosive oesophagitis. This 
is in agreement with our findings. Lee et al (2004) also found reduced autonomic tone 
in patients with erosive oesophagitis (even in patients without symptoms) compared 
with the non-erosive group suggesting, “It is the structural state of the oesophagus and 
not the symptomology which dictates the autonomic function status.” This is entirely in 
keeping with our findings, showing that GERD Impact Scores are not statistically 
different between the two groups, but HRV is reduced significantly in the erosive 
oesophagitis group. 
 
 
9.7 Pupillary Dark Adaptation (Pupillometry) 
 
We performed pupillary dark adaptation measures on all subjects. Statistical analysis 
was performed for the ERD and NERD group (see Table 24). There was a statistically 
significant difference in the number of standard deviations below age matched normal 
values for iris: pupil ratio, before and after eight weeks of PPI therapy in the ERD 
group (P= 0.037), (see Table 24). This indicates an improvement in autonomic 
functions after 8 weeks treatment with PPI therapy in the ERD group. 
On the other hand, although the NERD group also shows some increase in their 
pupillary dark adaptation response after 8 weeks of PPI therapy compared with their 
own baseline measurements (at visit 1), these differences were not statistically 
significant.  Possible conclusions that we can draw from this are:  
 
 That the autonomic nervous system controlling the pupil response is affected by 
inflammation resulting from erosive oesophagitis in the ERD group.  
 It could be suggested that the attenuating effect of inflammation on autonomic 
function is reversible as evidenced by the improvement in HRV after 8 weeks 
PPI therapy. However, it could be argued that the possibility of PPI drugs 
themselves exerting certain unknown (or not yet reported) pharmacological 
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effects on the improvement (or recovery) in autonomic function cannot be ruled 
out as a possible confounding factor. This is especially true, as this study did 
not have a control group to compare the collected data against. 
 That the measurement technique on this occasion appears to be sufficiently 
sensitive to determine changes in autonomic tone.  
 However, it is important to note here that the sample size was too small to be 
confident in the measurement.  
 
 
9.8 Implications of This Study 
 
This study has demonstrated a link between autonomic dysfunction and GORD. We 
have established that metronome guided breathing at six breaths per minute 
implemented during this research was sufficiently sensitive to measure small but 
statistically significant changes in autonomic tone related to inflammation in the ERD 
group. The results are in keeping with our earlier research relating to the Influenza 
vaccination whereby there was deterioration in autonomic tone following vaccination, 
especially in the severe symptomatic group. We are confident in this technique and 
have again validated the use of extended forced breathing in conjunction with spectral 
analysis as a sensitive method of assessing changes on autonomic tone. 
 
Given the reversible nature of the HRV changes seen in this study it could be argued 
that there may be justification for the treatment of GORD patients, particularly those 
who are elderly and/or with diabetes, with anti-inflammatory medication alongside 
conventional PPI therapy to reduce the impact on the autonomic nervous system.  
 
9.9 Limitations of the Study 
 
The project was limited by a number of factors, which were largely outside of our 
control. The first was the tragic and unexpected death of our consultant and principal 
investigator (PI). We were able to approach our gastroenterology colleagues for help 
with recruitment but struggled to recruit patients similar to those having endoscopy for 
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upper GI reflux who would normally be listed for assessment by the PI. A new 
consultant was recruited but unfortunately the patients on his endoscopy list were more 
complicated cases and not suitable for recruitment to the project. A nurse endoscopist 
performed the majority of the recruitment for the project.  
Furthermore it is also important to report here, one limitation related to heart rate 
variability testing is it relies on a normal sinus rhythm. Performing autonomic function 
testing on patients with arrhythmias, frequent ectopic heart beats or significant tremor 
is often very difficult and results in an unsatisfactory study. The study group chosen did 
not have pre-existing heart disease, diabetes or other co-morbidities and were an 
essentially healthy group apart from gastro-oesophageal reflux disease.  
 
We encountered a second issue, which was the use of sedation during endoscopy. If a 
patient had opted to have sedation, ethical approval stipulated we were not allowed to 
approach them or recruit them on the same day. Patients were identified in the same 
way during endoscopy and were given patient information leaflets to take home. We 
did not get any response from the patients who had been sedated. 
 
The third issue we encountered was the dropout rate. We had a number of patients who 
attended for their first visit following endoscopy and were re-booked at a convenient 
time and date eight weeks later but did not attend despite a follow up call. We think it 
was the combination of the time and effort needed to make a repeated visit to the 
hospital and a delay of eight weeks was long enough for them to forget the appointment 
or decide they did not wish to continue in the trial, despite a telephone reminder. 
 
A fourth issue was the small sample size; the power of the statistics could be improved 
by increasing participant numbers. Recruitment is on-going to further delineate whether 
there is a statistical difference between the two groups. Caution needs to be taken when 
interpreting the statistical significance of multiple parameters as the likelihood of one 
reaching the threshold for significance is additive.  
 
The fifth issue is the absence of a control group and the study is not a randomised 
double-blinded study. The researcher was not blinded to either the ERD or to the 
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NERD group for ethical and pragmatic reasons (availability of clinical / technical 
expertise, day to day running of the clinics, limited staffing, and unpredictability of 
volunteer recruitment). 
 
9.10 On-going Work 
 
We are continuing to recruit patients to the reflux study to give more power to the 
statistics and hope to publish this work in due course.  
We have established there are statistically significant changes in HRV in the ERD 
group which are likely to result from inflammation which are temporary and reversible 
after 8 weeks of PPI therapy. The reversible nature of the heart rate changes in this 
study lead to questions relating to other inflammatory conditions in chronic disease.  
 
The next study is related to the previous work examining the effects of inflammation on 
autonomic tone and is assessing the effects of obesity related inflammation from 
increased adiposity in an obese cohort of healthy individuals with a family history of 
type 1 diabetes. We will assess autonomic tone prior to and after eight months of 
intensive lifestyle and exercise intervention. 
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10 Chapter 10: The Effect of an Intensive 8-months Lifestyle Intervention on Autonomic Function in an Obese Non-diabetic 
Adult Population with a Familial History of Diabetes 
Chapter 10: The Effect of an Intensive 8-month Lifestyle 
Intervention on Autonomic Function in an Obese Non-
diabetic Adult Population with a Familial History of Diabetes 
 
10.1 Introduction to the Project 
 
This project was initiated by the diabetes research team at The Royal Bournemouth 
Hospital and was a result of an earlier pilot study that showed promising results in a 
similar field. I was involved with the diabetes team in the development of the study 
protocol, which was successfully submitted for ethical approval.  
 
There were three distinct areas related to different areas of expertise within the research 
group. These were provided by the following: 
 
 Physiological measurement and autonomic assessment was performed by 
myself and another colleague under my supervision. 
 Anthropomorphic and nutritional education was performed by research dietician 
specialising in diabetes. 
 Phlebotomy and haematology was performed by research nurses and Royal 
Bournemouth haematology department. 
 
10.2 Review of Literature 
 
10.2.1 Obesity and Diabetes 
 
The World Health Organisation (2006) cites obesity as becoming a growing and 
significant public health problem. Evidence from various national surveys show the 
prevalence of obesity in adults in England has increased threefold since 1980
 
(NICE 
2006).  
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Obesity promotes abnormal blood glucose metabolism, insulin resistance, abnormal 
blood lipid metabolism and raised blood pressure and is a major cause of a number of 
diseases such as Type 2 diabetes and cardiovascular disease, as well as increasing the 
risk of developing breast, ovarian, cervical, prostate and colorectal cancers
 
(Avenell et 
al 2004).  
 
In the UK, the rate of diabetes between 1995 and 2005 increased from 2.8% to 4.3% of 
the adult population (Lujan et al 2009). This increase may primarily be the result of the 
increased prevalence of obesity, as the number of people newly diagnosed with type 2 
diabetes who are obese increased from 46% to 56% over the same time period (Lujan 
2009). Family history of diabetes is also a recognised major risk factor for developing 
the condition, with the risk for people with familial diabetes that is increased by a 
factor
 
of 2 to 6 as compared with
 
those without familial diabetes (Meigs et al 2000 and 
Weijnen et al 2002). 
 
There is no clear evidence available to explain the epidemic levels of obesity. A 
number of neuro-endocrine factors have a role in the regulation of food intake and in 
the control of insulin secretion. Glucagon-like peptide-1 (GLP-1) is an incretin 
hormone, the name based on the observation that the insulin response to an oral glucose 
load was greater than following intravenous administration of an equivalent amount of 
glucose (McIntyre et al 1964). Incretin hormones are secreted from the small intestine 
in response to the presence of nutrients in the intestinal lumen. Physiologically, GLP-1 
enhances glucose-mediated insulin secretion and suppresses glucagon secretion. GLP-1 
also induces satiety and improves gastric emptying.  
 
10.2.2 Inflammation and Obesity 
 
In recent years there has been increasing evidence identifying the role of inflammation 
in the aetiology of disease states and the mechanism behind the pathogenesis of obesity 
related disease states (Zulet et al 2007). Hotamisligil (2006) introduced the concept of 
meta-flammation to describe the low grade inflammatory response to obesity. 
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Obesity induced inflammation is generally chronic and produces low grade activation 
of the immune system. It is clear that low grade inflammation is implicated in the link 
between obesity and disease. “Few other chronic inflammatory diseases are 
characterised by the features of pancreatic, liver, adipose, heart, brain and muscle 
inflammation as seen in obesity” (Lumeng and Saltiel 2011). Osorio (2013) states that 
inflammation seen in obesity may be caused by adipocytes. When a high calorie diet is 
consumed, the excess nutrients are stored as fat and the hormone leptin is produced. 
Excess leptin stimulates white blood cells known as CD4 T cells to produce another 
molecule called interferon gamma. This molecule causes adipocytes to produce a group 
of proteins known as major histocompatibility complex II (MHCII). The presence of 
MHCII stimulates immune cells in the area and this leads to inflammation. 
 
 
10.2.3 Weight Loss, Glucagon-like Peptide-1 (GLP-1) and Autonomic Function 
 
In studies of patients with established diabetes, GLP-1 levels and the response to oral 
glucose have been shown to be attenuated (Nauck et al 1986) and administration of 
GLP-1 normalized both fasting and post-prandial glucose levels. More recently it has 
been reported that obese subjects with associated inflammation resulting from 
adipocytes with normal glycaemic control also seem to have attenuated basal and 
postprandial GLP-1 concentration, but the evidence is unclear (Verdich et al 2001). 
Very few studies have looked at the effect of weight loss on GLP-1 concentration and 
heart rate variability. One study by Adam et al (2006) showed reduced postprandial 
GLP-1 levels after 6 weeks weight loss, induced by Very Low Calorie Diet (VLCD), 
however after 3 months weight maintenance period the GLP-1 levels returned to the 
baseline levels. Other research showed that weight loss of 18.8 kg induced by VLCD 
resulted in a GLP-1 concentration increase to a level between that of obese and lean 
subjects at 6-months (Verdich et al 2001). Poirier et al (2003) and (2006) suggest a 
significant improvement in cardiovascular function related to weight loss in obese 
individuals. Subjects after jejuno-ileal bypass surgery show that after weight loss there 
is an increase in postprandial GLP-1 response to a level above that of lean subjects 
(Naslund et al 1998) effectively resolving diabetes mellitus (Cummings et al 2004|).  
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A study comparing patients with type 2 diabetes, patients with impaired glucose 
tolerance and healthy volunteers, suggested that impairment in glucose homeostasis can 
develop independently of any impairment in GLP-1 levels (Vollmer et al 2008). 
Therefore it remains uncertain whether lower GLP-1 levels in established diabetes 
contribute to the pathogenesis of the condition or are a consequence of chronic 
hyperglycaemia or other hormonal and metabolic changes. The observation that GLP-1 
levels are lower in obese subjects suggests the possibility that the former may be the 
case.  
 
None of the previous research has addressed how gradual healthy lifestyle changes with 
sensible weight loss goals and increased activity levels affect Heart rate variability and 
GLP-1 levels in an obese but otherwise healthy population. The aim of this study is to 
investigate HRV and GLP-1 concentration in obese, non-diabetic subjects with a family 
history of diabetes during an 8-month lifestyle programme. 
 
10.3 Leptin and Autonomic Function 
 
Leptin is a protein hormone produced by adipose tissue, which has a key role in 
regulating energy intake and expenditure through a suppressive effect on appetite and 
an increase in metabolism. Circulating leptin levels reflect body fat mass during energy 
balance and fall in periods of energy deficit (Weigle et al 1997). 
Leptin can enter the central nervous system (CNS) and interact with centres in the 
regulation of appetite and metabolism (Spiegelman and Flier 2001). Despite these 
suppressive effects, elevated levels have often been noted in obesity, possibly 
suggesting a resistance to the hormone, though this may be a result of stimulation by 
increased insulin levels, which would be expected in obesity. Leptin in turn can inhibit 
insulin release so a fall in leptin resulting from weight loss may enhance insulin 
production and may therefore be beneficial in patients with diabetes and patients with 
impaired glucose tolerance. It could be argued that in newly diagnosed diabetics there 
is evidence of inflammation with the activation of inflammatory cytokines such as 
leptin. Vinik (2012) suggests that “understanding the relationship between autonomic 
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dysfunction and adipose tissue inflammation seen early in the development of diabetes 
will lead to further measures for determining which individuals are at highest risk for 
cardiovascular disease and mortality, and will also lead to the development of new 
therapies for reducing that risk.” There is strong correlation between vagal nerve 
activity and inflammatory disease (Tracey 2009) and suggestion that an afferent reflex 
arc responding to inflammatory markers may be involved in the inflammation seen 
early in type-two diabetes, “by eliciting a cholinergic anti-inflammatory effector 
response, mediated by the parasympathetic nervous system.” (Vinik 2012 and Tracey et 
al 2009). Research by Vinik shows the earliest detectable changes in the evolution of 
diabetes is abnormalities in autonomic balance. Leptin has been shown to stimulate 
sympathetic nervous system (SNS) activity in thermogenic and non-thermogenic 
organs (Collins et al 1996) and in animal models (Haynes 1997). Paolisso et al (2000) 
demonstrated that increasing fasting plasma leptin concentrations were associated with 
a shift of the sympathovagal balance towards an increase in sympathetic activation and 
an increased response to orthostatic stimulus in non-obese subjects with different body 
fat content.  
 
10.4 Adiponectin and Autonomic Function 
 
Adiponectin is a collagen like protein that modulates a number of metabolic processes, 
including glucose regulation and fatty acid catabolism, and may have a role in the 
metabolic derangements of type 2 diabetes (Yamauchi et al 2001). Despite being 
expressed in adipose tissue, plasma adiponectin levels are decreased in obesity as a 
consequence of down regulation (Arita et al 1999). Adiponectin plays an important role 
in insulin sensitivity (Wolfson et al 2012) and has central effects on energy 
homeostasis, promoting weight reduction. Levels of adiponectin have been found to be 
reduced in type-2 diabetes compared with non-diabetic controls, hypertension and 
coronary artery disease. Weight reduction can increase circulating levels of 
adiponectin. Pischon et al (2004) found doubling the circulating adiponectin levels was 
associated with a 30% decreased risk for myocardial infarction. Schulze et al (2005) 
similarly found in type one and two diabetes that there was a corresponding reduction 
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in coronary risk associated with an increase in adiponectin. These findings suggest, 
“adiponectin may have a direct anti-atherogenic role or mediate its effects via obesity-
independent mechanism” (Wolfson et al 2012). Wakabayashi et al (2004) demonstrated 
that sympathovagal balance favoring relative sympathetic activation is associated with 
low serum concentrations of adiponectin in type two diabetic patients. 
 
 
10.5 Role of the Sympathetic Nervous System (SNS) in Inflammation 
 
Both the sympathetic nervous system (SNS) along with the hypothalamic-pituitary-
adrenal axis (HPA) represent key peripheral regulators in maintaining internal 
homeostasis via a mutual positive feedback loop (Koopman et al 2011). When the fine 
internal balance is disrupted both the SNS and the HPA become activated to restore 
homeostasis. In response to stimuli, pro-inflammatory cytokines can signal the brain 
via afferent vagal nerve fibres (Watkins et al 1995) or via the circulation (Steinman 
2004), which can trigger central activation of the SNS, stimulating release of adrenalin, 
dopamine and noradrenaline produced in lymphoid organs, via efferent sympathetic 
fibres. The role of the sympathetic nervous system in the immune response is complex. 
“The immune system influences the SNS and the innervation of lymphoid organs 
allows the SNS to influence the immune cells directly” (Koopman et al 2011). 
Heightened sympathetic activity is known to be associated with increased mortality.  
 
 
10.5.1.1 Role of the Parasympathetic Nervous System (PNS) in Inflammation 
 
The parasympathetic nervous system is also jointly responsible for maintaining 
homeostasis. The role of the PNS in the immune system is still under investigation 
despite much research. It is widely acknowledged that the PNS plays a key role in the 
regulation of inflammation. Stimulation of peripheral afferent vagal nerve fibres can 
activate the HPA axis and the sympathetic nervous system centrally, resulting in 
release of anti-inflammatory glucocorticoids and noradrenaline (Elenkov et al 2000). 
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Efferent nerve fibres are also involved in the anti-inflammatory process known as the 
cholinergic anti-inflammatory pathway (Tracey 2009). 
 
 
10.5.2 Inflammatory Markers and Autonomic Balance 
 
There is evidence to suggest that there is a reduction or loss of HRV and the loss of 
sympathetic/parasympathetic balance before any markers of inflammation can be 
measured (Lieb et al 2011). Thayer and Fischer (2009) found heart rate variability was 
diminished early in diabetes, this correlated well with increasing levels of CRP and IL-
6. Laitinen et al (2011) suggest it is likely that the diabetic process, even before the 
onset of diabetes, is involved in the progression of parasympathetic dysfunction. Figure 
31 shows circulating molecular weight adiponectin and leptin levels in diabetics may 
be predictive markers for autonomic dysfunction in early asymptomatic diabetics. 
Vinik (2012) suggests “there is strong evidence of inflammation with activation of 
inflammatory cytokines such as IL-6 and leptin in newly diagnosed type 2 diabetes. 
These changes correlate with abnormalities in sympathetic-vagal balance.”  
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Figure 31 Graph showing development of autonomic dysfunction and early loss of HRV 
correlating with an increase in inflammatory markers. From Vinik (2012) 
 
KEY: 
rmSSD Root mean square of the successive differences (time domain tool for 
measuring HRV) 
R-R Interval R wave to R wave timing 
HMWA/L ratio High molecular weight adiponectin / Leptin ratio 
IL-6 Interleukin -6 
TSP Total spectral power 
TA/L Ratio Total adiponectin to leptin ratio 
PAI-1 Plasminogen activator inhibitor 
 
 
 
 
10.5.3 The Link between Diabetes, Obesity and Autonomic Function, and the 
Association with Exercise  
 
It was previously thought that loss of autonomic tone was irreversible. We now know 
that this is not necessarily true, Maser and Lenhard (2007) suggest autonomic 
disturbances appear to be reversible with weight reduction. 
It is well established that disease states such as diabetes have a significant impact on 
the autonomic nervous system. It was cited by Lieb et al (2011) that newly diagnosed 
type two diabetics and patients with an impaired glucose tolerance test (IGT) would 
both be associated with a decreased parasympathetic tone and augmented sympathetic 
tone. Wu et al (2007) also noted a “shift towards augmented sympathetic tone in the 
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development from normal glucose tolerance to IGT and finally diabetes.” Previous 
research (Perring and Jones 2003)
 
showed a significant difference in autonomic tone 
between age-matched normal subjects and asymptomatic type 1 diabetics (in the 
absence of autonomic symptoms e.g. postural hypotension).  
 
There is a host of evidence linking performance of the autonomic function with obesity, 
weight loss, exercise and diabetes. Despite advances in research, the physiological 
connection between physical activity and diabetes still remains unclear. Laitinen et al 
(2011) suggest levels of obesity in men play an important role in the early development 
of cardiovascular autonomic neuropathy. Carnethon et al (2006) reported an increase in 
heart rate variability and a decrease in heart rate associated with lifestyle modification 
compared with therapy and placebo arms of a diabetes prevention programme. Gaede 
et al (2008) showed multifactorial intervention controlling blood pressure, lipids and 
hyperglycaemia reduces abnormalities in autonomic function by 68%. Bassuk and 
Manson (2005) conclude that 30 minutes of daily exercise can reduce the incidence of 
diabetes and heart disease. They state that the underlying mechanisms of these 
“protective effects likely include the regulation of body weight; the reduction of 
adiposity, insulin resistance, blood pressure, dyslipidemia, and inflammation; and the 
enhancement of insulin sensitivity, glucose tolerance, and fibrinolytic and endothelial 
function.” A study by Yates et al (2007) showed group based education promoting 
increasing activity using a pedometer was effective for improving glucose tolerance 
compared to the same programme without a pedometer. 
In this PhD project, the addition of autonomic function testing allowed us to establish 
whether it is possible to detect changes in the autonomic tone between the baseline visit 
and the four and eight month follow-up visits. In subjects where significant weight loss 
has occurred (average 11%) and a sustained level of increased physical activity has 
been achieved we may see a positive change in autonomic tone, which should correlate 
well to these lifestyle changes and with biochemical results of the blood samples. The 
autonomic nervous system is an important system to evaluate in the association 
between diabetes and physical activity. One motivation for such a study is the 
responsiveness of the autonomic nervous system to lifestyle changes. The positive 
impact of physical activity and weight loss on autonomic function may prove to be a 
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key benefit in the prevention of diabetes, improving quality of life and reducing 
morbidity in the long-term. 
 
10.6 Inflammation, Obesity and Autonomic Function 
 
Inflammation is typically described as the principal response of the body to deal with 
injury. This often short-term adaptive response is a crucial component of tissue repair 
and involves integration of many complex signals in distinct cells and organs. 
However, the long-term consequences of prolonged inflammation are often not 
beneficial. This appears to be the case in metabolic diseases. Although many of the 
same mediators are involved in obesity and diabetes, few, if any, of the classic features 
of inflammation are observed (Hotamisligil 2005). “Unequivocal experimental, 
epidemiological and clinical evidence produced during the past decade causally links 
inflammation to the development of metabolic diseases and/or the complications that 
emerge from these pathologies, particularly in the context of obesity and type 2 
diabetes” (Shoelson 2006). Hotamisligil (2005) described a new term for chronic 
inflammation as ‘meta-flammation” a subclass of inflammation “which is principally 
triggered by nutrients and metabolic surplus, and engages a similar set of molecules 
and signaling pathways to those involved in classical inflammation.” During the past 
decade, it became clear that inflammation is a key feature of obesity and type 2 
diabetes (Wellen and Hotamisligil 2005). The inflammatory response that emerges in 
the presence of obesity seems to be triggered by and to reside predominantly in adipose 
tissue, although other metabolically critical sites, particularly the liver, might also be 
involved during the course of the disease (Shoelson et al 2006). The role of 
inflammation associated with obesity is an important factor relating to morbidity and 
mortality. Sajadieh et al (2004) concluded “increased heart rate and reduced heart-rate 
variability are associated with subclinical inflammation (meta-flammation) in middle-
aged and elderly subjects. An autonomic imbalance in favour of the sympathetic system 
may interact with inflammatory processes to play a more important role in the process 
of atherosclerosis than previously thought.” Results from a study by Laitinen et al 
(2011) suggest that, additional pathological changes related to central obesity (other 
than impaired glucose tolerance could also be active in cardiovascular autonomic 
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dysfunction including low-grade inflammation, oxidative stress and a genetic link 
between autonomic dysfunction and central obesity. Obesity, insulin resistance and 
type 2 diabetes are closely associated with chronic inflammation characterized by 
abnormal cytokine production, increased acute-phase reactants and other mediators, 
and activation of a network of inflammatory signalling pathways (Wellen 2005). 
 
        
Figure 32 Clustering of metabolic diseases.  
Obesity is considered to be a central feature that increases the risk for a vast array of diseases, with 
significant morbidity and mortality. In general, the mechanistic basis of the link between obesity and 
disease is poorly understood Cited in (Hotamisligil 2005) 
 
 
10.7 Aims of the Study 
 
The main aims of this study were to investigate the effects of weight loss achieved after 
eight months intensive lifestyle programme on: I) autonomic function II) glycaemic 
indices, III) serum lipid profiles and IV) markers of obesity. 
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11 Chapter 11: Methods (Lifestyle Study)  
Chapter 11: Methods (Lifestyle Study) 
 
11.1  Study Design:  
 
An experimental, interventional, prospective follow up study design with weight, 
cardiovascular risk factors, autonomic function testing and hormonal regulators on food 
intake and glucose homeostasis measured at baseline, and following 4, and 8 months of 
lifestyle intervention.  
 
11.2  Recruitment:  
 
Subjects with BMI 30.00 – 39.99kg/m2 (class I and class II obesity) with family history 
of Diabetes of 1
st
 degree relatives (self-reported) were recruited from patients attending 
the Hospital Biochemistry department for oral glucose tolerance test (OGTT), direct 
from local GP practices and through local newspaper and radio advertising. 
 
Subjects who indicated an interest in participating were given a study information sheet 
with a contact telephone number and invited for an individual appointment with the 
dietician or nurse. During the appointment the study structure, aims, and procedures 
were explained. If the subjects indicated they were willing to participate and they 
fulfilled the study inclusion criteria, they were required to sign a consent form. 
 
11.2.1  Exclusion Criteria 
 
People with a BMI of less than 30 and therefore not categorised as obese were 
excluded according to the World Health Organisation definition for obesity (World 
Health Organisation 2013) and people with a BMI over 39.9 kg/m
2
 were also excluded 
firstly, to recruit more homogenous group of subjects and secondly, because the NICE 
guidelines recommend that for adults with a BMI ≥ 40 bariatric surgery is 
recommended as a treatment option (NICE 2006).  
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Individuals who were either: unable to give consent, or who were unable to attend at 
least 75% of the programme sessions for medical or other reasons, or who were 
prescribed oral hypoglycaemic, anti-obesity or any other prescription medications that 
may interfere with the study results, or had no family history of Diabetes in 1
st
 degree 
relatives, were excluded.  
 
11.3  Study Protocol  
 
11.3.1 Blood Sampling 
 
Following an overnight (8-12 hour) fast, participants were asked to attend for clinical 
assessment, autonomic function testing and blood sampling. They were required to 
attend at baseline, 4 and 8 months intervals.  
 
Blood samples were taken for basal measurement of fasting blood glucose, HbA1c, 
lipids, insulin, glucagon, GLP-1, leptin, ghrelin and adiponectin. Sampling was 
repeated at 30 minutes after a standard 75 g glucose load (for peak GLP-1 levels).  
 
At the baseline assessment, an additional blood test was taken 2 hours after a standard 
75g glucose load as per oral glucose tolerance test (OGTT) protocol
 
to eliminate the 
possibility of undiagnosed diabetes or Impaired Glucose Tolerance (IGT), (World 
Health Organisation 1999). If the test confirmed diabetes, the subject was withdrawn 
from the study and referred to his/her GP to initiate the Diabetes care pathway. In the 
case where the test confirmed IGT, the subject continued with the study and repeated 
OGTT at 8-month assessment. If at this stage Diabetes was confirmed, the subject was 
excluded from the study and referred to their GP for further management. Baseline 
measurements of weight, height, percentage body fat, waistline circumference, 
autonomic function, and blood pressure were also taken during the three assessment 
sessions.  
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11.3.2 Food / Activity Diary 
 
Subjects were asked to keep a 7-day food and activity diary 1-3 weeks prior to starting 
the programme and prior to the 4 and 8-month assessments. To help patients record 
their activity levels they were provided with pedometers. They were also enrolled at a 
local leisure centre where they took part in group exercise sessions. 
 
11.3.3 Weight Management Programme 
 
A Specialist Research Dietician ran the weight management programme. It consisted of 
an initial 4 month intensive weight loss phase, followed by a 4 month weight loss / 
maintenance phase. The initial 4-month programme consisted of 7 group education 
sessions. The following 4-month programme consisted of 4 group sessions and 1 
individual appointment. Each education session lasted 60 minutes. Before the 1
st
 
session and, at the 4 month and 8 month sessions, autonomic function testing was 
performed and blood samples were taken. Prior to the remaining sessions 15 minutes 
were devoted to weight assessment.  
 
The programme was based on portion control and healthy eating and was supported by 
behavioural and cognitive change interventions. Interventions included self-monitoring, 
stimulus control, goal setting, problem solving, and relapse prevention. The specialists 
from “Bournemouth HealthLink” (a partnership backed by the local NHS, Council and 
University) took part in helping participants to increase their activity levels. 
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11.3.4 Schematic for Lifestyle Study Protocol. 
 
The schematic below shows the participant pathway from recruitment, assessment and 
repeat visits at four and eight months. 
 
 
Figure 33 Schematic of the lifestyle study protocol 
 
Physiological 
measurements  
Weight, height, % body  
fat, waistline 
Adiponectin 
Leptin 
4 month testing 
as above (V2) 
75g Glucose load 
30 minute repeat testing 
GLP-1 only 
Baseline only. 2hr repeat blood 
test 
Diabetics excluded 
8 month testing as 
above (V3) 
HBA1C Lipids Insulin Glucagon 
GLP-1 
IGT+ve continue in 
trial 
Autonomic 
function 
assessment 
Non diabetic patients recruited 
(BMI >29.9 and <39.9) 
8-12 hour fasting baseline bloods 
Baseline visit (V1) 
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11.3.5 Autonomic Function Testing 
 
Autonomic function testing took approximately 20 minutes per patient and was 
performed during the 3 scheduled sessions at the hospital by myself and another Health 
Scientist from the Medical Physics department. All measurements were completely 
non-invasive. The measurement protocol was as per the influenza study and the GORD 
study except for the absence of the 10 breaths per minute provocation.  
 
11.3.6  Ethics 
 
This study received ethics approval by the Dorset Research Ethics Committee (ref 
09/H0504/61) and the Royal Bournemouth Hospital Research and Development 
Committee see Appendix 16.4.3 
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12 Chapter 12: Results (Lifestyle Project)  
Chapter 12: Results (Lifestyle Project) 
 
12.1 Recruitment Information 
 
Recruitment for this study was very successful through a range of media including 
adverts in the local newspapers. We assessed 38 patients over the eight-month period 
with relatively low drop out and good compliance with the programme. 
51 subjects were recruited for the study in total. 38 participants completed the full eight 
month lifestyle study (74%). 10 subjects did not complete the study, equating to a 
19.6% drop out rate. 3 additional participants (5.8%) were found to be diabetic on 
blood samples taken (see Table 26) and did not continue with the study as per the 
protocol. 6 participants were initially identified as being “pre diabetic” on blood 
samples taken at the baseline visit; one of whom dropped out early in the study. The 5 
“pre-diabetic” subjects continued with the lifestyle study and were monitored at the 
scheduled intervals for diabetes. 
 
Table 26 Table showing study recruitment numbers.  
 Initial 
recruitment 
Number completed 
full study including 
pre-diabetics 
Dropout 
rate from 
initial 51 
Diabetics identified 
and later excluded 
from study 
Total recruited 51 38 10 3 
Percentage of 
total recruited 
100% 74.5% 19.6% 5.8% 
Participant recruitment numbers and percentages including drop-out rate and those identified as 
diabetics 
 
12.2 Variation in Demographic and Lifestyle Factors  
 
The participants were a mixed gender group with an average age of 52.2 years (+/- 
9.39). All participants were considered obese with a range of BMI from 30.21 to 
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39.9kg/m
2
 with a mean BMI of 34.85 (+/-3.03). All took part in the eight-month 
intensive lifestyle programme. 
 
Table 27 Inter-individual variation for males, females and the total group.   
 Participant 
Numbers 
Mean Age (years) 
(±SD) 
BMI (kg/m2) 
Mean (±SD) 
BMI 
(kg/m2) 
Max 
BMI 
(kg/m2) 
Min 
Male 5 45  (11.59) 33.2 (1.56) 34.7 30.73 
Female 33 53 (8.78) 35 (3.14) 39.9 30.21 
Total 38 52.2 (9.39) 34.85 (3.03) 39.9 30.21 
Mean (±SD) age in years, BMI and BMI min /max are shown for the total cohort and for males and 
females. 
 
12.3 Anthropometric Measurements 
 
12.3.1 Weight Related Parameters at Each Visit  
 
Participants in the study lost a significant amount of weight through increased exercise, 
measuring activity via a pedometer, group and individual sessions with the dietician, 
diarising food intake and changing the way they shop, cook and eat.  The 
measurements in Table 28 show the changes in body size at baseline and for the 
following two visits. The percentage change in all parameters between visit one and 
three was dramatic. There was an 11.7% mean change in weight in kg equating to a 
mean loss of 19.01% of body fat (kg). Mean waist circumference changed, reducing by 
13.9% equating to a mean loss of 13.86cm. The changes in anthropometric measures 
between visit 1 (baseline), visit 2 and visit 3 were analysed using analysis of variance 
(ANOVA). Significant differences were seen over the study period, (the results are 
shown in Table 29 and Figure 34). 
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Table 28 Anthropometric measurements for whole group (n=38) at each visit.  
N=38 Mean V1 
(±SD) 
Mean V2 
(±SD) 
Mean V3 
(±SD) 
% Diff 
(v1-v3) 
P Val 
BMI 34.85 (3.03) 31.85 (2.9) 30.84 (3.5) -11.5 <0.001 
Weight (kg) 96.7 (12.8) 88.2 (12.1) 85.4 (23) -11.7 <0.001 
% Body fat 44.04 (6.49) 40.6 (6.7) 40.06 (7.3) -9.04 <0.001 
Kg body fat 42.6 (9.2) 36.2 (8.5) 34.5 (9.4) -19.01 <0.001 
Waist circumference (cm) 109.47 (10.1) 97.86 (9.6) 94.3 (11.7) -13.9 <0.001 
Mean (±SD) values for each anthropometric parameter at each visit and the percentage difference in 
each parameter (V1-V3). ANOVA was performed; the results that reach significance (p=<0.05) are 
shown in bold. 
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Figure 34 Anthropometric measures for the total cohort.  
(A-E) Box and whiskers plots showing: minimum, first quartile, median, third quartile and maximum 
values. Mean values for the full cohort for each visit. (F) Box plot showing percentage change in weight 
(kg) between (v1-v2) labelled (1) and percentage change in weight (kg) between (v1-v3) labelled (2).  
Figure 34 (A) weight (kg) for the total cohort 
over the 3 visits. 
Figure 34 (B) BMI for the total cohort over the 3 
visits 
Figure 34 (C) % Body fat for the total cohort over 
the 3 visits 
  
Figure 34 (E) Waist Circumference (cm) for the total 
cohort over the 3 visits 
Figure 34 (F) Graph showing percentage weight loss 
(kg) between baseline and 4 months labelled (1) and 
baseline and eight months labelled (2)  
Figure 34 (D) KG Body fat for the total 
cohort over the 3 visits 
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All participants lost a considerable amount of weight over the eight month period, with 
the majority losing between 5% to 26% between visit one and three equating to an 
average of 11.3kg. Six patients did not lose more than 5% in weight over the eight 
month period, this loss equated to an average 5kg. 
 
Table 29 Participant weight loss and percentage change in weight loss.  
 Weight loss 
(kg)  
V1 -V2 
% Weight 
change 
V1-V2 
Weight loss 
(kg)  
V2 – V3 
% Weight 
change 
V2 - V3 
Weight loss 
(kg)  
V1 – V3 
% Weight 
change  
V1 – V3 
Mean 
(±SD) 
8.3 (3.55) 8.6% (3.3) 2.8 (3.5) 3.3% (3.9) 11.1 (6.3) 11.7% (6.0) 
Mean and Standard deviation for weight loss (kg) and percentage weight loss between visit one and 
three for the full group. 
 
12.3.2 Blood Pressure Measures for the full cohort 
 
Although we saw a statistically significant change in weight over the eight-month 
period, when comparing the blood pressure data from baseline and at visit 3 the 
percentage change was very small. Statistical analysis of blood pressure for the three 
visits using analysis of variance (ANOVA) shows there was no significant change in 
blood pressure for the full group (see Table 30).  
 
Table 30 Mean (±SD) blood pressure (mmHg) for total group during all visits.  
 Visit 1 Visit 2 Visit 3 % Diff  
(V1-V3) 
P Value 
Mean Systolic BP  
mmHg (±SD) 
142 (17.3) 142 (18.8) 140.1 (16.7) -1.34 0.51  
Mean Diastolic BP 
mmHg (±SD) 
83.9 (7.01) 84 (7.3) 83.5 (7.04) -0.48 0.37  
Analysis of data using paired data ANOVA. P value (<0.05). There were no significant differences in 
blood pressure. 
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12.4 Biochemical Measurements 
 
Percentage change for all biochemical measures reduced significantly between baseline 
and eight months apart from HDL, which increased 2.04%. For measures of GLP-1, 
HbA1c (%), HbA1c (mmol), triglycerides and lipid ratio we saw a significant statistical 
difference using analysis of variance between measures over the eight-month period 
(The results are shown in Table 31). At 8 months there was a significant improvement 
in glycaemic control, with a reduction in HbA1c from 5.78% ±0.41 at baseline to 
5.66% ±0.35 at 8 months (p<0.003), fasting glucose reduction from 8.54 ±01.5mmol/l 
at baseline to 7.92 ±1.76mmol/l at 8 months (p<0.001) and for lipids, triglycerides 
reduced from 1.39 +0.58 mg/dL at baseline to 1.16+0.6 mg/dL, total cholesterol 
reduced from 5.72 ±1.08 to 5.55 ±0.95 and LDL reduced from 3.66 ±0.91 to 3.52 ±0.85 
at eight months (see Table 31). 
 
Table 31 Biochemical measures for the full cohort (n=38).  
 Mean V1  
(±SD) 
Mean V2  
(±SD) 
Mean V3 
(±SD) 
% diff 
(V1-
V3) 
P Val 
Blood Glucose (0min) (GLP-1) 5.12 (0.46) 4.84 (0.94) 4.89 (0.47) -4.49 0.081 
Blood Glucose (30min) (GLP-1) 8.54 (1.51) 7.85 (1.33) 7.92 (1.76) -7.26 0.001 
Total Cholesterol mg/dL 5.72 (1.08) 5.42 (0.96) 5.55 (0.95) -2.97 0.006 
Low Density Lipid (mg/dL) 3.66 (0.91) 3.4 (0.84) 3.52 (0.85) -3.83 0.007 
High Density Lipid (mg/dL) 1.47 (0.4) 1.45 (0.4) 1.5 (0.38) +2.04 0.075 
Triglycerides (mg/dL) 1.39 (0.58) 1.25 (0.68) 1.16 (0.6) -16.5 0.011 
Lipid Ratio 4.23 (1.19) 3.99 (1.19) 3.88 (1.07) -8.27 0.002 
HbA1c (%) 5.78 (0.41) 5.72 (0.38) 5.66 (0.35) -2.08 0.003 
HbA1c (mmol) 39.76 (4.5) 39.13 (4.22) 38.37 (3.93) -3.5 0.001 
Mean standard deviation and percentage difference between visit 1 and visit 3 for biochemical measures 
at each visit. Analysis of data using paired data ANOVA. P value (<0.05). Significant results are shown 
in bold. 
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The change in biochemical measures for the full group was assessed between visits one 
and 3. All measures were significantly reduced at eight months apart from HDL, which 
as expected increased (see Table 32 and Figure 35). 
 
Table 32 Change in biochemical measures (V3-V1).  
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Figure 35 Bar chart showing change in blood sample measures between V1 and V3.  
Changes in serum lipid, blood glucose and HbA1c between baseline and visit three with standard error 
bars are shown. 
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12.5 Measures of HRV 
 
12.5.1 Results of HRV Measurements: Analysis of total cohort (n=38).  
 
Heart rate variability measurements were made at the three scheduled visits. There was 
a percentage rise in all but one of the Ewing parameters between baseline and visit 3 
suggesting a generalised improvement in autonomic tone. Statistical analysis of the 
Ewing measures using analysis of variance shows significant differences in all but one 
of the parameters (lying/standing) (see Table 33). However, for measures of HRV 
during metronome guided breathing there was a percentage rise in only half of the 
HRV measures and there were no statistically significant differences between visits.  
HR data from lifestyle study (n=38) during metronome breathing (visit 1) was 
compared using an unpaired t-test with data from the full group of healthy participants 
from the influenza study (N=71) during metronome breathing (visit 1). Although all 
HR values are lower for the lifestyle group, there was one parameter (SD) showing a 
statistical difference (p=0.048) between the two groups (see Table 34). 
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Table 33 HRV for the full Lifestyle cohort (n=38) (Ewing and metronome breathing parameters)  
Parameter Mean V1 
(±SD) 
Mean V2  
(±SD) 
Mean V3  
(±SD) 
% Diff 
(V1-V3) 
P Value 
Ewing Measures 
Resting (%) 5.6 (3.5) 6.9 (4.36) 6.5 (4.5) 16 0.001 
Forced Breathing (%) 14.06 (5.8) 15.5 (7.8) 14.58 (5.05) 3.7 0.001 
I/E Diff (bpm) 9.2 (3.79) 11.02 (5.28) 10.5 (3.4) 14.1 0.001 
Valsalva (ratio) 1.26 (0.12) 1.28 (0.14) 1.29 (0.14) 2.4 0.001 
Hand grip (ratio) 1.1 (0.08) 1.2 (0.32) 1.2 (0.14) 9.1 0.04 
Lying/Standing (ratio) 0.12 (0.01) 1.14 (0.12) 0.12 (0.08) 0 0.82 
Metronome Breathing 
SD (bpm) 0.2 (0.99) 0.13 (0.85) 0.05 (0.85) -75 0.58 
A (bpm) 0.03 (0.79) 0.06 (0.77) 0.03 (0.91) 0 0.62 
LPP (unitless) 0.34 (0.91) 0.31 (0.89) 0.26 (0.87) -23.5 0.94 
CORR (unitless) -0.81 (1.52) -0.86 (1.86) -0.57 (1.26) 29.6 0.22 
FCORR (unitless) 0.02 (0.79) 0.02 (0.77) 0.04 (0.77) 50 0.93 
DEV -0.7 (0.92) -0.10 (1.01) -0.01 (0.91) 85.7 0.74 
Mean and standard deviation figures for HRV parameters (Ewing measures and metronome guide breathing) 
for total cohort. Results of analysis of variance (ANOVA) of paired data where p=<0.05 are shown in bold. 
Metronome breathing Parameters are described in section 3.10.6. 
 
Table 34 HRV data for the full lifestyle study cohort during metronome breathing parameters 
(n=38) compared with normal range HRV data from visit 1 influenza study (N=71) 
 Lifestyle full cohort 
N=38 Mean V1 (±SD) 
Influenza Study Normal 
volunteers Mean V1 (±SD) 
P Value (t value) 
SD (bpm) 0.2 (0.99) 0.63 (1.0) 0.048 (-2.0) 
A (bpm) 0.03 (0.79) 0.33 (1.0) 0.117 (-1.58) 
LPP (unitless) 0.34 (0.91) 0.65 (0.8) 0.068 (-1.8) 
CORR (unitless) -0.81 (1.52) -0.28 (1.8) 0.230 (-1.2) 
FCORR (unitless) 0.02 (0.79) -0.1 (1.2) 0.618 (0.5) 
DEV -0.7 (0.92) 0.27 (1.2) 0.106 (-1.63) 
Mean and SD for each set of HRV data during metronome guided breathing from the Lifestyle group visit 1 
(n=38) and the influenza study, visit 1 (n=71). Analysis was performed using an unpaired t-test. Metronome 
breathing Parameters shown are described in section 3.10.6. 
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12.6 Correlational studies for the full lifestyle cohort (N=38)  
 
12.6.1 Weight loss (kg) between baseline and eight months correlated against 
change in glycaemic indices and serum lipids over eight months. 
 
The change in weight in kg between baseline and eight months was correlated against 
the change in serum lipids and glycaemic indices for the full cohort between baseline 
and eight months, using Pearson’s correlation. There was no significant correlation 
with any of the parameters except for HbA1c (%) (P=0.032, r=0.35) see (figure 36). 
 
 
Figure 36 Correlation between weight loss (kg) and change in HbA1c 
(P=0.032). Change in data from baseline and eight months. 
 
 
12.7 Pupillometry. Iris response to dark.  
 
Due to technical problems with the goggles a number of patients did not have 
pupilometry performed at every visit. The majority of missing data are from visit one. 
Comparison of paired data has been made where data for each visit is available. 
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Analysis of variance (ANOVA) does not show any statistical difference in pupillary 
response between visits (see Table 35). 
 
Table 35 Pupillometry Iris response to dark 
Mean Pupillary 
response (SD) 
 V1 (±SD)  
Mean Pupillary 
response (SD) 
V2 (±SD)  
Mean Pupillary 
response (SD) 
V3 (±SD)  
% Diff 
V1-V3 
P Val 
-0.75 (1.04) -0.33 (1.14) -0.12 (1.13) -84 0.84 
Mean and standard deviation values for the complete cohort at each visit. Analysis of variance 
significance p value (<0.05).  
 
12.8 Subgroup Analysis:  
Changes in Autonomic Function According to Participant Weight Loss.  
 
In this section participants were sub-grouped according to the percentage weight loss at 
the end of the eight month programme. Participant weight loss was measured at each 
visit during the eight-month period. For each participant the weight loss achieved was 
different. Previous analysis of HRV for the total cohort did not take weight loss into 
account. Some participants exceeded weight loss goals and others did not. The 
percentage weight loss at the eight-month visit was used to subdivide the total cohort 
into two subgroups according to the percentage of weight (kg) lost in the period. The 
following tables show results for two subgroups using a threshold of <12% weight loss 
(moderate) and ≥12% weight loss (large) weight loss. 
 
 
12.8.1 Autonomic Function in the Subgroup (<12% weight loss) (N=28) HRV 
data from Ewing measures and Metronome guided breathing 
 
Autonomic function was assessed for the subgroup of those with <12% weight loss. 
Statistical analysis, using analysis of variance (ANOVA) was performed on the HR 
data from the Ewing tests and for the 2 minutes of metronome guided breathing for this 
subgroup between baseline and at eight months. There were significant statistical 
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differences between most of the Ewing test provocations apart from handgrip and 
lying/standing, (the results are shown in Table 36). Although there appears to be an 
improvement in some HRV parameters with a percentage change increase between 
visit one and three, there were no statistically significant differences between the 
metronome guided breathing HRV data over the eight months (see Table 36), which 
was the same as for the full cohort.  
 
Table 36 Assessment of autonomic function in the subgroup with the threshold of <12%  
 V1 Mean 
(±SD) 
V2 Mean 
(±SD) 
V3 Mean 
(±SD) 
% 
Diff 
 P 
Ewing Measures 
Resting (%) 5.01 (3.9) 8.00 (4.87) 8.86 (4.42) 77 0.001 
Forced Breathing (%) 13.80 (4.85) 19.36 (9.19) 19.44 (7.5) 41 0.001 
I/E Diff (bpm) 9.01 (2.8) 11.72 (5.64) 11.85 (4.15) 24 0.001 
Valsalva (ratio) 1.26 (0.13) 1.36 (0.22) 1.36 (0.13) 7.9 0.008 
Hand grip (ratio) 1.09 (0.09) 1.14 (0.16) 1.17 (0.12) 6.8 0.079 
Lying/Standing (ratio) 1.13 (0.12) 1.12 (0.12) 1.14 (0.08) 0.88 0.89 
Metronome Breathing 
SD (bpm) 0.22 (0.98) 0.21 (0.86) 0.18 (0.83) 18.2 0.99 
A (bpm) 0.077 (0.90) 0.078 (0.79) 0.004 (0.75) -43 0.82 
LPP (unitless) 0.35 (0.90) 0.44 (0.83) 0.37 (0.81) 5.7 0.93 
CORR (unitless) -0.62 (1.14) -0.55 (1.1) -0.50 (1.3) 19.4 0.35 
FCORR (unitless) 0.02 (0.74) 0.18 (0.31) 0.03 (0.76) 50 0.66 
DEV -0.004 (0.91) 0.008 (0.76) 0.002 (0.88) 150 0.71 
      
 Mean (SD) and % difference (between v1-v3) HRV parameters for the subgroup with BMI<12%. 
Parameters shown are described in section 3.10.6. 
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12.8.2 Assessment of Autonomic Function using Ewing assessment and during 
metronome guided breathing (6 breaths per minute) for the Subgroup 
with >12% Weight Loss (N=10). 
 
Statistical analysis was also performed on the heart rate data for the Ewing tests and for 
metronome guided breathing for a subgroup of 10 participants that lost >12% in weight 
over the eight month period. There is an overall tendency towards an improvement in 
autonomic tone with an increase in percentage difference between baseline and eight 
months for both Ewing measures and metronome guided breathing. Using analysis of 
variance there was a statistically significant difference between the resting data 
(p=0.001), LPP (p=0.038), FCORR (p=0.022), and DEV (p=0.005) (see Table 37).  
 
Table 37 Assessment of autonomic function in the subgroup with the threshold of >12% weight 
loss.  
 V1 Mean 
(±SD) 
V2 Mean 
(±SD) 
V3 Mean 
(±SD) 
% Diff 
V1-V3 
P Val 
Ewing Measures 
Resting (%) 6.7 (4.4) 8.0 (4.9) 14.1 (6.4) 110.5 0.001 
Forced Breathing 
(%) 
14.5 (8.3) 19.3 (9.2) 21.7 (8.8) 49.6 0.067 
I/E Diff (bpm) 9.5 (5.4) 11.7 (5.6) 12.9 (4.6) 35.8 0.21 
Valsalva (ratio) 1.3 (0.1) 1.4 (0.22) 1.4 (0.17) 7.8 0.149 
Hand grip (ratio) 1.1 (0.1) 1.14 (0.2) 1.3 (0.2) 18.2 0.203 
Lying/Standing 
(ratio) 
1.1 (0.1) 1.12 (0.11) 1.1 (0.1) 0 0.93 
Metronome Breathing 
SD (bpm) -0.016 (0.62) 0.013 (0.77) -0.029 (0.79) -81.3 0.322 
A (bpm) -0.2 (0.63) -0.06 (0.67) 0.09 (0.7) 145 0.23 
LPP (unitless) 0.4 (0.95) 0.41 (0.73) 0.52 (0.82) 30 0.038 
CORR (unitless) -0.82 (1.55) -0.72 (0.87) -0.51 (1.38) 37.8 0.860 
FCORR (unitless) -0.21 (0.55) 0.019 (0.35) 0.026 (0.23) 112 0.022 
DEV -0.39 (0.98) -0.04 (0.62) 0.17 (0.89) 143 0.005 
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Mean and SD values for each HR parameter at each visit. Analysis performed using analysis of variance 
(p=<0.05) significant results are shown in bold. Metronome breathing parameters shown described in 
section 3.10.6. 
 
12.9  Further Subgroup Analysis:  
 
The total cohort was further subdivided into three subgroups:  
 Subgroup A containing those participants with a BMI ≥36 (N=14) 
 Subgroup B containing those participants with a BMI <36 (N=24) 
 Subgroup C containing those participants who were pre-diabetic (N=5). 
 
 
12.9.1  Subgroup A: Participants with Body Mass Index (BMI) ≥36) (N=14) 
 
A threshold of BMI ≥36 was used to identify individuals with the highest BMI in the 
cohort at baseline. There were 14 people in this subgroup; all were female with a mean 
BMI of 38.2 (+/-1.04), 2 of the 14 participants were in the group identified as pre-
diabetic. Calculating the percentage change between the starting point and the end 
point of the study there is a marked percentage decrease in all weight related 
parameters. Percentage weight loss dropped 12.5% equating to 13.2kg overall weight 
loss with a mean loss of -19.7% loss in body fat. BMI fell from 38.1 (+/-1.04) to 33.5 
(+/-3.3) equating to a 12.07% reduction and waist circumference reduced by an average 
16.2 cm (-13.8%). 
Analysis using analysis of variance for paired data shows that all weight related 
parameters were markedly changed between visits for the subgroup with the highest 
BMI ≥36 (see Table 38 and Figure 37). There is a significant difference between visits 
for all weight related parameters with a fall in both systolic and diastolic pressure 
coinciding with the concurrent weight loss. Figure 37 (A-E) shows the changes in 
weight related parameters in subgroup A, between visit one and visit three as box and 
whisker plots. 
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Table 38 Table showing mean and (±SD) weight related parameters and blood pressure (mmHg) 
for subgroup A with BMI≥36.  
Parameter Mean Visit 
1 (±SD) 
Mean Visit 2 
(±SD) 
Mean Visit 
3 (±SD) 
% 
Diff 
V1-V3 
P Val 
Weight kg 105.6 (7.0) 95.7 (7.1) 92.4 (9.56) -12.5 0.001 
BMI 38.1(1.04) 34.7 (1.97) 33.5 (3.3) -12.07 0.001 
% body fat 48.9 (3.3) 46.18 (2.65) 44.4 (4.7) -9.2 0.001 
Kg body fat 51.7 (5.7) 44.26 (4.69) 41.5 (7.9) -19.7 0.001 
Waist Circumference (cm) 117.2 (7.2) 104.1 (10.02) 101 (13.4) -13.8 0.001 
Systolic BP mmHg 139 (11) 132 (11.72) 127 (17) -8.6 0.002 
Diastolic BP mmHg 83 (6.6) 80 (8.64) 74 (9.1) -10.8 0.001 
Mean, SD and percentage difference (v1-v3) are shown. Analysis of variance was performed (p=<0.05). 
Significant results are shown in bold. 
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Figure 37 Changes in mean weight related parameters in subgroup A, over the 3 scheduled visits. 
(A-E) Box and whiskers plots showing minimum, first quartile, median, third quartile and maximum 
values 
 
 
Figure 37 (A) Graph showing weight 
related parameter (weight kg) for the 
cohort with BMI≥36  
Figure 37 (B) Graph showing weight related 
parameter (BMI) for the cohort with BMI≥36 
Figure 37 (C) Graph showing weight related 
parameter (% body fat) for the cohort with 
BMI≥36 
Figure 37 (D) Graph showing weight related 
parameter (body fat kg) for the cohort with 
BMI≥36 
Figure 37 (E) Graph showing weight related 
parameter (waist circumference cm) for the 
cohort with BMI≥36 
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12.9.1.1 Analysis of Biochemical Data for Subgroup A (BMI ≥36, N=14)  
 
There were marked changes in the biochemical data for this subgroup with a 
percentage drop noted for all parameters. The largest reduction was seen in GLP-1 
representing a 9.6% drop in blood glucose values after the 30 minute repeat test for the 
group. The smallest percentage reduction was for LDL, which fell 2.8% 
After statistical analysis of paired data of the blood samples for this subgroup using 
analysis of variance there were significant differences representing an improvement in 
all but blood glucose (0 min) and two of the lipid values (HDL and Triglyceride), (see 
Table 39). This improvement may be associated with increased exercise and the 
significant weight loss that occurred during the intensive eight month programme (See 
Table 38). 
 
Table 39 Analysis of Biochemical Data for Subgroup A (BMI ≥36)  
Parameter Mean Visit 1 
(±SD) 
Mean Visit 2 
(±SD) 
Mean Visit 
3 
(±SD) 
% 
Diff 
v1-v3 
P Val 
Blood Glucose 
(0min) (GLP-1) 
5.1 (0.40 4.86 (0.43) 4.85 (0.42) -4.9 0.073 
Blood Glucose 
(30min) (GLP-1) 
8.3 (1.18) 7.66 (1.08) 7.5 (1.85) -9.6 0.012 
Total Cholesterol 
mg/dL 
5.77 (0.87) 5.55 (0.71) 5.5 (0.87) -4.7 0.026 
Low Density Lipid 
(mg/dL) 
3.6 (0.89) 3.49 (0.76) 3.5 (0.81) -2.8 0.05 
High Density Lipid 
(mg/dL) 
1.56 (0.45) 1.53 (0.40) 1.51 (0.48) -3.21 0.83 
Triglycerides 
(mg/dL) 
1.32 (0.43) 1.16 (0.35) 1.22 (0.56) -7.6 0.24 
Lipid Ratio 4.14 (1.36) 3.90 (1.22) 4.0 (1.28) -3.4 0.001 
HbA1c (%) 5.9 (0.36) 5.74 (0.36) 5.7 (0.33) -3.4 0.011 
HbA1c (mmol) 40.7 (3.87) 39.29 (4.03) 38.4 (3.43) -5.7 0.01 
Table showing mean (±SD) and percentage difference for biochemical measures for subgroup A 
(BMI≥36) at each visit. Results of analysis of variance (p=<0.05) are shown in bold. 
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Figure 38 (A-F) Box and whiskers graphs showing biochemical measures for statistically 
significant results for subgroup A (BMI≥36) at visit 1, 2 and 3. (A) shows blood glucose (30 minutes). 
(B) shows Total cholesterol. (C) shows LDL. (D) shows Lipid ratio. (E) shows HbA1Cmmol. (F) shows 
HbA1c%. Box and whiskers plots show minimum, first quartile, median, third quartile and maximum values. 
Figure 38 (B) Analysis of biochemical data 
(Total cholesterol) for subgroup A 
(BMI≥36) in the cohort at baseline and 
eight months 
Figure 38 (C) Analysis of biochemical 
data (low density lipids) for subgroup A 
(BMI≥36) in the cohort at baseline and 
eight months 
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Figure 38 (A) Analysis of biochemical data 
(Blood Glucose 30 minutes) for subgroup A 
(BMI≥36) at each visit. 
Figure 38 (D) Analysis of biochemical 
data (ratio) for subgroup A (BMI≥36) at 
each visit. 
Figure 38 (E) Analysis of biochemical data 
(HbA1c mmol) for subgroup A (BMI≥36) at 
each visit. 
Figure 38 (F) Analysis of biochemical data 
(HbA1c %) for subgroup A (BMI≥36) at each 
visit. 
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12.9.2  Changes in Serum Adiponectin and Leptin Levels for Sub-group A (BMI 
≥36) (N=14) 
 
There was a rise in serum adiponectin between baseline and visit three (24.3%) and a 
modest decrease in serum leptin (-5.6%). This would be expected with significant 
weight loss (Vinik 2013). Serum levels of adiponectin and leptin for subgroup A were 
analysed using analysis of variance for data over eight months. There is a statistically 
significant difference (increase) between the serum adiponectin levels values, 
(p=0.001) from baseline and visit three. We also found after statistical analysis, mean 
leptin levels were higher at baseline associated with the higher BMI in this obese group 
and this was significantly lower (p=0.001) at eight months after considerable weight 
loss (see Table 40 and Figure 39). The results indicate an inverse relationship between 
obesity and low adiponectin and a rise in serum adiponectin levels is associated with 
significant weight loss. Correlational studies in section 12.10 also support this. 
 
Table 40 Serum Adiponectin and Leptin levels for each visit for sub-group A (BMI ≥36) (N=14)  
 Visit 1  Visit 2  Visit 3 
% Diff 
(v1-v3) 
P Value 
Mean Adiponectin 
serum level μg/ml 
(±SD) 
9.21 (0.68) 9.85 (0.69) 11.45 (10.87) 24.3 0.001 
Mean Leptin serum 
level ng/ml (±SD) 59.5 (1.16) 58.0 (0.76) 56.17 (1.52) -5.6 0.001 
Mean (±SD) and Percentage difference between visit 1 and visit 3 Results of analysis of variance 
(ANOVA) are shown in table below. Statistically significant values (<0.05) are shown in bold. 
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Figure 39 Bar charts showing mean serum adiponectin (A) and Leptin (B) for each visit for 
subgroup A (BMI≥36).  
Standard error bars are shown. Analysis of variance shows a statistically significant difference 
(p=0.001) between visits with an increase in adiponectin and a decrease in leptin in association with 
concomitant weight loss 
 
 
 
12.9.3  Assessment of Heart Rate Variability for Subgroup A (N=14) (BMI ≥36).  
 
For subgroup A, percentage change was calculated between visit one and visit 3. There 
is an overall increase for most HRV parameters, apart from LPP (-6.7%) and 
lying/standing (0%) see (Table 41). Analysis of the HRV data for the three visits using 
analysis of variance there was a statistically significant difference in the Ewing 
parameters, resting (p=0.001), forced breathing (p=0.013), I/E diff (p=0.021) and 
Valsalva (p=0.002) (see Table 41 and Figure 40). Comparison of HRV data during 
metronome guided breathing using analysis of variance, showed there were no 
statistically significant differences between data, despite percentage increases between 
most parameters at baseline and visit three. This percentage increase in HR data does 
however suggest a trend towards an increase in the HRV parameters over the eight 
months; these are shown in Table 41.  
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Table 41 Assessment of Heart Rate Variability for Subgroup A (N=14) with a BMI ≥36.  
 V1 Mean 
(±SD)  
V2 Mean 
(±SD) 
V3 Mean 
(±SD) 
% Diff   
v1-v3 
P Value 
Ewing Measures of HRV 
Resting (%) 4.84 (2.9) 7.35 (5.6) 7.6 (3.1) 58 0.001 
Forced Breathing 
(%) 
13.2 (5.4) 18.5 (10.2) 22.03 (9.2) 66.9 0.013 
I/E Diff (bpm) 8.3 (3.1) 11.15 (6.2) 11.9 (4.9) 43.4 0.021 
Valsalva (ratio) 1.21 (0.1) 1.37 (0.18) 1.37 (0.15) 7.4 0.002 
Hand grip (ratio) 1.08 (0.05) 1.25 (0.50) 1.23 (0.21) 13.9 0.291 
Lying/Standing 
(ratio) 
1.13 (0.11) 1.16 (0.14) 1.13 (0.07) 0 0.734 
Metronome Breathing 
SD (bpm) 0.02 (0.67) 0.04 (0.93) 0.05 (0.68) 150 0.064 
A (bpm) -0.34 (0.53) -0.04 (0.89) -0.02 (0.86) 94 0.424 
LPP (unitless) 0.15 (0.71) 0.13 (1.03) 0.14 (0.96) -6.7 0.242 
CORR (unitless) -0.12 (1.2) -0.12 (1.08) -0.041 
(0.85) 
65 0.197 
FCORR 
(unitless) 
-0.26 (0.88) -0.06 (0.34) -0.26 (0.59) 0 0.242 
DEV -0.52 (0.73) -0.03 (1.01) -0.04 (1.0) 92 0.077 
HRV was assessed using Ewing measurements and Metronome guided breathing during two minutes at 6 
breaths per minute. Mean, SD and percentage difference are shown. Metronome breathing parameters 
described in section 3.10.6. HR data was analysed using ANOVA. Significant results are shown in bold. 
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Figure 40 HRV parameters for Subgroup A (BMI≥36) during Ewing assessment  
(A-D) show (A) Resting, (B) Forced Breathing, (C) I/E Diff, (D) Valsalva). Box and whisker 
 plots represent the parameters with statistically significant differences after analysis  
of variance, showing minimum, first quartile, median, third quartile and maximum values. 
 
 
Figure 40 (A) Graph showing HRV values for 
cohort with a BMI ≥36. Assessment of HRV at 
visit 1 and visit 3 for Ewing measurement (resting 
parameter). 
Figure 40 (B) Graph showing HRV values for 
cohort with a BMI ≥36. Assessment of HRV 
at visit 1 and visit 3 for Ewing 
measurement (forced breathing 
parameter). 
Figure 40 (C) Graph showing HRV values for 
cohort with a BMI ≥36. Assessment of HRV at 
visit 1 and visit 3 for Ewing measurement (I/E 
Diff parameter). 
Figure 40 (D) Graph showing HRV values for 
cohort with a BMI ≥36. Assessment of HRV 
at visit 1 and visit 3 for Ewing measurement 
(Valsalva parameter). 
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12.9.3.1 Analysis of HRV measures at baseline and at eight months using a paired 
t-test 
 
Due to the percentage increase in heart rate data noted between visit 1 and 3 for the 
metronome breathing data in Table 41, the data for subgroup A from baseline and at the 
end of the study (eight months) was re-analysed using a paired t-test. Results show a 
significant difference in all Ewing measures and metronome guided breathing HRV 
parameters apart from LPP and FCORR (see Table 42). 
 
 Table 42 Analysis of HRV measures at baseline and at eight months using a paired t-test  
 V1 Mean (±SD) V3 Mean (±SD) % Diff  
V1-V3 
P Value 
Ewing Parameters 
Resting (%) 4.84 (2.9) 7.6 (3.1) 58 0.005 
Forced Breathing (%) 13.2 (5.4) 22.03 (9.2) 66.9 0.01 
I/E Diff (bpm) 8.3 (3.1) 11.9 (4.9) 43.4 0.01 
Valsalva (ratio) 1.21 (0.1) 1.37 (0.15) 7.4 0.004 
Hand grip (ratio) 1.08 (0.05) 1.23 (0.21) 13.9 0.02 
Lying/Standing (ratio) 1.13 (0.12) 1.13 (0.08) 0 0.05 
Metronome Breathing 
SD (bpm) 0.02 (0.67) 0.05 (0.68) 150 0.02 
A (bpm) -0.34 (0.53) -0.02 (0.86) 94 0.04 
LPP (unitless) 0.15 (0.71) 0.14 (0.96) -6.7 0.11 
CORR (unitless) -0.12 (1.2) -0.041 (0.85) 65 0.05 
FCORR (unitless) -0.26 (0.88) -0.26 (0.59) 0 0.07 
DEV -0.52 (0.73) -0.04 (1.0) 92 0.05 
Mean (±SD) measures of HRV for subgroup A. Analysis using a paired t test for data from baseline visit 
and at eight months, statistical significance at p=<0.05. Significant results are shown in bold. 
Metronome guided breathing parameters shown are shown in section 3.10.6. 
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12.9.3.2 Comparison of Heart Rate Variability for Subgroup A (BMI ≥36) and the 
Cohort of healthy volunteers from the Influenza Study (N=71). 
 
Analysis was performed using an unpaired t-test to compare baseline HRV data for 
subgroup A (BMI ≥36) (during metronome guided breathing) and the baseline HRV 
data for the cohort of healthy volunteers from the Influenza study (during metronome 
guided breathing). Results show a significant difference in heart rate variability 
parameters (SD, A, LPP and DEV), see Table 43. Heart rate variability is attenuated in 
Subgroup A at baseline compared to a normal range, which is likely to be linked to the 
level of obesity and raised BMI in this group, we note an improvement in autonomic 
tone at eight months after significant weight loss. 
 
Table 43 Comparison of Subgroup A (BMI≥36) (N=14) HRV data from visit one with the Healthy 
Volunteers from the influenza study HRV data from visit one (N=71) 
 V1 Mean (±SD) 
Subgroup A BMI>36 
(N=14) 
V1 Mean (±SD) 
Influenza Study 
Healthy Volunteers 
(N=71) 
P Value (t val) 
SD (bpm) 0.02 (0.67) 0.63 (1.0) 0.011 (-3.76) 
A (bpm) -0.34 (0.53) 0.33 (1.0) 0.001 (-2.71) 
LPP (unitless) 0.15 (0.71) 0.65 (0.8) 0.001 (-3.37) 
CORR (unitless) -0.12 (1.2) -0.28 (1.8) 0.640 (0.47) 
FCORR (unitless) -0.26 (0.88) -0.1 (1.2) 0.649 (-0.46) 
DEV -0.52 (0.73) 0.27 (1.2) 0.013 (-2.55) 
HRV was assessed during two minutes of Metronome guided breathing at 6 breaths per minute. Mean 
and are shown. Metronome breathing parameters described in section 3.10.6. HR data was analysed 
using an unpaired t-test. Significant results are shown in bold. 
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12.9.3.3 Summary of Resting Heart Rate Variability for Subgroup A (BMI≥36) 
during Eight Month Lifestyle Programme  
 
Analysis of resting HRV was performed using analysis of variance. A table of results 
(Table 44) summarises the differences between measures of resting heart rate 
variability. Other measures include Fractal dimension as defined by Higuchi’s 
algorithm. SDNN = Standard deviation of RR interval. PNN50 = percentage of RR 
intervals where the gap between adjacent intervals is greater than 50ms. LF/HF ratio = 
ratio of integrated spectral power of the portions of the heart rate frequency plot in the 
low frequency (0.04-0.15 Hz) and high frequency (0.15 – 0.4 Hz) bands. Assessment 
with analysis of variance showed there were no statistically significant differences 
between any heart rate variability measures during the eight month study period. 
 
Table 44 Analysis of extended resting heart rate data for Subgroup A (BMI ≥36) N=14 
Parameter Visit 1 Mean 
(±SD)  
Visit 2 Mean 
(±SD) 
Visit 3 Mean 
(±SD) 
P 
value 
*Resting Heart Rate 
(bpm) 
73.79 (9.83) 73.57 (10.11) 74.18 (11.14) 0.481 
Fractal Dimension -1.24 (0.04) -1.25 (0.04) -1.25 (0.06) 0.233 
SDNN (ms) 59.03 (36.42) 86.09 (76.2) 80.3 (52.30) 0.237 
PNN50 (%) 11.09 (17.07) 13.08 (14.9) 17.39 (18.08) 0.384 
LF/HF Ratio 2.84 (2.05) 3.36 (1.98) 2.94 (2.40) 0.525 
Mean and Standard deviation for each visit. Fractal dimension as defined by Higuchi’s algorithm. 
SDNN = Standard deviation of RR interval. PNN50 = percentage of RR intervals where the gap between 
adjacent intervals is greater than 50ms. LF/HF ratio = ratio of integrated spectral power of the portions 
of the heart rate frequency plot in the low frequency (0.04-0.15 Hz) and high frequency (0.15 – 0.4 Hz) 
bands. *Extended resting period. ANOVA performed. P values are shown as significant at p=<0.05. 
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12.10  Correlational Studies: Change in Serum lipids and glycaemic indices 
between baseline and eight months against change in weight (kg) between 
baseline and eight months for subgroup A. 
 
Correlational analyses were performed using Pearson’s product moment correlation 
coefficient to ascertain the degree of correlation between change in weight in 
kilogrammes for subgroup A between visit 1 and visit 3 and serum lipids and 
glycaemic indices. There was a significant correlation between weight loss and the 
change in triglyceride (p=0.05) and HbA1c levels (p=0.029) between baseline and visit 
3 (see Figure 41 (A) and Figure 41 (B)) 
  
Table 45 Correlational Studies: Change in Serum lipids and glycaemic indices between baseline 
and eight months against change in weight (kg) between baseline and eight months for subgroup 
A. 
Parameter Pearson’s r T value P value 
Blood Glucose (0min) (GLP-1) -0.24 -0.84 0.414 
Blood Glucose (30min) (GLP-1) -0.40 -1.5 0.15 
Total Cholesterol mg/dL -0.35 -1.28 0.22 
Low Density Lipid (mg/dL) -0.24 -0.89 0.39 
High Density Lipid (mg/dL) 0.19 0.6 0.51 
Triglycerides (mg/dL) 0.53 (gradient = 0.0236 
mg/dL/Kg weight loss) 
2.4 0.05 
Lipid Ratio -0.3 2.08 0.29 
HbA1c (%) 0.58 (gradient = 0.0198 
%/kg weight loss) 
2.4 0.029 
HbA1c (mmol) 0.46 1.8 0.08 
Results using Pearson’s correlation coefficient for the change in Serum lipids and glycaemic indices 
between baseline and eight months against change in weight (kg) between baseline and eight months for 
subgroup A. Significant results (p=<0.05) are shown in bold 
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Figure 41 (A)                                                                     Figure 41 (B) 
 
Figure 41 Correlation of change in weight and change in HbA1c and triglyceride.  
Graphs showing correlation between (A) Change in Serum triglyceride correlated against change in 
weight (kg) over eight months for subgroup A and (B) Change in HbA1c correlated against change in 
weight (kg) over eight months for subgroup A (BMI ≥36) 
 
 
 
12.11  Correlational Studies: Change in HRV parameters correlated against 
weight change (kg) between baseline and eight months for Subgroup A 
(BMI≥36) 
 
Correlational analyses were performed using Pearson’s product moment correlation 
coefficient to ascertain the degree of correlation between the change weight (kg) in 
subgroup A between visit 1 and visit 3 and HRV parameters during 2 minutes of 
metronome guided breathing and for Ewing measures. 
 
Statistical analysis shows a significant correlation between HRV parameters (forced 
breathing (p=0.03), handgrip (p-0.04), LPP (p=0.028), CORR (p=0.03), DEV (p=0.02)) 
and change in weight (kg). As weight decreased these HRV parameters increased 
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representing an improvement in autonomic tone (see Table 46, Figure 42 and Figure 
43). 
 
 
Table 46 Change in HRV parameters correlated against weight change (kg) between baseline and 
eight months for Subgroup A (BMI≥36) 
HRV correlated against 
weight change (kg) 
Pearson’s R T Value P Value 
Ewing Parameters 
Resting (%) 0.356 1.3 0.2 
Forced Breathing (%) 0.58 (gradient = 0.447%/kg weight loss) 2.4 0.03 
I/E Diff (bpm) 0.504 2.5 0.06 
Valsalva (ratio) 0.59 2.5 0.04 
Hand grip (ratio) 0.21 (gradient = 0.014/kg weight loss) 0.7 0.4 
Metronome Breathing 
SD (bpm) 0.44 1.5 0.06 
A (bpm) 0.45 1.15 0.08 
LPP (unitless) 0.58 (gradient = 0.0428/kg weight loss) 2.5 0.028 
CORR (unitless) 0.36 (gradient = 0.0428/kg weight loss) 2.4 0.03 
FCORR (unitless) 0.04 (gradient = 0.0187/kg weight loss) 0.17 0.86 
DEV 0.31 (gradient = 0.0296/kg weight loss) 2.15 0.02 
Results using Pearson’s correlation coefficient for the change in Ewing and metronome guided 
breathing HRV parameters and weight change (kg). Correlation between data from baseline and visit 3 
for subgroup A (BMI ≥36.) Metronome breathing Parameters shown are described in section 3.10.6. 
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Figure 42 Scatter graphs showing significant correlational data for Ewing measures of HRV  
(A) Forced breathing, (B) Handgrip correlated against a change in weight from baseline and visit 3 for 
subgroup A 
 
 
 
Figure 43 Scatter graphs showing significant correlation for measures of HRV during metronome 
guided breathing. (A) LPP (B) CORR and (C) DEV correlated against a change in weight (kg) from 
baseline and visit 3 for subgroup A. 
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12.12  Correlational Studies: Change in Serum levels of Adiponectin and Leptin 
between baseline and visit 3 correlated against changes in weight (kg) 
between baseline and visit 3 for Subgroup A (BMI≥36) (N=14).  
 
Correlational studies were performed on data from subgroup A (N=14) using Pearson’s 
correlation. Change in weight (kg) between visit one and visit three was correlated with 
the change in adiponectin and leptin levels between visit one and visit 3. There was a 
significant inverse correlation between a reduction in weight and a rise in serum 
adiponectin (p=<0.01) and a significant correlation with a fall in weight and a fall in 
serum leptin levels (p=<0.01) (see Table 47 and Figure 44). Analysis of variance shows 
levels of adiponectin and leptin both changed significantly over the course of the eight 
month study (see Table 40 and Figure 39). 
 
Table 47 Change in Serum Adiponectin and Leptin correlated against change in weight (kg).  
 Pearson’s R T Val 
 
P Val 
Weight loss correlated 
against Adiponectin (V3-V1) 
0.839 (gradient = 0.0139/kg weight 
loss) 
5.34 <0.01 
Weight loss correlated 
against Leptin (V3-V1)  
-0.917 (gradient = 0.0454/kg weight 
loss) 
-7.97 <0.01 
Data from Subgroup A. Results of Pearson’s r correlation where (p=<0.05). significant figures are 
shown in bold. 
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Figure 44 Graphs showing the significant results of correlational studies for subgroup A:  
Changes in (A) Serum Adiponectin and (B) Serum Leptin between baseline and visit 3 were correlated 
against the change in weight (kg) between baseline and visit 3. Lines of best fit have been added. 
 
 
12.13  Correlational Studies: Change in Serum levels of Adiponectin and Leptin 
between baseline and visit 3 correlated against changes in Heart Rate 
Variability Parameters for subgroup A 
 
The change in serum adiponectin and leptin levels between baseline and visit 3 were 
also correlated with changes in HRV parameters between baseline and visit 3. There 
was no significant correlation between HRV measures and serum adiponectin or serum 
leptin levels apart from handgrip and leptin (p=0.02, r =-0.58). 
 
 
12.14  Pupillometry: Iris response to dark. In Subgroup A (N=14) with a BMI ≥36  
 
Pupillometry was performed and analysed for subgroup A for visits two and three. The 
reason for this was that we had technical difficulties with the infrared goggles during 
the first visit for a number of the participants making this subgroup too small to 
perform paired analysis with the other visits. 
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Although there was a 10.5% increase in pupil: iris ratio noted between visit 2 and visit 
3, statistical analysis did not show any differences (p=0.63) between the pupilometry 
data for visit 2 and visit 3. 
 
Table 48 Pupillometry for Subgroup A.  
 Mean 
V2 
SD  
V2 
Mean 
V3 
SD  
V3 
% Diff 
V2-V3 
P Val 
V2 vs. V3 -0.86 1.2 -0.77 1.2 10.5 0.63 
A Comparison of Standard Deviation from the age matched normal range for a Subgroup A (N=14) with 
a BMI ≥36. No statistically significant differences.  
 
 
12.15  Further Subgroup Analysis: Subgroup B: Participants with Body Mass 
Index (BMI) <36 (N=24) 
 
12.15.1 Changes in Anthropometric Measurement for Subgroup B Over Eight 
Month Period 
 
Individuals with a BMI <36 were identified from the total cohort. There were 24 
subjects in this subgroup. This subgroup lost a significant amount of weight over the 
eight month period equating to a mean percentage loss of 10.9% of their original 
weight and a mean difference of -18.2% in body fat. The average BMI of the subgroup 
at the end of the programme was 29.2 (+/-2.3) a reduction of 11% and waist size 
dropped a significant 13.5%. 
Weight related data for subgroup B were analysed using analysis of variance. Statistical 
analysis shows all parameters were significantly different between visits. The results 
are shown in Table 49. Blood pressure was also measured at each visit and the 
percentage difference fell between the start and end of the study, however using 
analysis of variance only the diastolic blood pressure was significantly different with a 
mean fall from 85mmHg to 78 mmHg 
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Table 49 Table showing anthropometric parameters for subgroup B (BMI<36)  
Parameter Mean  
Visit 1 
(±SD) 
Mean 
Visit 2 
(±SD) 
Mean 
Visit 3 
(±SD) 
% Diff 
(v1-V3) 
P Value 
Weight kg 91.1 (12.1) 83.5 (12.1) 81.2 (12.6) -10.9 0.001 
BMI 32.8 (1.7) 30.1 (1.8) 29.2 (2.3) -11.0 0.001 
% body fat 40.8 (6.2) 38 (6.7) 37.1 (7.4) -9.1 0.001 
Kg body fat 36.9 (6.2) 31.5 (6.8) 30.2 (7.8) -18.2 0.001 
Waist Circumference (cm) 104.2 (8.6) 94.6 (8.7) 90.14 (8.7) -13.5 0.001 
Systolic BP (mmHg) 129 (13.1) 126 (12.1) 125 (10.4) -4.6 0.09 
Diastolic BP (mmHg) 85 (7.5) 79 (6.8) 78 (6.7) -8.2 0.002 
Mean (±SD) values for anthropometric measures are shown. Analysis using ANOVA was performed with 
significant results shown in bold. 
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Figure 45 Anthropometric parameters at visit 1 and visit 3 for subgroup B the cohort with 
BMI<36 
(A-E) show box and whiskers plots showing minimum, first quartile, median, third quartile and maximum 
values. 
Figure 45 (A) Graph showing weight 
related parameter (weight kg) for the 
cohort with BMI<36  
Figure 45 (B) Graph showing weight 
related parameter (BMI) for the 
cohort with BMI<36  
Figure 45 (C) Graph showing weight 
related parameter (% body fat) for the 
cohort with BMI<36  
Figure 45 (D) Graph showing weight 
related parameter (body fat kg) for 
the cohort with BMI<36  
Figure 45 (E) Graph showing weight related 
parameter (waist circumference cm) for 
the cohort with BMI<36  
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12.15.2 Statistical analysis of biochemical data for subgroup B (BMI <36)  
 
All biochemical measures reduced between baseline and visit 3. After statistical 
analysis of the blood samples for this subgroup using a repeated measures analysis of 
variance (ANOVA) there were significant differences in blood glucose (p=0.01), HDL 
(P0.012), Triglyceride (p=0.021) and HbA1c (p=0.05) values (see Table 50).  
 
 
Table 50 Statistical analysis of biochemical data for participants with BMI <36 baseline and eight 
months 
Parameter Mean  
Visit  
1 (±SD) 
Mean  
Visit  
2 (±SD) 
Mean  
Visit 3 
(±SD) 
% Diff 
(v1-v3) 
P Val 
Blood Glucose (0min) 
(GLP-1) 
5.2 (0.5) 4.8 (1.2) 5.0 (0.5) -3.8 0.325 
Blood Glucose (30min) 
(GLP-1) 
8.6 (1.7) 8.0 (1.5) 8.3 (1.7) -3.5 0.001 
Total Cholesterol mg/dL 5.6 (1.1) 5.5 (1.04) 5.4 (0.98) -3.6 0.092 
Low Density Lipid 
(mg/dL) 
3.6 (0.88) 3.5 (0.84) 3.4 (0.86) -5.6 0.069 
High Density Lipid 
(mg/dL) 
1.4 (0.4) 1.4 (0.39) 1.37 (0.32) -19 0.012 
Triglycerides (mg/dL) 1.4 (0.67) 1.3 (0.8) 1.1 (0.64) -21.4 0.021 
Lipid Ratio 4.3 (1.1) 4.1 (1.2) 3.8 (0.96) -11.6 0.001 
HbA1c (%) 5.8 (0.4) 5.7 (0.4) 5.7 (0.35) -1.7 0.09 
HbA1c (mmol) 39.6 (4.5) 38.9 (4.6) 38.5 (3.89) 2.78 0.05 
Mean, SD and percentage difference are shown for all measures. Results of repeated measures ANOVA 
are shown in bold where p=0.05 
 
 
 
 
 
  
 
Figure 46 Box and whiskers plots show the biochemical data for subgroup B, (BMI<36) for visit 
one and visit three.  
Statistically significant differences were seen for all parameters shown above 
 
 
 
Figure 46 (A) Graph showing blood 
glucose 30 minutes for the cohort 
with BMI<36 at visit 1 and 3 
Figure 46 (B) Graph showing HDL for 
the cohort with BMI<36 at visit 1 
and 3 
Figure 46 (C) Graph showing triglycerides 
for the cohort with BMI<36 at visit 1 and 
3  
Figure 46 (D) Graph showing ratio 
for the cohort with BMI<36 at visit 
1 and 3 
Figure 46 (E) Graph showing HbA1c 
mmol for the cohort with BMI<36 at 
visit 1 and 3  
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12.15.3 Assessment of Heart Rate Variability for Subgroup B (BMI <36)  
 
For subgroup B (BMI <36), the percentage change in HR data between visits one and 3 
was calculated. For the Ewing measures there was a percentage increase in all but the 
lying/standing parameter. For the metronome breathing data the result was more mixed 
with a percentage rise seen in HR data in only the (A) and (FCORR) parameter. 
Analysis was performed using a paired ANOVA; there were statistical differences in all 
Ewing measures apart from the lying/standing parameter (see Table 51). There were no 
statistically significant differences in HRV for the same subgroup during metronome 
guided breathing.  
 
Table 51 HRV for Ewing parameters and metronome guided breathing parameters for subgroup 
B (BMI <36).  
 V1 Mean (±SD) V2 Mean (±SD) V3 Mean (±SD) % Diff 
(V1-V3 
P Value 
Ewing Measures 
Resting (%) 6.6 (4.3) 8.6 (4.4) 11.8 (5.8) 78.8 0.001 
Forced breathing 
(bpm) 
14.0 (6.8) 19.5 (8.56) 19.6 (7.5) 40 0.001 
I/E Diff (bpm) 9.4 (4.3) 12.0 (5.5) 12.1 (4.1) 28.7 0.004 
Valsalva (ratio) 1.30 (0.1) 1.34 (0.13) 1.35 (0.1) 3.85 0.237 
Handgrip (ratio) 1.18 (0.09) 1.2 (0.14) 1.12 (0.11) 1.7 0.014 
Lying/standing 
(ratio) 
1.12 (0.11) 1.14 (0.1) 1.12 (0.08) 0 0.758 
Metronome Breathing 
SD (bpm) 0.4 (1.0) 0.35 (0.95) 0.39 (0.8) -2.5 0.464 
A (bpm) 0.12 (0.8) 0.15 (0.93) 0.14 (0.75) 16.7 3.438 
LPP (unitless) 0.7 (0.85) 0.44 (0.93) 0.43 (0.7) -38.6 0.364 
CORR (unitless) -0.07 (1.6) -0.97 (2.2) -0.09 (0.9) -28.6 0.254 
FCORR (unitless) -0.06 (0.68) -0.05 (0.97) -0.04 (0.57) 33.3 0.491 
DEV (unitless) 0.23 (0.83) 0.12 (1.19) 0.21 (0.78) -8.7 0.391 
Mean (±SD) values for HRV parameters for each visit. Analysis of variance for repeated data. 
Significant results are shown in bold. 
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Figure 47 Box and whisker plots show statistically significant HRV measures from Ewing 
assessments for subgroup B with BMI<36.     
 
       
 
12.16  Further Subgroup Analysis: Subgroup C (N=5) 
 
12.16.1 Subgroup C: Pre-diabetic Heart Rate Variability Measures 
 
A small subgroup (n=5) of patients was identified by the specialist diabetes nurse as 
being in the “pre-diabetic range” according to their (IGT) blood results at visit one. 
Figure 47 (A) HRV during Ewing assessment 
(resting) for the subgroup with the BMI 
<36 for visit one and visit three.  
Figure 47 (B) HRV during Ewing assessment 
(forced breathing) for the subgroup with the 
BMI <36 for visit one and visit three.  
  
Figure 47 (C) HRV during Ewing assessment 
(I/E Diff) for the subgroup with the BMI 
<36 for visit one and visit three.  
Figure 47 (D) HRV during Ewing 
assessment (handgrip) for the 
subgroup with the BMI <36 for visit 
one and visit three. 
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These results still put them within a normal range and they were not classified as 
diabetic. They were able to continue with the trial as per the normal protocol.  
Overall there was a percentage increase in HRV data between visit one and three for 
both Ewing measures and metronome guided breathing, only handgrip (-3.3%) SD (-
62%) and A (-33%) reduced. Statistical analysis was performed using analysis of 
variance on the HRV data from subgroup C. Despite the increase in percentage change 
between baseline and eight months there was no statistical difference between the data 
(see Table 52). 
 
 
Table 52 Subgroup C: Pre-diabetic Group HRV Measures 
Parameter Mean V1  
(±SD) 
Mean V2  
(±SD) 
Mean V3 
 (±SD) 
% Diff 
 (V1-V3) 
P Value 
Ewing Measures 
Resting (%) 2.52 (2.49) 6.65 (5.47) 6.83 (1.81) 170 0.052 
Forced breathing 
(bpm) 
10.85 (3.02) 19.9 (9.33) 18.4 (5.65) 70 0.051 
I/E Diff (bpm) 7.67 (1.71) 12.65 (6.13) 11.32 (2.00) 47.6 0.124 
Valsalva (ratio) 1.28 (0.13) 1.33 (0.19) 1.32 (0.05) 3.1 0.787 
Handgrip (ratio) 1.1 (0.05) 1.05 (0.27) 1.16 (0.08) -3.3 0.525 
Lying/standing 
(ratio) 
1.17 (0.12) 1.11 (0.11) 1.19 (0.06) 1.7 0.590 
Metronome Breathing 
SD (bpm) 0.52 (1.08) 0.51 (0.61) 0.2 (0.57) -62 0.701 
A (bpm) 0.06 (0.84) 0.06 (0.62) 0.04 (0.59) -33 0.751 
LPP (unitless) 0.2 (0.45) 0.67 (0.49) 0.48(0.51) 140 0.613 
CORR (unitless) -0.6 (0.89) -0.2 (0.44) 0.09 (0.47) 115 0.067 
FCORR (unitless) -0.55 (1.32) 0.08 (0.7) 0.03 (0.07) 105 0.296 
DEV (unitless) 0.2 (0.83) 0.3 (0.43) 0.3 (0.39) 50 0.173 
Mean and standard deviation figures for HRV measures for Ewing assessment and metronome guided 
breathing for subgroup C. Analysis of variance was performed. No result was below the p= <0.05 
threshold. 
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12.16.2 Pre-diabetic (N=5) Autonomic Measures Compared With the Rest of the 
Lifestyle Cohort (N=33) on the First Baseline Visit 
 
It was decided to further analyse data from subgroup C in order to ascertain whether it 
would have a confounding effect if included with the full data from the rest of the 
lifestyle cohort. 
Baseline data from the remaining lifestyle cohort (n=33) were compared with baseline 
data from a small subgroup of patients (N=5) who were identified as “pre-diabetic” 
using an unpaired t-test. Despite being pre-diabetic, this group of participants did not 
show any significant differences in HRV compared to the rest of the group (see Table 
53). 
 
Table 53 Pre-diabetic HRV Data Compared with the rest of the Lifestyle Cohort (N=33) for visit 1. 
Parameter Mean total group  (±SD) Mean pre diabetics (±SD) P value 
Ewing measures 
Resting (%) 6.17 (4.14) 2.5 (2.49) 0.06  
Forced breathing (bpm) 9.5 (4.0) 7.6 (1.71) 0.33  
I/E Diff (bpm) 1.2 (0.12) 1.2 (0.13) 0.74  
Valsalva (ratio) 1.1 (0.08) 1.1 (0.05) 0.92  
Handgrip (ratio) 1.11 (0.12) 1.17 (0.12) 0.31  
Metronome Breathing 
SD (bpm) 0.23 (0.95) 0.448 (1.13) 0.65 
A (bpm) 0.10 (0.83) -0.14 (0.9) 0.77 
LPP (unitless) 0.42 (0.89) 0.32 (1.1) 0.83  
CORR (unitless) -0.88 (1.63) -1.03 (1.06) 0.84 
FCORR (unitless) 0.09 (0.59) -0.55 (1.32) 0.35  
DEV -0.03 (0.89 0.3 (0.39) 0.42 
Mean and SD heart rate variability measures for the total group and for subgroup C at visit 1. Analysis 
performed using an unpaired t-test (p=<0.05) There were no significant differences between the groups. 
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13 Chapter 13: Discussion (Lifestyle Project) 
Chapter 13: Discussion: (Lifestyle Project) 
 
13.1  Demographic Factors and their Effects on HRV 
 
Recruitment for this study was good with participant retention remaining high (see 
Table 26). 51 participants were initially recruited; however 38 participants completed 
the full eight month study. The drop-out rate was 19%. The participants were a mixed 
gender group with an average age of 52 years (+/- 9.39). All took part in the eight-
month intensive lifestyle programme. All subjects all had a BMI 30.00 – 
39.99kg/m
2
with a self -reported family history of Diabetes of 1
st
 degree relatives. 3 
participants were identified as diabetic on the blood analysis and did not continue with 
the study, (see Table 26). Six participants were established as pre-diabetic but 
continued with the study, one of these participants dropped out of the study before 
completion.  
 
13.2 Diversity of the Study Cohort 
 
The study group was not ethnically diverse. There was a significant bias, as greater 
than 95% of volunteers were Caucasian. A literature search does not suggest any 
evidence relating ethnicity with heart rate variability. There was a bias towards female 
participants and all came from the local area. 
 
13.3 Study Protocol 
 
At baseline, 4 months and at the end of the 8-months programme participants were 
required to attend for measurements. There were 7 additional group sessions in the first 
4 month period and four additional group sessions and one individual session in the 
second four month period. There was a focus on increasing activity and exercise, which 
all participants managed to achieve, and many reported a wish to maintain new 
healthier lifestyle. 
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13.4 Anthropometric Parameters 
 
Anthropometric measures were made at the baseline and at visit 2 and 3; these 
measurements are shown in Table 28. Participants lost a statistically significant amount 
of weight and body fat and changed shape in terms of a reduction in waist 
circumference. All of the anthropometric parameters were significantly different 
between each visit.  
 
13.5 Biochemical Measurement 
 
Biochemical measures taken during the study improved over the eight months of 
intensive lifestyle coaching and exercise with a significant percentage reduction in 
values for all parameters apart from HDL, which increased 2.04% (see Table 32). This 
is in keeping with research by Horton et al (2010) who found blood sample analysis for 
glycaemic control, and lipids all improved in association with weight loss apart from 
HDL, which rose. Statistical analysis shows a significant difference in many of the 
measures particularly those relating to glycaemic control. Change in weight over eight 
months was correlated against change in HbA1c levels and a significant correlation 
(p=0.032) was demonstrated (see Figure 36) 
 
We are confident that the intensive lifestyle programme, which was responsible for the 
weight loss and increased exercise, is the reason for these findings. This is in keeping 
with research by Stanford et al (2012) who found fasting blood glucose correlated with 
a change in weight and that as with this study diet and exercise is effective in reducing 
HbA1c and fasting blood sugars in both diabetics and non-diabetics. 
 
 
13.6  Blood Pressure Measures 
 
Blood pressure was also measured but did not change significantly between the visits 
for the full group despite the significant weight loss, (see Table 30) whereas Horton et 
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al (2010) found a significant correlation between weight loss and blood pressure. We 
did however see a significant difference in blood pressure between visits for subgroup 
A (BMI≥36). Systolic and diastolic blood pressure decreased at the same time weight 
in this group significantly reduced (see Table 38). 
 
13.7 Heart Rate Variability (Ewing Measures) for the full cohort. 
 
During analysis of the lifestyle study data statistically significant differences were seen 
between the data for all Ewing parameters apart from lying/standing, (see Table 33). 
The reasons for seeing such changes are not entirely clear but may be in part due to 
attenuation in inflammation resulting from weight loss, and increased levels of activity, 
as vigorous exercise is known to be implicated in increasing heart rate variability. It is 
also possible that during HRV assessment on subsequent visits there was better 
participant compliance with the test provocations resulting from familiarity with the 
protocol rather than true increased heart rate variability. True changes in HRV at rest 
are sometimes difficult to accurately identify, as there is no specific provocation that 
results in large changes in heart rate (as is the case during the Valsalva manoeuvre or 
during deep inspiration)..  
 
13.7.1 Heart Rate Variability in the full cohort (2 minute metronome guided 
breathing measures) 
 
Results for frequency analysis of heart rate data collected during 2 minutes of 
metronome guided breathing for the full cohort suggest there were no statistically 
significant differences in autonomic tone between visits (see Table 33) This is 
surprising given the results of the Ewing tests which are statistically significant (see 
section 13.7), the reason for this is unclear although this is similar to the previous 
findings in the influenza study where we did not see heart rate changes relating to the 
metronome breathing provocation, (see section 4.4). This was either due to changes in 
HRV being subtle and temporary or could be due to the small sample size. It is 
important to note that the changes occurring between visit one and visit three suggest 
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that more time is needed to see subtle changes in HRV than for biochemical measures 
which occur from four months. However the heterogeneity of the group may have been 
an issue in that as a cohort they were all obese but with a range of BMI’s over 30-39.9 
with a wide range of percentage weight lost over the eight months.  
The baseline HR data for the full cohort (n=38) during metronome breathing was also 
compared with baseline HR data for the cohort of healthy volunteers during metronome 
breathing from the Influenza study (n=71). There were no statistical differences in heart 
rate variability between the groups apart from the SD parameter (see Table 34). The 
results show although mean parameter values are lower for the lifestyle cohort than the 
healthy group, although obese; the lifestyle group is not statistically dissimilar to the 
healthy normal range.  
 
13.8  Subgroup Analysis  
 
13.8.1 Analysis of Heart Rate Data According to the Percentage Weight Loss 
between Baseline and Eight Months 
 
During the eight month study period, the study group as a whole lost a significant 
amount of weight through implementing lifestyle change, diet and exercise. The total 
cohort was subdivided for analytical purposes using two different approaches. The first 
approach uses arbitrary thresholds of percentage weight loss for each individual 
between, visit one and visit three. The percentage thresholds were <12% (moderate) 
weight loss and >12% (large) weight loss. Analysis was performed on each set of heart 
rate variability data for each subgroup.  
For the subgroup of <12% weight loss, statistical analysis showed significant 
differences between all Ewing parameters except for the handgrip and lying/standing 
provocation. Metronome breathing parameters were not statistically different between 
visits (see Table 36).  
 
For the subgroup with >12% weight loss, there was a reversal in which set of HRV 
measures recorded statistical differences. The Ewing assessment parameters showed a 
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significant statistical difference for only the resting parameter, (see Table 37), but the 
metronome guided breathing assessment of HRV showed that LPP, FCORR and DEV 
parameters were statistically different (Table 37). Our findings are very similar to those 
of Sjoberg et al (2011) in which moderate weight loss (10%) in type two diabetics was 
enough to elicit changes in HRV and were correlated with a change in BMI alongside 
the same physiological, biochemical and anthropometric measures. However Tompkins 
et al (2011) found physical activity induced improvement in insulin dynamics without 
changes in body fat in obese type two diabetics which may suggest “increased physical 
activity alone and not weight loss may be the key to promoting cardiovascular 
autonomic function.” Results of our lifestyle programme are in agreement with 
research by Carnethon et al (2006) who found that indexes reflecting autonomic 
function and fitness improved in the lifestyle modification arm of their study where 
74% of participants met the required amount of physical activity a week. 
 
13.8.2 Analysis of Heart Rate Data According to BMI at Baseline 
 
The second approach was to subdivide the cohort according to baseline BMI. The total 
cohort was subdivided into three subgroups, those in Subgroup A (N=14) had a BMI 
≥36, those in Subgroup B (N=24) had a BMI<36 and Subgroup C (N=5) were a small 
group identified as pre-diabetic on blood sampling. 
 
13.8.2.1 Analysis of HRV Data for Subgroup A (BMI≥36) N=14 
 
Subgroup A contained participants with the highest BMI (≥36). Anthropometric 
measures were assessed by analysis of variance and were all significantly different 
between visits. The percentage change in data between the starting point and the end 
point of the study shows there is a marked decrease in all weight related parameters. 
Percentage weight loss dropped 12.5% equating to 13.2kg overall weight loss with a 
mean loss of -19.7% loss in body fat. BMI fell from 38.1 (+/-1.04) to 33.5 (+/-3.3) 
equating to a 12.07% change and waist circumference reduced by an average 16.2 cm 
(-13.8%), see Table 38. There were marked changes in the biochemical data for this 
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subgroup with a percentage drop noted for all parameters. The largest reduction was 
seen in GLP-1 representing 9.6% drop in blood glucose values after the 30 minute 
repeat test for the group. The smallest percentage reduction was for LDL, which fell 
only 2.8%. Biochemical data for this group was analysed using analysis of variance for 
repeated measures. Many of the lipid and glycaemic values were statistically different, 
however triglyceride, HDL and blood glucose (0min) were not statistically different 
(see Table 39). For the participants in subgroup A, we would expect lower levels of 
adiponectin at baseline with a subsequent rise following significant weight loss. 
Associated with this subgroup there may be obesity-associated inflammation (Wolfson 
et al 2012). We saw lower levels of serum adiponectin at baseline and a percentage 
increase of 24% between the start and end of the study with significant statistical 
difference between the baseline and eight month data, (see Table 40 and Figure 39 (a)) 
We also saw a significant drop (-5.6%) in serum leptin levels in association with 
concomitant weight loss over eight months (see Figure 39 (b)).   
The heart rate data for these participants were analysed using analysis of variance and 
there were significant statistical differences between the data collected for most of the 
Ewing parameters, (resting, forced breathing, Insp/Exp and Valsalva) (see Table 41). 
The heart rate data collected during two minutes of metronome guided breathing at 6 
breaths per minute was also analysed using ANOVA, no significant differences were 
seen in any of the parameters measured comparing visit data (see Table 41), there is 
however a trend in the data with an increase in all parameters apart from CORR.  
HRV data for subgroup A was compared using an unpaired t-test with the full cohort of 
healthy volunteers from the influenza group during metronome breathing (visit1), 
There were statistical differences in SD, A, LPP and DEV parameters (see Table 43). 
All HRV parameter values were lower in the lifestyle subgroup A compared with the 
influenza group apart from the CORR parameter, which was higher. These findings are 
in direct contrast to those in Table 34 where the full lifestyle group was compared to 
the full influenza cohort and no differences were seen apart from the SD parameter. We 
can infer from this result that the increased adiposity and associated inflammation in 
subgroup A is marked enough to show a statistical difference in heart rate variability, 
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which was reduced compared to a normal range and improved after significant weight 
loss and increased physical activity. 
 
HRV data from baseline and visit 3 of the lifestyle study was also compared using a 
paired t-test to establish differences between the start and end point of the study. The 
results are all significantly different apart from the FCORR parameter and it is 
potentially the resulting inflammation from increased adiposity that is the confounding 
factor in a change in HRV. We can say that in this particular subgroup (BMI≥36) there 
is a significant difference in HRV that may be due to the intensive lifestyle programme 
which includes significant increase in exercise, dietary control, weight loss and other 
lifestyle modifications. Associated with these lifestyle changes we would also expect to 
see a reduction in inflammation related to a reduction in adiposity. We cannot comment 
on this directly as inflammatory markers were not measured, however we can infer 
from this result that in a subgroup of obese individuals (where significant weight loss 
occurred with correlated changes in HbA1c, lipids and serum adiponectin and leptin 
(see below)) the significant changes in heart rate variability are related to the reduction 
in adipose tissue which determines the associated levels of inflammation present.  
 
Analysis of an extended period of resting heart rate using analysis of variance was 
performed for subgroup A. Assessment of resting heart rate, fractal dimension, SDNN, 
PNN50 and LF/HF ratio during the eight months lifestyle study was made. There were 
no statistically significant differences in measures for either group see (Table 41). This 
was the same finding for the analysis performed on resting heart rate data from the 
influenza study where no significant differences were found. 
 
 
13.8.3 Correlational studies for Subgroup A (BMI≥36) 
 
Correlational analyses were performed using Pearson’s product moment correlation 
coefficient to ascertain the degree of correlation between change in weight in 
kilogrammes for subgroup A between baseline and visit 3 and serum lipids and 
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glycaemic indices. There was a significant correlation between weight loss and the 
change in triglyceride and HbA1c levels between baseline and visit 3, (see Figure 41 
(A), Figure 41 (B) and Table 45). This is particularly relevant to this group as they have 
the highest BMI and are most likely to go on to develop diabetes. A significant drop in 
HbA1c is directly proportional to a drop in blood sugar levels, suggesting a reversal in 
the predisposition toward disease.  
 
Correlational analyses were performed using Pearson’s product moment correlation 
coefficient to ascertain the degree of correlation between the change in weight (kg) in 
subgroup A between baseline and visit 3 and the change in HRV parameters between 
baseline and visit 3 during 2 minutes of metronome guided breathing and for Ewing 
measures. Statistical analysis shows a significant correlation between changes in some 
HRV parameters and change in weight over eight month period. As weight decreased 
some HRV parameters increased representing an improvement in autonomic tone (see 
Table 46). 
 
Correlational studies were also performed on data from subgroup A for the change in 
weight (kg) between baseline and visit three and the change in adiponectin and leptin 
levels between baseline and visit 3. There was a significant inverse correlation between 
weight loss and a rise in serum adiponectin (P=<0.001) and a significant correlation 
with a reduction in weight a fall in leptin levels (P=<0.001) (see Table 47 and Figure 
44), Levels of adiponectin and leptin both changed significantly over the course of the 
eight month study (see Table 40 and Figure 39 ). In this obese subgroup with the 
highest BMI who lost the highest percentage of weight over the eight month study 
period, we saw a significant correlation with weight loss and serum adiponectin and 
leptin levels. This was not replicated in the total cohort and may be due to the variation 
in weight loss where some participants did not lose as much weight as others.  
 
The changes in serum adiponectin and leptin levels between baseline and visit 3 were 
also correlated with changes in HRV parameters. There was no significant correlation 
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between HRV measures and adiponectin and leptin levels apart from for handgrip and 
leptin (p=0.02). 
 
 
13.8.4 Analysis of Heart Rate Data for a Subgroup (B) BMI <36 (N=24) 
 
Statistical analysis of anthropometric data for this subgroup showed that all parameters 
changed significantly between visits (p=0.001). Systolic and diastolic blood pressure 
also decreased between visits but only diastolic blood pressure was statistically 
different (p=0.002) (see Table 49). Analysis of biochemical data for this sub group 
between visits showed statistical differences in five out of nine of the parameters 
measured (see Table 50). However there are fewer statistically different changes in 
biochemical measures in this cohort compared with subgroup A. 
Heart rate variability parameters were assessed for this subgroup. The Ewing 
assessments showed statistically significant differences in all parameters apart from 
lying/standing (see Table 51). For HRV assessment during metronome guided 
breathing there was no statistically different differences (see Table 51). There were 
more participants in this subgroup (N=24) than for subgroup A (N=14), with greater 
heterogeneity (BMI of >30 - <36). Although we did see some heart rate changes in this 
group they were not the group with the highest BMI (with assumed higher levels of 
inflammation) nor the group with the greatest mean weight loss (with associated rise in 
adiponectin and drop in leptin) and therefore we would not have expected HRV in this 
group to change as significantly as for subgroup A. 
 
13.8.5 Comparison of Subgroup (C) Pre-diabetic Data against the rest of the 
Lifestyle Cohort. 
 
The cohort was also subdivided into those identified on blood measurements as being 
pre-diabetic (N=5) although still within the normal range. Heart rate data for this 
subgroup was compared with the rest of the group (N=33) using an unpaired t test. For 
the Ewing measures and for the metronome guided breathing frequency analysis there 
  
209 
were no differences in HRV between the groups. This meant that including the pre-
diabetic data with the rest of the cohort was valid and would not affect the results of the 
rest of the group. Wu et al (2007) found in pre-diabetics there was a move towards 
increased sympathetic tone and attenuation in parasympathetic modulation in 
association with the development of impaired glucose tolerance leading towards 
diabetes. We did not see these changes in the small cohort of pre-diabetics identified by 
an impaired glucose tolerance test. Our findings from this research are in keeping with 
research by Lee et al (2010) who assessed pre-diabetic obese adolescents. Their 
findings did not correlate obesity with attenuation in HRV and these HRV measures 
were not significantly different from those with normal glucose levels. Schroeder et al 
(2005) also suggested only a weak link between adult HRV measures and pre-diabetes. 
 
13.9   Obesity, Inflammation and Heart Rate Variability  
 
Vinik et al (2012) found that a modest increase in weight can have a negative effect on 
HRV, we did not see this in the full cohort and there was no significant difference on 
statistical analysis. We did however; see an improvement in HRV in subgroup A (BMI 
≥36) relating to weight loss, (see Table 41). We also saw concomitant changes in serum 
lipids, leptin, adiponectin and HbA1c. Freedman et al (1995) and Windham (2012) 
suggest one explanation for obesity-related autonomic dysfunction is that the 
distribution of body fat may be more important than a measure of overall obesity, such 
as BMI, due to the metabolic activity of visceral or abdominal adipose tissue.  
 
13.9.1 Obesity 
 
Obesity has reached unprecedented levels worldwide in adults and children with one in 
ten of the world’s population obese (WHO 2013). It is the fifth leading risk for global 
deaths and is implicated in the development of many health related problems. In the 
cohort that lost >12% in weight we saw significant differences in the frequency 
parameters between visits and in the full group and sub group A (BMI≥36), there were 
significant differences between Ewing measures of heart rate variability over the eight 
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month study period (see Table 37 and Table 41). Small sample size may account for the 
lack of statistical difference between visits for the metronome guided breathing 
frequency parameters of HRV. Assessing the differences between measures of HRV for 
subgroup A at the baseline visit and at eight months using a paired t test there were 
significant differences in all of the Ewing and Frequency parameters (see Table 42). 
Long-term exercise is associated with enhanced cutaneous blood flow (Colberg et al 
2003), restoration of baroreflex sensitivity, (Colberg et al 2003) and improved vagal 
activity in early cardiac autonomic neuropathy (Michalsen et al 2006). This study 
group underwent a programme of lifestyle modification including exercise, diet and 
nutrition in a bid to slow or reverse the progression towards disease states such as 
diabetes and cardiovascular disease with associated dysautonomia.  
 
13.9.2 Adipose Tissue 
 
In addition to containing adipocytes, adipose tissue is involved in maintaining 
homeostasis through secretion of leptin, adiponectin, resistin, TNF-α, Interleukin-6 
angiotensinogen and others. In our research all subjects were considered obese, all had 
struggled to lose and maintain weight loss throughout adulthood and all had a strong 
family history of diabetes. There is evidence that dietary excess and obesity may both 
activate inflammatory signalling pathways in cells, leading to sub-acute chronic 
inflammation. This obesity-induced inflammation can in turn play a part in the 
development and progression of diseases such as diabetes (Shoelson 2007).  
We saw significant differences in HRV parameters in the full cohort and for some 
measures in the subgroups. This was particularly true for subgroup A, we saw a 
significant statistical difference between all heart rate variability measures before and 
after the occurrence of significant weight loss, when comparing baseline measures and 
those at eight months (see Table 42). Correlational analyses also demonstrate a 
significant correlation between HRV measures and weight loss (see Table 46). The 
significance of this suggests that in essentially healthy yet obese individuals there are 
some positive changes in HRV associated with a significant weight loss. However, the 
participants with the highest BMI who demonstrated the greatest percentage change in 
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weight benefit most significantly from lifestyle modification, increased physical 
activity and resultant weight loss with respect to improving heart rate variability. 
 
13.9.3 Obesity Induced Inflammation 
 
In recent years there has been increasing evidence identifying the role of inflammation 
in the aetiology of disease and the mechanism behind the pathogenesis of obesity 
related disease states (Zulet et al 2007, and Shoelson 2007). Research has revealed a 
“close relationship between nutrient excess and derangements in cellular and 
molecular mediators of immunity and inflammation” (Lumeng and Saltiel 2011). The 
third part of this PhD research aimed to assess the link between obesity / pro-
inflammatory adiposity, weight loss and the resulting effect on heart rate variability. 
We found that in a cohort of essentially healthy yet obese individuals with a family 
history of diabetes there were significant differences in HRV parameters in subgroups 
of participants where varying amounts of weight loss had occurred, particularly in a 
subgroup A (identified with a BMI ≥36) where the greatest percentage weight loss 
occurred. All participants taking part in the lifestyle programme lost a significant 
amount of weight; all had increased levels of physical activity and had taken part in 
nutrition and dietary group sessions. We saw an increase in HRV between baseline and 
eight months in participants where we saw the greatest reduction in weight. We would 
argue that this increase in HRV potentially resulted from a reduction in the 
inflammatory response to obesity through reduced adiposity. 
The inflammatory response triggered by obesity is similar to the response to pathogens 
including a systemic increase in inflammatory cytokines and acute phase reactants, and 
the recruitment of leukocytes and generation of reparative tissue responses. Obesity 
induced inflammation is generally chronic and produces low grade activation of the 
immune system and diminished vagal nerve activity. It is clear that this low grade 
inflammation is implicated in the link between obesity and disease. “Obesity triggers 
inflammatory pathways in the brain and adipose tissue that dysregulate physiological 
responses that maintain insulin and leptin sensitivity. Lipid accumulates in muscle, 
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liver and blood vessels that activate leukocytes contributing to tissue specific disease 
and exacerbates systemic insulin resistance (Lumeng and Saltiel 2011).  
In subgroup A we saw a statistically significant difference in adiponectin and leptin 
levels (p=0.001), (see Table 40) and all other biochemical measures apart from HDL 
and triglycerides (see Table 39), over the eight month study period. In this subgroup 
there was an improvement in autonomic tone (HRV) with concurrent weight loss, 
increased activity, and dietary modification, (see Table 41 and Table 42). “Since weight 
loss and exercise are each associated with increasing vagus nerve activity, one can 
consider whether enhanced activity in the cholinergic anti-inflammatory pathway 
might decrease cytokine production and reduce the damage and metabolic 
derangements mediated by chronic, low-grade systemic Inflammation that is 
characteristic of the metabolic syndrome.” (Tracey 2007, p294).  It could be argued 
that the level of weight loss is an important factor in reducing the associated 
inflammatory process thus restoring HRV to normal levels. But it may be a 
combination of factors including peer support, shared learning, reduced calories and 
increased activity that contribute to the overall effect. The improvement in quality of 
life was evident within the group, with participants suggesting they felt generally 
better, had lost weight, and had more energy and that the programme was benefitting 
the other members of the family with a significant shift in attitude towards nutrition, 
dietary modification and exercise. 
 
13.9.4 Measures of Serum Adiponectin in Subgroup A (BMI≥36) 
 
Adiponectin has an important role in lipid metabolism, atherogenesis, inflammation 
and insulin sensitivity (Wolfson et al 2012). It circulates in several sized complexes in 
serum. Despite the fact it is produced in adipocytes (fat cells) serum levels are lower in 
obese patients, it has widely been accepted as a marker in the context of obesity and 
diabetes and cardiovascular disease (Scherer 2006). “Other than weight loss the only 
approach to improve adiponectin serum levels is through the use of pharmacological 
activators of nuclear receptor peroxisome proliferator-activated receptor by 
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thiazolidinediones, which are widely used as insulin sensitizers in diabetes” (Scherer 
2006).  
Serum adiponectin was sampled at baseline, four months and eight months after 
starting the programme. There has been a delay in analysis of the samples and we await 
the results for the total cohort. Blood samples from subgroup A were analysed 
separately. (The results are shown in Table 40). In this research we see a significant 
statistical difference (P=0.001) between the samples over the study period confirming a 
significant increase in adiponectin (see Table 40). Correlational studies comparing 
change in weight between baseline and at eight months and the change in serum 
adiponectin over the same period confirmed an inverse correlation (p=0.01) between 
weight loss and a rise in adiponectin, (see Table 47 and Figure 44). Several studies 
have found an inverse association between adiponectin concentration and different 
markers of central obesity (Kwon 2005). The results of the present study confirm this 
relationship between plasma adiponectin levels and markers of central obesity.  
 
13.9.5 Measures of Serum Leptin from Subgroup A (BMI≥36) 
 
Leptin is a hormone expressed in adipose tissue and is strictly correlated with reduced 
body fat content. It acts centrally, acting on the hypothalamus increasing energy 
expenditure and decreasing appetite (Pelleymounter et al 1995). There is an association 
between leptin and its impact on the autonomic nervous system namely stimulating the 
sympathetic branch (Paolisso et al 2000), which has been indicated in cardiovascular 
disease.  Previous studies by Collins et al (1996) have shown that leptin may affect the 
autonomic nervous system, enhancing noradrenaline turnover in brown adipose tissue 
suggesting increased sympathetic outflow. Murialdo et al (2007) reported, “bulimia 
nervosa patients have reduced heart rate variability associated with low leptin levels 
and apparent sympathetic insufficiency.” Results show a significant statistical 
difference (P=0.001) over the eight month study period (see Table 40) with a decrease 
in levels in association correlated with concurrent weight loss (p=<0.01) (see Table 47 
and Figure 44). Our result shows a reduction in leptin at eight months, which is 
correlated with a reduction in weight. This is in keeping with work by Quillot et al 
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(2008) who found that the relationship between leptin and the autonomic nervous 
system is disturbed in obese subjects. This finding could strengthen the argument that 
weight loss and decrease in adipose related inflammation may be responsible for 
restoring HRV. 
 
The immune process is regulated by neural reflexes, which comprise an afferent arm 
that senses inflammation and an efferent that inhibits innate immune responses “This 
inflammatory reflex, now termed the cholinergic anti-inflammatory pathway (Tracey 
2002)” has been extensively studied in terms of its immunomodulating function and 
protective effects against a wide range of inflammation related disorders (Wang et al 
2011). In obesity the cholinergic signalling pathway may already be suppressed in 
adipose tissue, which may contribute to increased adipose tissue inflammation typically 
seen in obesity (Wang et al 2011). Heart rate variability as a marker for vagal activity is 
significantly reduced in inflammatory conditions (Bruchfeld 2010), indicating that 
reduced cholinergic activity may be a common feature in chronic inflammation, 
including obesity (Wang et al 2011). In our research there was a significant statistical 
improvement in autonomic tone (HRV) after eight months of lifestyle coaching and 
significant weight loss from within the full cohort and particularly from subgroup A. 
This suggests that weight loss may be responsible for the improvement in HRV by 
reducing the inflammatory process. The cholinergic anti-inflammatory pathway, which 
regulates immunity and has an important immunoprotective effect against diverse 
inflammation related disorders (Bencherif et al 2010), may also be protective against 
obesity induced inflammation and insulin resistance (Wang et al 2011). 
 
13.10  Weight Loss and Changes in Heart Rate Variability 
 
It has been stated that obesity significantly increases the likelihood of developing 
health problems including heart disease and diabetes and is implicated with increased 
mortality and sudden death (Poirier et al 2000). “In diabetes reduced cardiovascular 
autonomic activity is associated with a number of clinically significant manifestations 
including exercise intolerance, intraoperative cardiovascular lability, orthostatic 
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hypotension, silent myocardial ischaemia and increased risk of mortality” (Vinik et al 
2007). Obesity and the cardiac autonomic nervous system are intrinsically linked. A 
10% increase in body weight is associated with a reduction in parasympathetic tone and 
accompanied by a rise in mean heart rate (Hirsch et al 1991). In our lifestyle study in 
subgroup A, where an average weight loss of 14% was seen, and for the full group who 
lost an average of 11% weight, our findings concur with those of Poirier et al (2003) 
who found “weight loss of 10% in obese patients was associated with a significant 
improvement in autonomic nervous system cardiac modulation, translating into 
increased HRV and decreased heart rate” (see Table 29, Table 39 and Table 41). In 
obesity it has been noted that parasympathetic autonomic activity is reduced with a 
shift towards augmented sympathetic tone. Autonomic dysfunction increases 
cardiovascular load, haemodynamic stress, arrhythmias and significant cardiac 
pathology (Maser and Lenhard 2007). Autonomic dysfunction in new onset diabetes is 
reversible with weight reduction. Proper diet and exercise is the first line therapy to 
promote weight loss and improve glycaemia (Horton et al 2010). “Physical activity is a 
key element in the prevention and management of obesity and diabetes. Regular 
physical activity efficiently supports diet-induced weight loss, improves glycemic 
control, and can prevent or delay type 2 diabetes diagnosis (Voulgari et al 2012).” Our 
cohort undertook an eight month exercise and lifestyle regime resulting in significant 
weight loss and improved autonomic tone and reversal of the likelihood of developing 
disease with improved HbA1c. Anthropometric measures, biochemical measures and 
autonomic function parameters all largely showed an improvement over eight months 
associated with significant weight loss, this is in keeping with similar work by Sjoberg 
et al (2011) who found weight loss improves heart rate variability in overweight and 
obese patients with diabetes. 
 
13.11 Pharmacological Therapy in Obesity.  
 
There are currently no effective treatments applicable to the large majority of obese 
people and most treatment is aimed at targeting the complications of obesity. Previous 
obesity medications have caused unacceptable morbidity and mortality. Currently 
  
216 
Sibutramine, Orlistat and Rimonabant are licensed in Europe (Pagotto et al 2008) and 
when used properly reduce body weight and improve cardio-metabolic risk factors 
(Pagotto et al 2008). Patients identified as those who may benefit from anti-obesity 
therapy are those with a body mass index between 27-29.9kg/M
2 
with obesity related 
comorbidities such as diabetes and hypertension dyslipidaemia and metabolic 
syndrome (Pagotto et al 2008). Another non-pharmacological and more radical 
treatment option, which is becoming increasingly used to treat obesity, is gastric 
bypass, banding or ligation bariatric surgery, which will also serve to eradicate diabetes 
in diabetic patients. Aside from such radical steps, augmenting heart rate variability 
through weight loss and improving cardiovascular fitness in overweight and obese 
people is a simple cost effective solution to health improvement. Lifestyle studies such 
as ours show a marked improvement in all measures at eight months and a change in 
eating habits and how often they exercise, alongside nutritional education. It is the 
combination of approaches to changing behaviours and the group support, which 
appears to work, Follow up will show whether these changes are maintained in the 
long-term. 
 
13.12  Targeting Inflammation 
 
Attenuated vagal activity and the loss of the critical homeostatic balance between 
parasympathetic and sympathetic branches of the ANS (sympathovagal balance) has 
been shown to cause exaggerated pro-inflammatory responses and increased morbidity 
and mortality (Thayer and Fischer 2009). Early in the development of autonomic 
dysfunction there is an established correlation between increasing inflammatory 
markers and a reduction in HRV due to the cholinergic anti-inflammatory pathway. 
Activation of this pathway through administration of acetylcholine receptor agonist 
causes a decrease in pro-inflammatory cytokine production and a reduction in disease 
severity (Van Maanen et al 2009).  
Lieb et al (2011) identified a loss of heart rate variability and sympatho-vagal balance 
before the advent of inflammation and Vinik (2012) suggests that “adiponectin and 
leptin levels may be early predictive markers and the mechanism may be via insulin 
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resistance or direct actions of leptin on the hypothalamus and the autonomic nervous 
system.” Vinik (2012) found newly diagnosed diabetics had significantly lower levels 
of adiponectin and leptin ratios and correlated the adiponectin / leptin ratios with 
measures of increased sympathetic autonomic tone.  
In subgroup C (pre-diabetic group), we did not see any changes in heart rate variability 
over the eight month period (see section 12.16.1), and (Table 51). There were also no 
significant differences between this small subgroup and the rest of the lifestyle cohort. 
When biochemical data are available I will analyse serum adiponectin and leptin levels 
in the pre-diabetic group to identify whether levels are lower as in the Vinik (2012) 
research but these are not available at the current time.  
Ziegler et al (2011) found antioxidant therapy with alpha lipoic acid restores autonomic 
function towards normal and is one of the few drugs endorsed by the Toronto 
Consensus to target the autonomic nervous system. Pavlova et al (2007) showed that 
“selective muscarinic acetylcholine receptor suppresses innate immune response by 
increasing the firing rate of action potential in the vagus.” Gaede et al (2008) showed 
that controlling BP, Lipids and hyperglycaemia reduces autonomic dysfunction by 
68%. Vinik (2012) suggests “the earliest changes that are detectable in the evolution of 
diabetes are abnormalities in autonomic balance” and implicates the hypothalamus as 
the “conductor of the endocrine orchestra.” Our lifestyle study shows that in an obese 
group of patients with a family history of diabetes there is a statistically significant 
difference in heart rate variability alongside a concurrent reduction in weight. 
Correlational studies were performed on data from subgroup A (BMI≥ 36). Change in 
weight (kg) between baseline and visit three was correlated with the change in serum 
adiponectin and serum leptin levels between baseline and visit 3, a significant 
correlation was demonstrated, (see Table 45). The change in adiponectin and leptin 
levels over the study period was also correlated with the change in HRV parameters 
(see Table 46). Results show a significant correlation between leptin and handgrip 
parameter. Other measures of HRV did not correlate with either leptin or adiponectin. 
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13.13 Pupillometry 
 
Statistical analysis was performed on the pupillometry data for the total group (see 
Table 35) and for the other weight related subgroups. There was no significant 
difference in the number of standard deviations below age matched normal values for 
iris:pupil ratio. It is difficult to draw conclusions from these findings, as the sample was 
small. The measurement technique on this occasion is insufficiently sensitive to 
determine changes in autonomic tone.  
 
13.14  Limitations of the lifestyle study 
 
Throughout this document limitations of the measurement technique or protocol have 
already been discussed in 5.6 and 9.9. We have encountered similar limitations during 
this study with regard to sample size, technical aspects and protocol limitation.  
  
We were again involved in research where there were limitations on the amount of 
influence we had over the protocol as we were working in collaboration with another 
department. We joined this project slightly later than we would have liked and were not 
able to implement changes to the blood sampling regime. Ideally we would have 
measured inflammatory markers (CRP and Il-6) but as with the other projects we were 
not able to do so for practical, financial and logistical reasons. Future work in this field 
will allow for inflammatory markers to be measured. 
 
The most significant limitation of this study was getting blood samples analysed. Some 
were analysed by the haematology department throughout the eight month period and 
were available on completion however the adiponectin and leptin results were not 
analysed or available for statistical analysis. The adiponectin and leptin results for 
subgroup A (n=14) BMI≥36 were analysed separately at additional cost. Unfortunately 
the remaining results of the full cohort will not be available until after the submission 
of this document.  
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Another issue we encountered was the repeat visits needed to commit to the study. We 
had a number of patients who attended for their first visit but did not continue to attend 
despite a follow up call. We think it was the combination of the time and effort needed 
to make repeated visits to the hospital. Despite this the dropout rate was relatively low 
and many of the participants could see immediate benefits from the sessions and had a 
vested interest to continue in the study. Many of the participants had experienced 
lifelong problems with their weight and found this lifestyle study had a positive effect 
on many aspects of their lives resulting in improved fitness, significant weight loss and 
the associated positive health benefits which accompany this. 
 
13.14.1 Limitations of HRV Testing 
 
The study group chosen did not have pre-existing heart disease, diabetes or other co-
morbidities and were an essentially healthy group apart from a high BMI putting them 
into an obese category. The selection of healthy participants for this study is in itself a 
limitation, as we would not expect heart rate variability to be much different to that of 
the healthy normal range even in an obese cohort. We would therefore also not expect a 
dramatic change in autonomic function (HRV) comparing baseline measures and those 
at eight months. The changes in HRV anticipated, were expected to be subtle and 
potentially relating to obesity and inflammation associated with obesity and the family 
history of diabetes. 
 
Care needs to be taken when interpreting the statistical significance of multiple 
parameters as the likelihood of one reaching the threshold for significance is additive. 
However, in this case multiple parameters display significant difference between 
baseline and eight months and we are confident that this is not due to chance.   
Contrary to the Influenza and GORD research projects, results from this lifestyle study 
suggest that the “Gold Standard” Ewing measures are comparable with other measures 
of heart rate variability. Therefore they remain an important part of the global 
assessment of autonomic function and will continue to be used in our routine clinical 
assessments.  
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 There is usually a bias towards an older patient for assessment for autonomic function. 
With increasing age often comes concomitant disease, which may preclude the patient 
from performing some of the test provocations. It is therefore advantageous to have a 
range of tests available to assess the different branches of the ANS. 
In hindsight there are inevitable changes that I would make to this project, some have 
already been discussed previously. The recruitment and retention for this project was 
good and the numbers were sufficient. I would like to recruit more participants to 
increase the number of participants classified as pre-diabetic and to investigate further 
this subgroup. There are some interesting questions that could be answered with a 
larger sample size, such as whether HRV and biochemical indicators that suggest 
autonomic tone is compromised earlier than first thought in this group. I would also 
like to look at a newly diagnosed diabetic group and consider the effect of weight loss 
and exercise on HRV and biochemical measures. I would also be very interested to see 
if we can detect early heart rate variability changes in early diabetes or pre-diabetes 
using our current assessment technique. 
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14 Chapter 14: Conclusions 
Chapter 14: Conclusions 
 
The effects of inflammation on the autonomic nervous system have been well 
documented, (Vinik et al 2012 and 2013, Tracey et al 2007, Sajadieh et al 2004, 
Lombardi et al 2004, Haensel et al 2008). The research incorporated in this thesis is 
collectively linked by the investigation into the association between low grade 
inflammation and changes to the autonomic nervous system in three different clinical 
settings; where a low grade inflammatory provocation was either introduced to bring 
about temporary changes in heart rate variability (as in the case of the influenza 
vaccine, see chapter 3), or was already identified (as in the case of GORD and erosive 
oesophagitis, see chapter 6), or present in clinically obese patients (see chapter 10). 
Inflammation was then reduced through either pharmacological means (PPI) or through 
other measures to reduce body weight to bring about an improvement in autonomic 
tone. The subject matter of “inflammation” has recently been addressed in a 2012 and 
2013 review-paper by leading authority in the field Professor Aaron Vinik which has 
made this research both relevant and timely. 
A host of research referenced throughout this document has reported a link between 
inflammatory disease and autonomic impairment. In clinical conditions characterised 
by a known increase in inflammatory markers, (for example in diabetes, rheumatoid 
arthritis, lupus, sepsis and acute coronary syndromes), a reduction in heart rate 
variability is consistently observed in high risk patients, strengthening the connection 
between inflammation and autonomic dysfunction (Lombardi 2004), and suggests that 
potentially many of these diseases may be diseases of autonomic dysfunction (Czura 
and Tracey 2005). Other inflammatory disease (such as asthma, reflux oesophagitis, 
arthritis, and inflammatory bowel disease) may all lead to a temporary reduction in 
autonomic tone. We questioned what physiological mechanisms are involved in this 
process. Vinik et al (2013) states, “there is increasing awareness that inflammation is 
central to the pathogenesis of diabetes and its complications.” The exact relationship 
between cardiac autonomic dysfunction and inflammation has yet to be fully 
elucidated. The traditional view of cardiac autonomic neuropathy is that there is 
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attenuation in parasympathetic function, however Vinik et al 2013 suggest it may be 
early augmentation of sympathetic tone with later sympathetic denervation Recent 
evidence suggests that the inflammatory response is in part controlled by the neural 
circuitry of ANS (Vinik et al 2013). The afferent arm senses endogenous or exogenous 
molecules from injury or infection and stimulate the vagal nerve. The increase in vagal 
nerve activity decreases the release of pro-inflammatory cytokines and suppresses 
inflammation (de Jonge and Ulloa 2007). In contrast the efferent arc of the 
inflammatory response is termed the cholinergic anti-inflammatory pathway, where the 
vagal nerve is implicated in a “hard wired” connection between nervous and immune 
systems and is considered the primary component of the immune-reflex (Czura and 
Tracey 2005), with consequent association between reduced heart rate variability and 
inflammation (Thayer 2009). Decreased vagal nerve activity and loss of inhibitory 
influence over the cholinergic anti-inflammatory reflex on immune responses and 
cytokine release may allow exaggerated cytokine responses to stimuli that would 
otherwise be harmless in good health.  
In disease where there is a constant rise in low-grade inflammation such as in diabetes 
there is an early reduction in parasympathetic activity and corresponding increase in 
sympathetic tone that initiates a cascade of inflammatory responses culminating in 
significant morbidity and mortality. Recent research by Vinik et al (2013) suggests that 
dysautonomia “impairs the ability of the ANS to regulate the cardiovascular system 
and may be a key component in the aetiology and clinical course of cardiovascular 
disease.” Vinik (2013) suggests “there is strong evidence of inflammation with 
activation of inflammatory cytokines in diabetes, which correlate with abnormalities in 
the sympatho-vagal balance.” In sepsis and multi-organ disorders, research has 
demonstrated an inverse correlation between HRV and the immune response 
(Papaioannou et al 2013). Lanza et al (2007) demonstrated a significant increase in 
heart rate variability in a group of patients with dysautonomia after treatment with 
atenolol, which correlated with a reduction in C-reactive protein. In contrast the healthy 
control group were not treated with atenolol and as expected, no changes in HRV or 
CRP over time were identified. In this paper, Lanza (2007) suggests “a causal link may 
exist between modulation of autonomic activity and inflammation.” Balance of opinion 
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in recent publications also suggests this is the case. We have not explicitly established 
such a causal link in our research. However we have shown a clear association between 
autonomic tone as measured by heart rate variability and 3 separate forms of mild 
inflammatory insults.  
 
Reproducibility of the autonomic function testing technique used in this research was 
assessed using heart rate data from healthy volunteers, who did not have the influenza 
vaccination. We are continuing to recruit to increase the normal range further. There 
was no significant difference between repeated visits separated by 2-5 days in healthy 
volunteers, (see Table 15). Statistical analysis suggests the technique is reproducible 
with no significant difference between the initial visit and a second visit. We also 
established that there is no significant difference between our previous healthy normal 
range quoted in a previous study by Perring and Jones (2003) and the new data 
collected from healthy volunteers during the influenza study, see section 4.9.2B and 
Table 16). 
 
The Influenza project extended over two vaccination periods over two years with 
successful recruitment in both years. Annually the composition of the trivalent vaccine 
reflects the strains of influenza that are predicted to cause disease for that year. 
Therefore the vaccine used was slightly different for each vaccination period. Analysis 
of the data collected showed no discernible statistical differences between the results 
for both years, (see Table 17). 
 
We established that the 6 breaths per minute breathing rate was a more significant heart 
rate provocation than a more natural breathing rhythm of 10 breaths per minute and 
resulted in more significant heart rate variability pre and post vaccination (see section 
4.5). We established that the inflammatory response to the influenza vaccination was 
large enough to have a significant effect on short measures of heart rate variability 
using frequency analysis during metronome guided breathing in subgroup 2 (most 
symptomatic post vaccination). Pupillometry was also performed and we found in a 
symptomatic subgroup there was a significant difference demonstrated in the standard 
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deviation of iris/ pupil ratio compared to an age matched normal range (see section 4.9 
and Table 14). These findings have been peer reviewed and published in Clinical 
Physiology and Functional Imaging (2012), 32: 437-444.  
 
The second tranche of research investigated the effects of gastro-oesophageal reflux 
disease on autonomic tone. We identified a non-erosive reflux disease (NERD) group 
of patients and an erosive oesophagitis reflux disease group of patients (ERD). 
Recruitment and retention was more difficult than expected and we encountered a 
noticeable dropout rate as a percentage of the total recruited due to the follow-up visit 
eight weeks later (see section 12.1). In keeping with our previous Influenza based 
research, we established that the presence of inflammation resulting from erosive 
oesophagitis had a significant effect on initial short measures of heart rate variability 
using frequency analysis during 2 minutes of metronome guided breathing. Analysis of 
the heart rate data during Ewing assessment showed significant differences between the 
two visits for the ERD group, in particular the result of forced breathing and 
lying/standing parameters (see section 8.5). Analysis of heart rate data collected during 
2 minutes of metronome guided breathing also suggested there was a statistically 
significant difference in autonomic tone (DEV parameter) between the baseline and 
follow up visit for the ERD group, (see Table 22). Although we acknowledge we did 
not sample inflammatory markers, other research suggests that pro inflammatory 
cytokines such as IL6 are frequently associated with oesophagitis (Rieder et al 2007). 
We can infer that the difference in HRV between the two groups may be associated 
with the oesophageal inflammation noted during endoscopy in the (ERD) group, which 
resolved after eight weeks of PPI therapy. The NERD group did not show the same 
statistically significant changes in autonomic tone pre and post PPI therapy, (see Table 
22). We could argue this is due to the absence of any inflammation. There was 
however, a trend in the NERD data towards a generalised improvement in HRV which 
supports other research by Dobrek 2004 and we posit that it may be possible that 
micro-inflammation related to GORD which is not identifiable during endoscopy may 
be present in the NERD group and therefore although not visible endoscopically, 
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inflammation may be present microscopically. We do not have evidence to support this 
at this time. 
Statistical analysis of pupillometry demonstrated there was a statistically significant 
difference in the number of standard deviations below age matched normal values for 
iris/pupil ratio, before and after eight weeks of PPI therapy in the ERD group, (see 
Table 24). This difference was not evident in the NERD group. 
 
This GORD based research demonstrated a link between autonomic dysfunction and 
gastro-oesophageal reflux disease. We established that the measurement technique 
implemented during this research was sufficiently sensitive to measure small but 
statistically significant changes in autonomic tone related to inflammation in the ERD 
group, (see Table 22). The results are in keeping with our earlier research relating to 
the Influenza vaccination whereby there was deterioration in autonomic tone following 
vaccination. We also saw a significant difference between GERD impact scale scores 
for both groups before and after eight weeks of PPI therapy (as shown in Table 20). We 
are confident in the use of this measurement technique and have validated the use of 
extended forced breathing in conjunction with spectral analysis as a sensitive method of 
assessing changes on autonomic tone. 
 
Autonomic function is already a key component and indicator for cardiovascular 
health. The autonomic nervous system, specifically the parasympathetic branch is 
known to play an inhibitory role in a wide range of disease states; in particular it is 
associated with the regulation of allostatic systems associated with glucose regulation, 
hypothalamic-pituitary-adrenal axis function and inflammatory processes (Thayer and 
Sternberg 2006). There is an inverse association between reduced HRV and increased 
fasting glucose, urinary cortisol, HbA1c, pro-inflammatory cytokines and acute phase 
proteins and poor health.  
 
Results of the third research project are in keeping with work by Thayer and Sternberg 
(2006). We saw an increase in serum adiponectin, and a decrease in leptin and 
biochemical measures correlating with concurrent and significant weight loss and 
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improved heart rate variability over an eight month period in subgroup A (participants 
with a BMI ≥36) (see section 12.9.1). Inflammation is known to play a key role in the 
development of heart disease and diabetes. Obesity is also a significant risk factor for 
both of these diseases and is a known inflammatory condition itself. The adipose tissue 
produces a variety of pro-inflammatory cytokines involved in insulin resistance and 
atherosclerosis (Bray et al 2009). In this third research project we performed 
measurement of autonomic function in essentially healthy, yet clinically obese 
individuals over an eight month period to assess subtle changes in autonomic tone 
relating to a significant change in weight and blood markers and associated adipose 
tissue related inflammation. 
 
During analysis of heart rate data, significant differences were seen between the Ewing 
data and metronome guided breathing data for the full group and for weight related 
subgroups over the eight month period. We suggest this may be due to the significant 
weight loss observed and increased levels of activity. This also highlights the 
importance of maintaining the full Ewing protocol in addition to other assessments as 
an integrated assessment of cardiac autonomic function.  
 
There were a small number of participants identified on the oral glucose tolerance 
blood test for impaired glucose tolerance as being pre-diabetic (N=5) although still 
falling within the normal range, (see section 12.16). Heart rate data for this group was 
compared with the rest of the group. There were no statistical differences in HRV 
between the groups.  
 
The complete group was assessed for weight loss and other weight related parameters 
over the eight-month period and lost a significant amount of weight through lifestyle 
changes, diet and exercise. The cohort was subdivided using a threshold of percentage 
weight loss for each individual between baseline and eight months. The percentage 
thresholds were <12% and >12% weight loss. Analysis was performed on heart rate 
variability data. Analysis showed that for the <12% group four of the Ewing parameters 
were statistically different (see Table 36). For the group with >12% weight loss, three 
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of the metronome breathing parameters were significantly different (see Table 37). The 
difference in the results may be due to the sample size for the groups and the weight of 
the participants in each group at the start. 
 
The full group was also subdivided according to their BMI. For subgroup A (those 
participants who had a BMI equal to or greater than 36 (N=14) at the baseline visit) 
(see section 12.9.1), data was analysed using analysis of variance (ANOVA) for heart 
rate data over the eight month period there were significant statistical differences 
between the data collected for four of the Ewing parameters (see Table 41). The heart 
rate data during two minutes of forced breathing at 6 breaths per minute was also 
analysed using ANOVA for paired data. No significant differences were seen in the HR 
parameters measured over eight months, (see Table 41). HR data for subgroup A was 
re-analysed using a paired t-test to look specifically for statistical differences between 
data from the start and the end of the study. Results show there was a significant 
difference in all parameters apart from (LPP and FCORR) (see Table 42); we suggest 
this is related to the increased BMI seen in this group. 
 
The heart rate data for the full lifestyle group was compared with the heart rate data 
from the full influenza pre vaccination group; results show no real differences between 
the full lifestyle group and the influenza group, (see Table 34). However, for subgroup 
A the same comparison was made and statistical analysis was much more discerning 
with significant differences in metronome guided breathing parameters, (SD, A, LPP 
and DEV), see Table 43. This suggests that the varying levels of obesity in the full 
group may not be high enough to induce HRV changes related to adipose related 
inflammation. However, in the group with the highest BMI (subgroup A), the 
differences in HRV were significantly attenuated compared with a group of healthy 
individuals and we would suggest this is related to increased adiposity and the related 
inflammation associated with it. 
 
A host of blood samples were taken during the study. Serum adiponectin and leptin for 
subgroup A (n=14) were sampled at baseline, four months and eight months. We saw a 
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significant statistical difference using analysis of variance between the samples over 
eight months. Correlational analysis also was performed and confirmed a relationship 
between serum adiponectin, leptin and concurrent weight loss; the results are shown in 
Table 40 and Table 45. The results of the present study confirm this relationship 
between plasma adiponectin and leptin levels and markers of central obesity. Vinik 
(2012) states “there is strong evidence of inflammation with activation of inflammatory 
cytokines and leptin in newly diagnosed type two diabetes.” 
 
Although inflammatory markers such as CRP and IL-6 were not measured directly in 
this study it is possible to infer from the adiponectin and leptin samples that the 
inflammatory process associated with obesity was active and had a subtle but negative 
effect on heart rate variability which improved in response to weight loss and lifestyle 
modification, (see section 12.9.2). We saw an increase in adiponectin, a decrease in 
weight and an improvement in heart rate variability, (see Table 40 and section 12.9.2).  
The results of this research show that mild adipose related inflammation is enough to 
negatively affect the performance of the autonomic nervous system with respect to 
HRV in this group of obese individuals with a familial history of diabetes.  
 
In other recent and unpublished research performed by the medical physics department 
(part of a national study) (The Hypocompass Trial) we found that heart rate variability 
data was 0.5 standard deviations below age matched normal data in type one diabetics 
who were asymptomatic for postural symptoms. This is in keeping with previously as 
yet unpublished research by Kerr 2009 (personal communication), which prompted our 
involvement in the current lifestyle project.  
 
Measures of extended resting heart rate variability were made for subgroup A (BMI 
≥36) from the lifestyle study, along with measures of Fractal dimension, SDNN, 
PNN50, and LF/HF ratio. There were no statistically significant differences between 
any of the extended resting heart rate measures for subgroup A over eight months (see 
Table 44); it is noted that this was also true for the GORD study (pre and post PPI 
therapy), (see Table 23) and for the Influenza study (pre and post vaccination), (see 
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Table 11).  Measures of extended resting heart rate is part of current clinical protocol 
and is useful in patients with chronic and long-term disease but has not proven to be a 
particularly sensitive measure of short term change in autonomic tone. 
 
Unlike measures of extended resting heart rate, measures of heart rate variability during 
two minutes of metronome guided breathing at six breaths per minute remain a 
sensitive measure of changes in autonomic tone. We have shown a drop in autonomic 
tone after influenza vaccination, a reversal (improvement) in autonomic tone after eight 
weeks of PPI therapy in the GORD study and an improvement in autonomic tone in 
association with lifestyle changes and weight loss in the lifestyle study. For the full 
lifestyle group and the full influenza group (post vaccination) HRV measures were 
reduced compared with normal age matched values but were not statistically significant 
in sub groups of the most symptomatic and the most overweight the reduction in HRV 
measures was significant. Results from this work suggest that mild inflammation and 
the resultant changes in autonomic performance are temporary and reversible. 
Our primary measure of HRV at six breaths per minute reflects respiratory variability 
which is associated with high frequency variation and is generally considered to be 
under parasympathetic control, however six cycles per minute falls just within the low 
frequency range, normally attributed to sympathetic activity. It is our suspicion that the 
changes we have observed during this research represent a generalised deterioration 
affecting the sympatho-vagal balance. 
 
 
14.1 Clinical Implications of the Research 
 
“Given that there are therapies that can reorient the functional abnormalities of the 
autonomic nervous system toward improved function, the importance of determining 
the presence of cardiovascular autonomic dysfunction early cannot be 
overemphasized” Vinik et al (2007 page 8). 
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The applications of this research are varied and may impact on clinical practice within 
the immediate department, and it is hoped in a wider clinical setting as well. We have 
ascertained that our measurement technique is sufficiently sensitive to be able to 
measure subtle and temporary changes in autonomic tone resulting from changes 
related to inflammation. The typical patients referred for autonomic assessment are 
usually symptomatic and on assessment are experiencing significant attenuation in 
heart rate variability compared to an age matched normal range. We can be confident 
that our assessment of autonomic function will be able to detect more subtle changes in 
HRV in patients with less marked symptoms or have been referred earlier in their 
management. With this in mind we are potentially in a position to offer routine annual 
screening for type two diabetics to detect subtle changes in HRV and direct patient 
management and focus input from the diabetes team where needed, as it is known that 
if caught early enough HRV deterioration can be reversed. Our assessment incorporates 
provocations that are directed at stressing different branches of the ANS or activating 
the resonant balance between the two branches, the majority of our testing provokes the 
vagal or parasympathetic branch, which is associated with respiration.  
The three research projects have all incorporated pupillometry as a measure of 
autonomic function with varying results. It could be argued that this measurement has 
not been shown to be adequately sensitive enough to be used in a cohort of essentially 
healthy individuals, although in the influenza study, subgroup 2 did appear to show a 
statistically significant difference (P=0.027) (see Table 14). (In the reflux study 
statistical differences were demonstrated in the ERD group (p=0.037) (see section 8.7). 
In the lifestyle study, (see section 12.7), no statistical differences were seen in our full 
cohort over the study period (see Table 35). Our experience clinically is quite different 
and for symptomatic patients with long-term disease it is a useful marker of gross 
changes in autonomic control.  
It could be suggested that for hospitalised patients where an acute or chronic 
inflammatory condition is diagnosed, autonomic assessment may be used to inform 
treatment in coronary care setting or other health management to assess improvements 
or deterioration in HRV alongside concomitant disease. 
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In order to restore or reverse the impact of dysautonomia on physiological function it is 
important to implement a range of therapeutic options, which target: identification, 
prevention and symptom relief. Motooka et al (2006) suggested dog walking in the 
elderly is enough to increase parasympathetic function. Vinik et al (2007) state that 
endurance training has been shown to improve vagal activity in diabetes. We have seen 
through a simple lifestyle and physical activity regimen, participants in subgroup A 
(BMI≥36) were able to improve HRV and serum markers.  
Development of autonomic dysfunction is a multifactorial process and needs a 
multifactorial strategy to intervene. Our autonomic function testing technique could be 
used alongside other methods as part of a strategy, using HRV results (I) as a 
prognostic marker of heart rate change; (II) as a method of determining patient 
susceptibility; or (III) for measuring patient health recovery. Gaede et al (2008) suggest 
tight glycaemic control and a strategy aimed at lifestyle change with pharmacological 
correction of hyperglycaemia, hypertension, dyslipidemia and microalbuminuria. 
Bourcier and Vinik (2010) suggest immune therapy for hypertension and Ziegler et al 
(2011) suggest antioxidant therapy. Pavlov et al (2007) have suppressed the innate 
immune response causing a decrease in pro-inflammatory cytokine production through 
the use of selective antimuscarinic acetylcholine receptor agonists. Vinik et al (2011) 
suggest that the use of anti-inflammatory drugs must have a part to play in the 
management of inflammatory disease and autonomic dysfunction along with glycation 
end-product inhibitors, statins, carnitine, peroxisome proliferator activated receptors 
(PPARS), protein kinase C-β inhibitors. The prospects for treatment and intervention in 
autonomic dysfunction are varied and numerous, but early detection remains the key to 
restoring or reversing autonomic tone. Vinik (2012) page 12 suggests “It is not beyond 
the realms of reason that we could reverse the unfortunate evolutionary profile by 
targeting the hypothalamic set point of autonomic balance.” 
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14.2 Future Work 
 
14.2.1 Future work related to the Influenza study 
 
 I intend to perform a small-scale study to establish whether changing the shape 
of the respiratory curve makes any difference to heart rate variability. This is 
on-going. 
 
 There is a need to further refine our age matched normal ranges of autonomic 
heart rate variation based on metronome guided breathing and simultaneous 
measurement of chest plethysmography. 
 
 A longer term study following up the most symptomatic volunteers at set 
periods after the vaccination would have been useful to establish when the 
autonomic tone returns to its pre vaccination state. This was not in the ethics 
protocol for this study and was not performed. Any future work will address 
this. 
 
 Additional analyses will involve re-analysing the pupillometry data with new 
dynamic software for automated pupil recognition and shape mapping. 
 
 If this study were repeated, collection and analysis of inflammatory blood 
markers would be an amendment to the protocol. 
 
 Vassallo and Allen (1997) identified that patients often remain non-specifically 
ill for a significant period following pneumonia and as a result of the 
inflammatory process recovery takes much longer than would be expected. We 
would like to be involved in the clinical assessment of HRV in patients with 
significant inflammatory disease to chart their recovery time, in association 
with improved HRV. The ANS does appear to recover after an eight month 
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lifestyle programme, we posit after true inflammation resulting from disease or 
infection this would be longer. 
 
14.2.2 Future work related to the reflux study 
 
 If this research is repeated in the future, a significant change in the protocol will 
be made to allow us to measure inflammatory markers alongside the other 
biochemical measures. 
 We are considering extending recruitment to the reflux study to give more 
power to the statistics. 
 We hope to publish this work in due course.  
 
 
14.2.3 Future work related to the obesity and lifestyle study: 
 
 If this research is repeated in the future, a significant change in the protocol will 
be made to allow us to measure inflammatory markers alongside the other 
biochemical measures. 
 
 Increasing recruitment in future projects may potentially increase the number of 
pre-diabetics in the study cohort. 
 
 For future projects of a similar nature we may be able to acquire another 
Portapres or equivalent device for measurement of beat to beat blood pressure 
thus allowing us to comment on blood pressure changes and the baroreflex. 
 
 Increasing recruitment in future projects may potentially increase the number of 
participants with a BMI≥36, which would improve statistical analysis of this 
subgroup, or changing the inclusion criteria to a higher BMI threshold. 
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 With obesity at epidemic levels worldwide one area for future work will involve 
assessment of how gastric bypass surgery will alter heart rate variability and 
change management of diabetes. We propose to work with the bariatric surgical 
team to put together a research project assessing autonomic function in patient’s 
pre and post-surgery. We anticipate that many of the patients referred for 
surgery will be diabetic. We will aim to look at whether the surgery and 
resultant weight loss will improve HRV alongside eradicating diabetes in these 
patients. 
 We are currently involved in a double blind randomised research project with 
the oncology department looking at the effect of two different chemotherapy 
options or stand-alone surgery for bowel cancer on the autonomic nervous 
system. Recruitment has started for this project. 
 
 Anecdotal evidence from our colleagues around the hospital suggests that 
patients with autonomic dysfunction take slightly longer to recovery from 
surgery and other health problems such as influenza. We propose to work with 
orthopaedic consultants to assess heart rate variability pre and post-surgery to 
identify those who are more likely to make an unremarkable recovery from 
surgery and focus efforts on patients with reduced autonomic tone prior to 
surgery that may need additional support in their post-op recovery. 
 
 We aim to work alongside our colleagues working in diabetes to implement the 
HRV assessment programme suggested by Boulton et al (2005) that all type 1 
diabetics should be assessed for autonomic dysfunction every 5 years and Type 
2 diabetics should be assessed annually after diagnosis to catch early 
attenuation in HRV.  
 
 Vinik et al (2011) suggest the use of anti-inflammatory medication in the 
management of inflammatory disease and autonomic dysfunction. It would be 
interesting to see whether a research project using anti-inflammatory drugs in 
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specific key groups of patients would improve HRV, namely in elderly 
medicine. More research is needed in this area.  
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16.2 Vaccine Evaluation Centre Questionnaire 
Adverse events reported following administration of influenza vaccine 
Adverse event  
Allergic reaction   
Allergic reaction -unspecified   
Allergic reaction -respiratory   
Allergic reaction -skin   
Allergic reaction -skin & respiratory   
Fever   
Fever -temperature not recorded   
Fever -39.9o-40.4o C   
Fever >= 40.5o C   
Severe vomiting and/or diarrhoea   
Rash   
Rashes -unspecified   
Rashes -generalized   
Rashes -localized   
Severe pain and/or swelling   
Severe pain and/or swelling -unspecified   
Severe pain and/or swelling -lasting >= 4 days   
Severe pain and/ or swelling -extending past nearest joint(s)   
Severe pain and/or swelling -lasting >= 4 days and extending past nearest joint(s)  
Arthralgia/arthritis   
Adenopathy  enlargement of glands  
Anesthesia/paresthesia   
Anaesthesia/paraesthesia -specified   
Anaesthesia/paraesthesia -localized   
Anaphylaxis   
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Abscess   
Sterile abscess/nodule/necrosis   
Infective abscess   
Infective abscess -virulent discharge   
Parotitis  (Inflammation of one or both parotid glands)  
Paralysis limb/facial/cranial   
Guillain-Barré syndrome   
Convulsions/seizures –febrile (fever) or afebrile (no fever)  
Meningitis/encephalitis/encephalopathy/encephalomyelitis   
Orchitis Inflammation of one or both testes  
Hypotonic-hypo responsive episode   
Allergic reaction   
Allergic reaction -unspecified   
Allergic reaction -respiratory   
GI symptoms   
Abdominal pain   
Diarrhoea   
Nausea   
Vomiting   
Anorexia   
Other: dyspepsia, appetite increased, faeces discoloured, flatulence, halitosis, 
hiccups, malabsorption, melaena  
 
Skin and local reactions   
Rash   
Pruritis (Itching)  
Urticaria (hives)  
Injection site reaction   
Facial oedema  swelling  
Cellulitis   
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Other: bullous eruption (blisters), erythema multiforme, herpes simplex, herpes 
zoster, hot flushes, purpura (subcutaneous bleeding), rash, rosacea (flushed skin), 
skin disorder, skin necrosis, dry skin, skin exfoliation, acne, anaphylactoid reaction  
 
Oculo-respiratory syndrome: bilateral red eyes and/or at least one 
chest/respiratory symptom (cough, sore throat, difficulty breathing, chest 
tightness, wheezing) and/or facial oedema  
 
Bilateral red eyes   
Chest/respiratory symptoms   
Bronchospasm A spasm of the bronchi that makes exhalation difficult and noisy; 
associated with asthma and bronchitis 
 
Chest pain   
Dyspnoea laboured breathing  
Cough   
Sore throat   
Difficulty breathing   
Chest tightness   
Wheezing   
Other: hyperapnoea, hypoapnoea, pneumonia, respiratory disorder, haemoptysis, 
hyperventilation, asthma, pulmonary congestion  
 
Facial oedema   
Other eye symptoms   
Eye pain   
Photophobia   
Abnormal vision   
Other: blepharitis (Inflammation of the eyelids), blepharospasm, (spasm of the 
eyelid), eye abnormality, eye infection, eyelid retraction, haemorrhage, lacrimation 
abnormal, retinitis  
 
Ear/nose/throat symptoms   
Laryngitis   
Pharyngitis   
Rhinitis   
Throat tightness   
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Oedema mouth   
Dysphonia  speech disorder  
Dysphagia difficulty swallowing  
Other: dry mouth, oedema mouth, saliva increased, sinusitis, tongue disorder, 
tongue paralysis, tongue oedema, upper respiratory tract infection, angioedema 
swelling, epistaxis nose bleeds, ear ache, ear disorder, hearing decreased, tinnitus, 
aphasia  
 
Neurological symptoms   
Myelitis  Inflammation of the spinal cord  
Paresthesia tingling itching or burning  
Paralysis   
Other: agitation, impaired concentration, confusion, abnormal coordination, 
abnormal crying, delirium, depression, diplopia (visual impairment), dyskinesia 
(abnormal voluntary muscle movements), euphoria, fall, gait abnormal, 
hallucination, insomnia, nervousness, somnolence, vertigo, tremors, stupor, 
hypertonia, hypoesthesia, hypokinesia, anxiety, ataxia  
 
Musculo-skeletal symptoms   
Skeletal pain   
Back pain   
Myalgia (muscle pain)  
Other cardiovascular symptoms: arrhythmia bradycardia (slow heart rate), cardiac 
arrest, cardiac failure, atrial fibrillation, hypotension, mitral insufficiency, 
palpitation, weak pulse, tachycardia, syncope, hypertension, hypertension 
aggravated  
 
Other metabolic disorders: glucocorticoid increase, hyperglycemia, metabolic 
disorder, thyroid stimulating hormone 
 
Others   
Dizziness   
Fatigue   
Asthenia   
Flushing   
Malaise   
Influenza-like illness   
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Headache   
Oedema (including peripheral oedema)   
Rigors   
Increased sweating   
Other: leg pain, livido (skin disclouration) reticularis, fatty liver, ischemic necrosis, 
neoplasm, orchitis, pallor, parotitis, polymyalgia rheumatica, speech disorder, 
splenomegaly (enlarged spleen), sputum increased, trigeminal neuralgia, tooth 
ache, xerophthalmia (dry eyes), yawning, sweating increased, taste perversion, 
torticollis, urine abnormal, urinary tract infection, vasculitis, temperature change 
sensation, aura, apathy, cystitis, dehydration, infection, muscle weakness  
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16.3  GORD Project Statistical Power Calculation 
 
-----Original Message----- 
From: Zoe Sheppard  
Sent: 17 March 2010 15:08 
To: 'Jones, Emma'; 'S.Perring@poole.nhs.uk' 
Cc: Peter Thomas; Reuben Ogollah 
Subject: Sample Size Recommendation for Pilot Study 
Dear Emma Jones and Steve Perring 
  
This e-mail is to confirm that you have consulted the Research and Development Support 
Unit with regards to the sample size for your pilot study investigating the influence of proton 
pump inhibitors on measures of autonomic function.  Because of the pilot nature of the study, 
a sample size of thirty participants is recommended (Browne 1995 cited by Lancaster et al. 
2004 p308).  We will continue to be available for advice and support during the course of your 
study. 
  
Many Thanks 
  
Zoe Sheppard 
  
References: 
Browne, R.H.  (1995).  On the use of a pilot sample for sample size determination.  Statistics 
in Medicine, 14: 1933-1940. 
Lancaster, G.A., Dodd, S., and Williamson, P.R.  (2004).  Design and analysis of pilot studies: 
recommendations for good practice.  Journal of Evaluation in Clinical Practice, 10 (2): 307-
312. 
 --------------------------------------------------------------------- 
Research Fellow in Research Methods 
Dorset Research and Development Support Unit 
School of Health and Social Care 
Bournemouth University 
Royal London House 
Christchurch Road 
Bournemouth 
Dorset.  BH1 3LT 
UK 
Tel: +44 (0)1202 962216 
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16.4  Ethics Documentation 
16.4.1 Influenza Study Ethics Documentation  
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16.4.2  Reflux Study Ethics Documentation 
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16.4.3 Lifestyle Study Ethics Documentation 
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